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116-Hydroxysteroid dehydrogenase catalyses the conversion of Cortisol to inactive
cortisone. In kidney, the enzyme confers aldosterone-specificity on mineralocorticoid
receptors by preventing their occupancy by Cortisol. The expression of 118-
dehydrogenase in many extra-renal sites suggests that it has a wide role in modulating
Cortisol sensitivity. When renal 118-dehydrogenase is defective (as occurs in
congenital deficiency and after inhibition of the enzyme by liquorice or
carbenoxolone) cortisol-dependent mineralocorticoid excess and hypertension ensue.
In this thesis I address the hypotheses that: (i) in addition to its role in the kidney,
118-dehydrogenase modulates Cortisol sensitivity in vascular smooth muscle; (ii) 11B-
dehydrogenase is regulated physiologically by the hypothalamic-pituitary-adrenal axis;
and (iii) deficiency of 1 lB-dehydrogenase, associated with increased Cortisol
sensitivity either in kidney or in blood vessels, contributes to pathophysiology in
other forms of hypertension, specifically ectopic ACTH syndrome and essential
hypertension.
I show that llB-dehydrogenase immunoreactivity and mRNA are localised to vascular
smooth muscle cells in rats, and bioactivity is greater in resistance vessels than
conduit arteries. In support of a diverse role for the enzyme in modulating vascular
tone I demonstrate: (i) potentiation of vasoconstrictor sensitivity to Cortisol - and
thereby to noradrenaline - in the forearm and dermis of men given enzyme inhibitors
or congenitally deficient in llB-dehydrogenase; and (ii) attenuation of noradrenaline
reactivity by glucocorticoids in rat aorta which is increased following in vitro
carbenoxolone administration.
By studying in vitro affinities of rat vascular 1 lB-dehydrogenase for its cofactors I
demonstrate its similarity to the hepatic isoform of the enzyme, and distinguish it from
that in kidney. Moreover, vascular but not renal 1 lB-dehydrogenase is induced by in
vivo administration of glucocorticoids. By contrast, ACTH is without effect on 116-
dehydrogenase in adrenalectomised rats, but inhibits the peripheral conversion of
Cortisol to cortisone in man. By selective venous catheterisation studies I confirm that
the major site for this conversion is the kidney. Thus ACTH, in addition to
stimulating Cortisol synthesis, may stimulate the secretion of an 1 lB-dehydrogenase
inhibitor from the adrenal, and thereby increase renal sensitivity to Cortisol.
In 9 patients with ectopic ACTH syndrome the ratio of plasma Cortisol to cortisone
was higher than in 17 patients with other forms of Cushing's syndrome, and
con-elated negatively with plasma potassium concentration. In patients with essential
hypertension 1 lB-dehydrogenase activity (measured by the half life of (lla3H)-
cortisol) was deficient in 7 of 20 patients studied. These patients did not have
evidence of mineralocorticoid excess. However, dermal vascular sensitivity to
Cortisol, although not significantly correlated with 1 lB-dehydrogenase activity, was
increased in the hypertensives.
In conclusion, 1 lB-dehydrogenase deficiency may mediate hypertension by more than
one mechanism. In ectopic ACTH syndrome inhibition of renal 1 lB-dehydrogenase
allows Cortisol to activate mineralocorticoid receptors and induce the characteristic
features of hypokalaemia and hypertension. By contrast, in essential hypertension
llB-dehydrogenase deficiency is not associated with mineralocorticoid excess, but
may underlie an increase in vasoconstrictor sensitivity to Cortisol. Thus the
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11B-HYDROXYSTEROID DEHYDROGENASE AND ENZYME-MEDIATED
RECEPTOR PROTECTION
Hypertension is one of the commonest clinical problems in First World Medicine,
affecting perhaps 10 % of the population. However, we can identify a cause of
"secondary" hypertension in fewer than 5 % of these individuals, leaving > 95 %
with "essential" hypertension. It is logical to suppose that the mechanisms which
raise blood pressure in the minority with secondary hypertension might contribute to
pathophysiology in a more subtle way in the majority. This logic has been pursued,
with limited success, for most of the endocrine syndromes which are associated with
hypertension [Fraser et al., 1989],
The role of the adrenal cortex in blood pressure regulation was first inferred from the
association of adrenocortical insufficiency with hypotension [Addison, 1855], and
subsequently when hypertension was recognised as a consequence of excessive
secretion of either Cortisol in Cushing's syndrome [Cushing, 1912] or aldosterone in
Conn's syndrome [Conn, 1955]. Cortisol has therefore been suggested to be a
pathophysiological mediator in patients with essential hypertension. This was
addressed initially by measurement of production rates of Cortisol, which were
disappointingly normal [Vermeulen & van der Straeten, 1963]. Nonetheless,
evidence has since emerged that the hypophyseal-pituitary-adrenal axis is abnormal in
patients with essential hypertension. Firstly, deranged Cortisol metabolism was
observed in hypertensive patients, who produce relatively large amounts of the polar
metabolites of Cortisol (66- and 20a- hydroxycortisol)[Kornel et al., 1975].
Secondly, the synthetic glucocorticoid receptor agonist dexamethasone was found to
lower blood pressure paradoxically in some patients with essential hypertension
[Hamilton et al., 1979; Whitworth et al., 1989a], suggesting that in this subgroup the
elevation of blood pressure is ACTH-dependent. If it is Cortisol which mediates
hypertension in these patients then, in the absence of excessive secretion or circulating
concentration, it must exert its effect by inducing a more sensitive response in one of
its target organs.
Curiously, the target mechanisms which mediate glucocoiticoid-induced hypertension
remain uncertain. Relevant effects have been observed in kidney, heart, central
nervous system, and peripheral blood vessels, but the relative contribution of each
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site is unclear (see below). Increased sensitivity to Cortisol at any of these sites might
increase blood pressure.
From a series of clinical and experimental observations made in this department by Dr
Paul Stewart, he and Professor Christopher Edwards uncovered a novel mechanism
for cortisol-dependent hypertension [Stewart, 1988a]. Paul's observations concerned
the enzyme 118-hydroxysteroid dehydrogenase, or the "cortisol-cortisone shuttle",
which he demonstrated to play an important role in dictating Cortisol sensitivity in the
kidney. In this thesis I address the possibility that this mechanism also dictates
Cortisol sensitivity in vascular smooth muscle, and that its deficiency in either kidney
or vasculature could contribute to pathophysiology in common forms of
hypertension.
Sensitivity to Glucocorticoids in the Kidney
Under the classical model of corticosteroid action, their effects are mediated by
binding to cytosolic steroid receptors. The steroid-receptor complex is translocated to
the nucleus where it binds to steroid response elements on DNA. These act as
promoter genes to influence mRNA transcription and thereby protein synthesis from a
number of genes [Gustafsson et al., 1987]. In the kidney aldosterone binds to
mineralocoiticoid (or type 1) receptors which have a restricted distribution in the distal
nephron [Funder et al., 1973a; Rundle et al., 1989], and whose activation results in
sodium retention and potassium loss [Fanestil & Park, 1981; Marver, 1984; Funder,
1985]. By contrast Cortisol binds to glucocorticoid (or type 2) receptors which have a
ubiquitous distribution [Funder et al., 1973b; Gasc et al., 1991] and have more
variable effects on tubular function [Fanestil & Park, 1981; Marver, 1984],
It is important in this model that there is little cross-reactivity between glucocorticoid
and mineralocorticoid activities (ie that Cortisol does not activate mineralocorticoid
receptors), because Cortisol is present in concentrations 100-1000 fold greater than
those of aldosterone and if it did bind to mineralocorticoid receptors they would be
permanently fully activated. This specificity of mineralocorticoid receptors for
aldosterone has been confirmed in vivo [Sheppard & Funder, 1987] and was
attributed originally to the intrinsic affinities of mineralocorticoid and glucocorticoid
receptors for their physiological ligand. Thus glucocorticoid receptors would have
high affinity for some ligands (principally Cortisol [=hydrocortisone] in man; also
corticosterone, the principal glucocorticoid in rat; and the synthetic steroids
dexamethasone, prednisolone, budesonide etc) and mineralocorticoid receptors would
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have high affinity for others (principally aldosterone in man and rat; also 11-
deoxycorticosterone, and synthetic mineralocorticoids such as fludrocortisone).
However, identification of receptors in rat hippocampus which bound corticosterone
but not the type 2 ligand dexamethasone raised doubts about this traditional
explanation [McEwen et al., 1976]. It emerged that these sites had an identical ligand
binding profile to type 1 receptors from kidney, and that both renal and hippocampal
type 1 receptors bound corticosterone and aldosterone with equal affinity in vitro
[Krozowski & Funder, 1983]. Moreover, when cloned, the type 1 and type 2
receptors were found to share remarkable structural and genetic homology in keeping
with their promiscuous ligand binding [Arriza et al., 1987]. Thus a mechanism not
dependent on intrinsic receptor affinity is required to explain the in vivo specificity of
renal type 1 receptors for aldosterone over corticosterone, when the same receptors
are not specific for aldosterone in hippocampus [Sheppard & Funder, 1987].
Several authors had hinted at the possibility that the aldosterone-specificity of
mineralocorticoid receptors might depend on local metabolism or sequestration of
cortisol/corticosterone. When Funder, Feldman and Edelman first described the type
1 receptor in kidney they recognised that its affinity for aldosterone, although high,
was not enough to explain its specificity when aldosterone levels are so low relative to
other corticosteroids [Funder et al„ 1973a]. The presence in rat kidney of another
binding site, which was unusual in preferring corticosterone above all other ligands,
led them to suggest that a type 3 receptor existed [Feldman et al., 1973]. However, a
functional effect of type 3 binding was never demonstrated. It was suggested that it
represented extra-vascular Cortisol binding globulin (CBG), and later that CBG might
absorb corticosterone in the kidney but not in hippocampus (beyond the blood-brain
barrier) and therefore might prevent the access of glucocorticoids to mineralocorticoid
receptors [Stephenson et al., 1984], However, the CBG hypothesis was untenable
after the description of aldosterone specificity in kidneys of 10-day old rats which are
deficient in CBG [Sheppard & Funder, 1987]. Diana Marver wrote that the type 3
"receptor" might be an enzyme, and also suggested that preferential metabolism of
corticosterone in rat distal tubules might result in specific binding for aldosterone
[Marver, 1984], This remark proved to be prophetic.
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11B-DH = 116-dehydrogenase and 11B-OR = 1 lB-reductase activities of the enzyme
1 lB-hydroxysteroid dehydrogenase (11B-OHSD).
HB-Hydroxysteroid Dehydrogenase
Biochemistry and Distribution
llB-hydroxysteroid dehydrogenase (11B-OHSD) is a microsomal enzyme which in
man catalyses the reversible inter-conversion of Cortisol to the inactive steroid
cortisone, and in rats the inter-conversion of corticosterone and 11-
dehydrocorticosterone (Figure 1.1). The two activities of the enzyme are separable,
an 1 lB-dehydrogenase (11B-DH) catalysing the forward reaction from Cortisol to
cortisone and from corticosterone to 11-dehydrocorticosterone, and 1 lB-reductase
(11B-OR) catalysing the reverse reactions. For many years there was controversy
about whether 11B-DH and 11B-OR were separate enzymes. Kinetic data indicated
the existence of two enzymes in lung [Abramowitz et al., 1982] and liver [Lakshmi &
Monder, 1985; 1988] and indeed that liver llB-dehydrogenase has distinct kinetic
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forms [Monder & Lakshmi, 1989]. However, the argument was recently settled with
the cloning of a rat cDNA encoding a protein which catalyses both reactions [Agarwal
et al., 1989; 1990]. Nonetheless, congenital deficiency of 11B-OR in man [Taylor et
al., 1984; Phillipou & Higgins, 1985] is dissociated from deficiency of 11B-DH
described below. It seems that although both activities can be expressed from the
same gene, the relative activities of the two reactions may vary independently.
Most work on the enzyme has relied on measurement of in vitro activity in tissue
homogenates or microsomes. In these studies 11B-DH activity predominates, and the
greatest activity was usually reported in liver [Hurlock & Talalay, 1959; Koerner,
1969; Lax et al., 1978; Monder & Shackleton, 1984; Monder & Lakshmi, 1990], It
was widely assumed that the enzyme was one of a variety of integrated hepatic
clearance mechanisms which facilitate excretion of Cortisol metabolites in urine
(Figure 1.2). If this were so then it seems curious that it should be a reversible
reaction. In human studies of Cortisol clearance, using measurement of urinary
steroid metabolites by chromatographic separation [Zumoff et al., 1974] or by
radioisotopic labelling [Kowarski et al., 1969; Zumoff et al., 1974], the conversion
of Cortisol to cortisone was shown to make a substantial contribution to Cortisol
clearance, though no study has simultaneously quantified the relative contributions of
all the pathways illustrated in Figure 1.2 [Brownie, 1992]. However, a discrepancy
was found between the in vivo half life of 14C-cortisol of -75 min and that of
(1 la3H)-cortisol of -40 min (3H is irreversibly removed from the latter molecule by
11B-DH), suggesting that reductase conversion of 14C-cortisone back to 14C-cortisol
is very active [Hellman et al., 1971]. Cortisol and cortisone therefore represent
interchangeable pools of active and inactive steroid respectively. Although total
circulating levels of Cortisol are higher than those of cortisone, cortisone is not
substantially protein bound and free plasma concentrations are approximately equal
[Meulenberg et al., 1987].
The assumption that the liver is the principal site of 11B-DH activity was also called
into question by several early findings. Firstly, in vitro 11B-DH activity was found in
abundance in kidney [Ganis et al., 1956; Jenkins, 1966]. The contribution of the
kidney was emphasised by Hellman and colleagues [Hellman et al., 1971], who
estimated from isotopic studies employing renal vein sampling that as much as 10 %
of Cortisol was subject to 11B-DH metabolism on single pass through the kidney.
Even more avid conversion of Cortisol to cortisone was then shown in perfused rat
kidney [Reach et al., 1977]. Secondly, in a single experiment in which human liver
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Figure 1.2 Principal metabolites of Cortisol
















was perfused with Cortisol, the metabolites of Cortisol (cortols) and cortisone
(cortolone) were produced in similar amounts and the free steroids were not
measurable [Wortmann et al., 1971]. This suggests that the liver rapidly exchanges
pools of Cortisol and cortisone, and that both pools are cleared to A-ring-reduced
metabolites. However, when free Cortisol and cortisone were measured in the
effluent from a perfused cat liver, it was Cortisol which was most abundant,
suggesting that in the cat the hepatic equilibrium favours the active steroid, ie that
116-OR predominates [Bush, 1969]. More recent experiments suggest that 11B-OR
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also predominates in human liver. Following an oral dose of cortisone peripheral
plasma Cortisol levels rise but cortisone concentrations do not [Stewart et al., 1990].
This suggests that a substantial proportion of the cortisone delivered to the liver via
the portal vein is converted on first pass to Cortisol by 11B-OR, and the rest of the
cortisone is probably converted to A-ring-reduced metabolites. Thus not only is
Cortisol subject to extensive turnover between active and inactive forms, but also the
relative concentrations of Cortisol and cortisone may vary between organs, with most
conversion to cortisone occurring in the kidney and conversion back to Cortisol
occurring in the liver. I address this question further in Chapter 4.
In addition to expression in liver and kidney, 11B-OHSD is expressed to some degree
in almost all mammalian tissues and also in non-mammals (Table 1.1). Mammalian
tissues studied include placenta [Osinski, 1960; Murphy, 1981b], lung [Murphy,
1978; Nicholas & Lugg, 1982; Abramowitz et al., 1982], testis [Phillips et al.,
1989], ovary, uterus [Benediktsson et al., 1992], salivary glands, colon [Whorwood
et al., 1992], skin [Teelucksingh et al., 1990], adipose tissue, skeletal muscle, brain
[Moisan et al., 1990a; 1990b; Monder & Lakshmi, 1990; Lakshmi et al., 1991; Sakai
et al., 1992], and vasculature [Kornel et al., 1982; Funder et al., 1989]. The
magnitude of the contribution which these other sites make to cortisol/cortisone
turnover is unknown.
Physiological Role of 11B-OHSD
The possibility that the conversion of the active steroid Cortisol to its inactive
metabolite cortisone may have greater significance than as a simple clearance
mechanism for Cortisol was first suggested in studies of placental 11B-OHSD.
Human placenta in midgestation has both 11B-DH and 11B-OR activities but the fetus
has predominantly 11B-OR activity [Pasqualini et al., 1970]. Placental equilibrium
between active and inactive steroids changes during gestation [Giannopoulos et al.,
1982], as does enzyme equilibrium in human fetal tissues around parturition
[Murphy, 1978; 1981b]. These authors suggested that the shift of equilibrium
towards the active steroid in late gestation may have a physiological role since Cortisol
is involved in the initiation of parturition in some species and is an important factor in
normal maturation of lung surfactant [Muiphy & Branchaud, 1983].
On this background observations of the clinical syndrome of 11B-DH deficiency in
the last 20 years have provided valuable clues to the physiological role of 11B-OHSD
in the kidney in adults.
7
Table 1.1 Distribution of 11B-OHSD in mineralocorticoid and glucocorticoid
target organs






















In 1974 Werder [Werder et al., 1974] described a case of a 3 year old girl with severe
hypertension and hypokalaemia. Plasma renin activity was undetectable and
mineralocorticoid excess was suspected. However plasma aldosterone was low and
no other mineralocorticoids could be identified. Cortisol metabolites as measured by
urinary 17-hydroxycorticosteroids were low as was urinary tetrahydrocortisone
(THE). After administration of exogenous ACTH it was noted that "surprisingly
THE remained low". The significance of this was not understood and it was
speculated that an unknown steroid with both mineralo- and gluco-corticoid activity
was causing the syndrome. A very similar clinical and biochemical picture was then
reported in a patient of Maria New's. They described a defect in the conversion of
Cortisol to cortisone associated with hypertension and hypokalaemia [New et al.,
1977; Ulick et al., 1977; 1979]. Again there was no demonstrable excess of
circulating mineralocorticoid and the syndrome was described as one of "apparent
mineralocorticoid excess". The link between the hypertension, hypokalaemia and
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inability to convert Cortisol to cortisone remained unexplained though a further 18
cases.were reported in children [Shackleton et al., 1980; 1985; Fiselier et al, 1982;
Oberfield et al., 1983; Honour et al., 1983; Harinck et al., 1984; Monder et al., 1986;
Dimartino-Nardi et al., 1987]. Two families had more than one affected member.
New's group proposed that Cortisol was acting as a hypertensive agent [Oberfield et
al., 1983] and Shackleton and colleagues [1980] demonstrated a beneficial response
to therapy with dexamethasone, as had Werder in the original case. Two possible
explanations were advanced for the mineralocorticoid effect of Cortisol. In the first
they proposed that Cortisol had an abnormal affinity for the mineralocorticoid
receptor. However, this would mean that there were two genetic defects, one in
cortisol-cortisone conversion and the other in the mineralocorticoid receptor. In the
second they suggested that the normal metabolism of Cortisol to cortisone did not
occur in the mineralocorticoid receptor tissue, resulting in accumulation of Cortisol
and activation of receptors [Oberfield et al., 1983].
In 1984 the oldest patient to have presented with this syndrome, a 20 year old man
(GB), was investigated in detail in this department by Professor Edwards [Edwards et
al., 1985; Stewart et al., 1988b]. The following features were confirmed: a) normal
circulating levels of Cortisol but a reduced Cortisol production rate; b) elevation of the
ratio of urinary metabolites of Cortisol (tetrahydrocortisol [THF] + allo-THF) to those
of cortisone (THE)(Figure 1.2); c) prolongation of the half life of (1 la3H)-cortisol
(which is acted on by 11B-DH to produce 3H-H?0 and unlabelled cortisone); d)
intact ability to convert orally administered cortisone to Cortisol; e) excess
mineralocorticoid activity in kidney (as judged by suppression of plasma renin activity
and aldosterone, hypokalaemia, and a very low urinary Na/K ratio) and colon (as
measured by subtraction potential difference) which could be reversed with
dexamethasone and reproduced by physiological doses of hydrocortisone; and f) no
demonstrable excess of any other mineralocorticoid. Family studies suggested that
GB's mother also had relative 1113-DH deficiency, with mild hypokalaemia and
hypertension [Stewart et al., 1988b; Shackleton & Stewart, 1990]. In then-
discussion of this case Stewart and Edwards offered a new hypothesis to explain the
syndrome, when they suggested that the normal kidney uses the cortisol-cortisone
shuttle to protect mineralocorticoid receptors in the distal nephron from Cortisol.
Failure to do so results in "Cushing's disease of the kidney" in which intra-renal
Cortisol levels rise and spill over to occupy type 1 mineralocorticoid receptors
[Edwards et al., 1985; Stewart et al., 1988b].
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An important step forward in testing this hypothesis followed with the recognition of
parallels between the findings in GB and the features of the hypertensive syndrome
produced by liquorice. Liquorice abuse had long been associated with hypertension
and hypokalaemia which responded to spironolactone [Salassa et al., 1962], and it
was thought that glycyrrhetinic acid (GE), the active derivative of liquorice, caused
the syndrome by binding directly to renal mineralocorticoid receptors [Ulmann et al.,
1975; Armanini et al., 1983]. However, previous studies had shown that the sodium
retention was dependent on the presence of Cortisol or another ACTH-dependent
steroid since it was reversible with dexamethasone [Hoefnagels & Kloppenborg,
1983] and absent in patients without intact adrenal glands [Borst et al., 1953].
Therefore it could not be a direct effect but might be mediated by inhibition of 1113-
DH by liquorice.
Figure 1.3 Chemical structure of liquorice-derived inhibitors of 1113-OHSD
Carbenoxolone Glycyrrhetinic Acid
In a metabolic balance study in subjects taking liquorice it was confirmed that sodium
retention and kaliuresis were associated with changes in urinary Cortisol metabolites
and prolongation of the half life of (lla3H)-cortisol which indicated inhibition of
118-DH [Stewart et al., 1987]. Others have confirmed that the effects of
confectionary liquorice on Cortisol metabolism in man can be reproduced by the
administration of either of its principal constituents, GE [MacKenzie et al., 1990] or
glycyrrhizic acid (converted to GE in v/vo)[Kageyama et al., 1992], Similar findings
were observed with the ulcer-healing drug carbenoxolone, which is the hemisuccinate
derivative of GE [Monder et al., 1989; Stewart et al., 1990](Figure 1.3).
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Furthermore, GE and carbenoxolone competitively inhibit rat 11B-DH in vitro and in
vivo [Monder et al., 1989] and carbenoxolone potentiated the mineralocorticoid
effects of corticosterone in the intact rat [Souness and Morris, 1989] and in toad
bladder mucosa [Brem et al., 1989; Gaeggeler et al., 1989]. It thus appears that in
both congenital and acquired 11G-DH deficiency, failure to inactivate Cortisol in man
or corticosterone in rat is associated with abnormal access of these glucocorticoids to
renal mineralocorticoid receptors and hence mineralocorticoid excess.
Specificity of Renal Mineralocorticoid Receptors
The data from congenital and acquired 11B-DH deficiency provide an alternative
explanation for the paradox of aldosterone-specificity of mineralocorticoid receptors
in the kidney. This is presented in Figure 1.4. In this model it is accepted that renal
mineralocorticoid receptors have equal affinity for Cortisol and aldosterone but are
protected from the high concentrations of Cortisol by the enzyme 11B-DH, which
converts Cortisol to cortisone. The 11-18 hemi-acetal structure of aldosterone protects
it from the action of 11B-DH [Edwards & Hayman, 1991], and so aldosterone gains
preferential access to the receptors.
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This hypothesis was confirmed in this department by studying in vivo binding of
corticosterone and aldosterone in rat kidney, with and without inhibition of 11B-DH
with subcutaneous glycyrrhizic acid [Edwards et al., 1988]. The results were very
dramatic, showing by autoradiography that 3H-corticosterone bound minimally in the
kidney in the absence of glycyrrhizic acid, but that after 11B-DH inhibition there was
abundant 3H-corticosterone binding in a distribution identical to that of 3H-
aldosterone, ie in the distribution of mineralocorticoid receptors. Furthermore,
glycyrrhizic acid had no effect on aldosterone binding. These findings were
confirmed by John Funder's group in Melbourne who demonstrated that when 3H-
corticosterone or 3H-aldosterone were given in vivo to rats and the kidneys then
removed, there was selective binding of aldosterone to type 1 receptors in the kidney
cytosol. However, this selectivity was lost when 11B-DH was inhibited with
carbenoxolone [Funder et al., 1988].
Controversies in the Role of 11B-OHSD in the Kidney
Cellular Localisation of 11B-OHSD
The anatomical relationship between 11B-OHSD and mineralocorticoid receptors in
the kidney has been debated. Initial localisation of the enzyme by
immunohistochemistry, using a polyclonal antibody raised against purified rat liver
11B-OHSD [Monder and Lakshmi, 1990], indicated that it was sited in proximal
tubules [Edwards et al., 1988]. By contrast mineralocorticoid receptors are
predominantly expressed in the distal nephron. This was confirmed by Rundle and
colleagues using the same antiserum and also a monoclonal antibody raised against
the mineralocorticoid receptor [Rundle et al., 1989] and by Castello and colleagues
using a monoclonal antibody to the enzyme [Castello et al., 1989]. The inference was
drawn that enzyme-mediated protection of the mineralocorticoid receptor was a
"paracrine" mechanism whereby conversion of Cortisol to cortisone occurs in one cell
and protects mineralocorticoid receptors in another cell.
More recent studies using in situ hybridisation indicate that mRNA for 11B-OHSD is
expressed in both proximal and distal renal tubular cells [Stewart et al., 1991; Yau et
al., 1991]. This was confirmed by measurement of in vitro conversion of
corticosterone to 11-dehydrocorticosterone when proximal and distal tubules were
separated, either on a density gradient [Edwards et al., 1988], by culture of purified
cortical collecting duct cells [Naray-Fejes-Toth et al., 1991], or by microdissection in
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rabbit [Bonvalet et al., 1990] and mouse [Bonvalet et al., 1991]. These showed 11B-
DH activity along the length of the nephron which was greatest at sites of highest
mineralocorticoid receptor expression. Therefore, enzyme-mediated receptor
protection is likely to be an "autocrine" mechanism whereby 11B-DH and
mineralocorticoid receptors are present in the same cell.
Tissue-Specific Isoforms of 11B-OHSD in Kidney
In addition to the discrepancy between immunohistochemical and in situ hybridisation
distribution of the enzyme, a variety of kinetic, immunological and molecular
evidence suggests that 11B-OHSD may be expressed in more than one form, and that
the isoform which protects renal mineralocorticoid receptors may differ from that in
tissues which are not target sites for aldosterone (Table 1.2). Carl Monder raised two
antisera to the purified liver enzyme and performed Western blots which showed
different sizes of immunoreactive proteins in different tissues [Monder & Lakshmi,
1990]. The first antiserum (56-125) identified a 34 kD protein in liver, and additional
species of 40 kD in kidney, 26 kD in brain, and 47 kD in testis. The second
antiserum (56-126) identified the 34 kD protein in all tissues and additional 68 kD
proteins in liver and kidney (possibly a dimer) and again a 40 kD protein in kidney.
Using the purified rat liver 11B-OHSD, an 11B-OHSD cDNA was cloned from a liver
cDNA library [Agarwal et al., 1989]. This predicts the amino acid sequence of a
protein of 31 kD, but when the cDNA was expressed in vitro the resulting 34 kD
protein was reduced to 31 kD when de-glycosylated with tunicamycin [Agarwal et al.,
1990]. Interestingly this de-glycosylation altered the relative activities of 11B-DH and
11B-OR in the expressed protein.
Experiments examining the cofactor preference of 11B-DH for NADP or NAD also
suggest different isoforms in the distal renal tubule. The reduction of tetrazolium to
diformazan blue in tissue slices depends on NADPH or NADH generated by 11B-
DH. Blue staining only occurred in distal tubules supplied with NAD rather than
NADP [Mercer & Krozowski, 1992], Tissue-specific cofactor specificity is
addressed in detail in Chapter 2. It may contribute to the differences in equilibrium
between 11B-DH and 11B-OR activity in kidney compared with liver described above.
The rat liver cDNA clone has been used as a probe to study 11B-OHSD expression in
various rat tissues. On Northern blots it cross-hybridised to a single species of
mRNA (-1.7 kb) in most sites, except in kidney where at least three other species
were detected (1.5 kb, 1.6 kb, and 1.9 kb)[Rrozowski et al., 1990], and in colon
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where a mRNA of 3.4 kb was found [Whorwood et al., 1992]. More recently cDNA
clones have been isolated from a rat kidney library which differ from the liver cDNA
clone in their 5' extremity [Krozowski et al., 1992]. One of these has been
sequenced and shows an identical open reading frame to the liver cDNA downstream
from amino acid Met 27. Interestingly, the amino acid sequence upstream from Met
27 is very hydrophobic and contains a putative signal peptide for membrane insertion.
Data from our department, derived from cloning of the 11B-OHSD rat gene, shows
that two isoforms (with and without signal sequence) are generated by alternative
promoters and start sites from a single gene [Moisan et al., 1992b]. It remains to be
seen whether probes from the two renal isoforms will show differential distribution
within rat kidney by in situ hybridisation, and whether different isoforms of 116-
OHSD are concentrated in different sub-cellular fractions.
Table 1.2 Tissue-specific heterogeneity of 116-OHSD
Enzyme species on Western blots * mRNA species on
Northern blots t
(kD mol wt) (size in nucleotides)
Antiserum 56-125 Antiserum 56-126
Liver 34 34 1700
68




Brain 26 34 1700




* Performed with rabbit antisera raised against purified rat liver 11B-OHSD (Monder
& Lakshmi, 1990)
f Performed with cRNA probes transcribed from cDNA encoding rat liver 116-
OHSD (Krozowski et al., 1990; and for colon, Whorwood et al., 1992)
14
Recently, a human cDNA clone derived from a testis library has been isolated, and the
human 11G-OHSD gene on chromosome 1 has been partially sequenced [Tannin et
al., 1991]. Surprisingly, only one mRNA species was detected in human kidney
using this cDNA as a probe. However, in sheep kidney heterogeneity of 11B-OHSD
mRNA has been observed [Yang et al., 1991].
It is possible that tissue-specific 11G-OHSD isoforms are expressed from a second
11B-OHSD gene. The mechanism whereby 11G-OHSD dictates tissue sensitivity to
Cortisol is analogous to the role of 5a-reductase in dictating sensitivity to testosterone
[Fraser, 1990]. Recently, a second gene for 5a-reductase has been cloned
[Andersson et al., 1991]. It codes for a second enzyme which differs from the first in
its tissue distribution, kinetics, and sensitivity to finasteride inhibition. Furthermore,
it is a defect in the second gene which accounts for male pseudohermaphroditism.
Paradoxes in the Influence of 11B-OHSD on Tubular Electrolyte Transport
The presence of immunoreactive 11B-OHSD in proximal tubules suggests that, in
addition to its autocrine role in the distal renal tubule, the enzyme may have other
roles in the kidney. Since mineralocorticoid receptors are not expressed in proximal
tubules [Bonvalet et al., 1991] this raises the possibility that local metabolism dictates
glucocorticoid activation of proximal type 2 receptors. Our information about the
influence of 11G-OHSD comes mainly from studies of the effects of liquorice and
carbenoxolone. Interestingly, there are differences between the renal effects of these
two agents (Table 1.3).
A metabolic balance study in man confirmed that carbenoxolone induces
antinatriuresis associated with prolonged half life of (1 la3H)-cortisol, increased
urinary free Cortisol excretion and reduced Cortisol production rates [Stewart et al.,
1990], Furthermore, carbenoxolone had previously been shown to provoke
excessive activation of colonic mineralocorticoid receptors as judged by increased
mucosal subtraction potential difference [Tomkins & Edmonds, 1975]. However,
carbenoxolone did not reduce levels of plasma cortisone and did not increase the
urinary (THF + allo-THF)/THE ratio. In addition, although plasma potassium fell
there was no kaliuresis with carbenoxolone [Stewart et al., 1990]. Others have
shown this before and excluded increased gastrointestinal potassium loss as the cause
[Baron et al., 1969]. This difference has not been clarified by studies in rats since
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[Souness & Morris, 1989]. In rats the kaliuresis is predominantly mineralocorticoid
receptor-mediated since it could be blocked in large part by a type 1 receptor
antagonist RU 28318 [Souness & Morris, 1991a] and not by a type 2 antagonist
RU38486 [Funder et al„ 1990],
In clinical practice we regard kaliuresis as an index of type 1 receptor activation
[Conn, 1955], and might conclude from the absence of kaliuresis in man that
carbenoxolone does not cause increased exposure of mineralocorticoid receptors to
Cortisol. It might therefore act by increasing exposure of glucocorticoid receptors.
However, this view is probably simplistic.
The type 1 receptor is distributed in distal convoluted tubule, connecting tubule and
collecting duct and mediates both sodium retention and kaliuresis [Fanestil & Park,
1981; Marver, 1984]. However, the effects on sodium and potassium may not be
mediated by the same mechanism. For example, it is paradoxical that actinomycin D,
an inhibitor of protein synthesis, blocked the antinatriuretic effect of aldosterone
without affecting its kaliuretic effect [Fanestil & Park, 1981], and type 1 receptor
antagonists have been shown to have a disproportionate effect on antinatriuresis
compared with kaliuresis [Mills et al., 1962], This might explain why up to 30 % of
patients with Conn's syndrome are normokalaemic [Bravo et al., 1982],
The type 2 receptor is more widely distributed along the nephron and has a less
clearly characterised role in which increased glomerular filtration rate and
antinatriuresis are most prominent [Fanestil & Park, 1981; Marver, 1984], However,
observations in vivo suggest that glucocorticoids exert both antinatriuretic and
kaliuretic effects [Johnson et al., 1982; Campen et al., 1983; Whitworth et al., 1984;
Connell et al., 1987b] and that only the kaliuretic effect can be prevented by type 2
antagonists [Clore et al., 1988; Montrella-Waybill et al., 1991]. By contrast, the
antinatriuresis can be prevented by type 1 antagonists [Mills et al., 1962; Clore et al.,
1988].
Moreover, there appears to be promiscuity between mineralocorticoid and
glucocorticoid receptors not only in their ligand binding, but also in their activation of
some steroid response elements. Thus pure type 2 receptor agonists can induce
mineralocorticoid effects in the distal tubule [Naray-Fejes-Toth & Fejes-Toth, 1990].
There are also interactions between type 1 and type 2 agonists, such that type 2
activation may impair the response to aldosterone [Kenyon et al., 1984],
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Thus, kaliuresis is far from a sine qua non of type 1 receptor activation; it remains to
be established whether carbenoxolone-induced antinatriuresis in man is mediated by
activation of a receptor other than the mineralocorticoid receptor; and it remains
speculative that 11B-OHSD has a role in regulating access of Cortisol to type 2
receptors in the kidney.
There are numerous potential explanations for the discrepancies between liquorice and
carbenoxolone in man. Both compounds have a number of biochemical effects which
are not related to 11B-OHSD inhibition [Monder, 1991b]. These include inhibition of
prostaglandin synthesis [Baker & Fanestil, 1991], alterations in hepatic aldosterone
metabolism [Latif et al., 1990], direct effects on Na/K transport [Baron & Green,
1986], and potentiation of the effects of steroids not subject to 11B-OHSD
metabolism (eg aldosterone, 11-deoxycorticosterone, and pure synthetic
glucocorticoid agonists)[Morris & Souness, 1990; Funder et al., 1990]. However,
the level of plasma GE attained in the metabolic balance studies was not high enough
to cause most of these effects [ Stewart et al., 1987; Teelucksingh et al., 1991].
Of greater interest is the observation that carbenoxolone has no effect on the ratio of
Cortisol to cortisone in plasma or of their metabolites in urine. This is explicable by
the hypothesis that in man (but not in rats [Monder et al., 1989]) carbenoxolone
inhibits both 11B-DH and 11B-OR activities of 11B-OHSD. This was confirmed by
measuring the accumulation of systemic plasma Cortisol after oral administration of
cortisone, which was reduced after carbenoxolone. By contrast conversion of
cortisone to Cortisol was not affected by liquorice (author's unpublished data).
Carbenoxolone may thus reduce cortisol/cortisone turnover rate without causing a net
change in cortisol/cortisone ratios [Stewart et al., 1990]. One might think that
absence of net effect on cortisol/cortisone ratio would prevent carbenoxolone from
influencing mineralocorticoid receptor activation. However, because 11B-DH
predominates over 116-OR in the kidney (see "Biochemistry and Distribution" above)
carbenoxolone would increase intra-renal Cortisol concentrations. Conversely, in
liver inhibition of predominantly 11B-OR activity would reduce intra-hepatic Cortisol
concentrations. The net effect would be no change in circulating or urinary levels.
It is tempting to suggest that the inhibition of 11B-OR by carbenoxolone accounts for
the difference in the effects of carbenoxolone and liquorice on urinary potassium
excretion. Isolated deficiency of the conversion of cortisone to Cortisol has been
reported in 3 female patients, 2 of whom were sisters [Taylor et al., 1984; Phillipou
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& Higgins, 1985]. In this syndrome the ratio of cortisone to Cortisol was elevated
and there was ACTH-dependent stimulation of adrenal androgens resulting in
hirsutism. Blood pressure and electrolytes were normal. Thus loss of 11B-OR alone
probably has no effect in the kidney. Perhaps of more relevance is the possibility that
inhibition of 11B-OR by carbenoxolone is a marker for differential inhibition of 116-
OHSD isoforms by liquorice and carbenoxolone. This may explain the difference in
potassium excretion if the isoforms were localised in different parts of the tubule
where increased corticosteroid receptor activation might have different effects. At the
time of writing no-one has been able to demonstrate differences in the inhibitory
activity of carbenoxolone and GE in different regions of the nephron.
Regulation of Renal 11B-OHSD
Despite the extensive literature reporting in vitro measurements of 11B-OHSD activity
in many organs there is relatively little information about the factors which might
regulate activity, particularly in the kidney. A number of competitive inhibitors of the
enzyme have been identified, including endogenous progestogens [Murphy, 1981a],
bile acids [Perschel et al., 1991] and several synthetic steroids [Monder &
Shackleton, 1984; Buhler et al., 1991](Table 1.4). In cultured fetal lung cells and
human skin fibroblasts 11B-DH activity could be induced by glucocorticoids [Smith et
al., 1973; Hammami & Siiteri, 1991] but this was not reproduced in the whole animal
[Lugg & Nicholas, 1978]. In liver of intact rats 116-DH activity was increased by
thyroxine [Koerner & Hellman, 1964] and testosterone [Lax et al., 1978] while
oestrogen inhibited it [Lax et al., 1978]. However, in intact baboon placenta
oestrogens increased 11B-DH activity [Baggia et al., 1990]. In keeping with the
possibility that a different isoform is responsible for 11B-DH activity in the kidney, its
regulation is not consistent with that in other sites. For example, it varies in a
different pattern during ontogeny in early life [Moisan et al., 1992b], and may be
increased by oestrogens [Smith & Funder, 1991]. Cloning of the rat 11B-OHSD
gene has identified consensus sequences of response elements for glucocorticoid,
thyroid, and oestrogen receptors and for cAMP [Moisan et al., 1992a].
Studies of the regulation of 11B-OHSD activity in man are hampered by confusion
about whether the activity being measured is in kidney or liver. There is good
evidence that hypothyroidism is associated with reduced 116-DH activity (see below).
ACTH may have an extra-adrenal effect to reduce the conversion of Cortisol to
cortisone [Kornel, 1970]. However, it remains to be seen whether the renal enzyme
represents a fixed barrier to cortisol/corticosterone, or whether it might be subject to
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Table 1.4 Inhibitors of 11B-OHSD
Exogenous Endogenous






physiological regulation. This possibility is addressed further in the rat in Chapter 2
and in man in Chapter 4.
The Physiological Role of Extra-Renal 11B-OHSD
Initially it seemed that only tissues with aldosterone selective mineralocorticoid
receptors express 11B-OHSD, and that the non-selectivity of the mineralocorticoid
receptor in heart and hippocampus could be explained by lack of the enzyme in these
tissues [Edwards et al., 1988]. Thus, bioactivity of 118-DH was not demonstrated in
vitro in initial studies with heart or hippocampus, but there was easily demonstrable
activity in specific mineralocorticoid receptor target organs such as salivary gland and
kidney. However, recently 118-DH bioactivity has been demonstrated in the
hippocampus when the in vitro reaction is driven in favour of the conversion of
corticosterone to 11-dehydrocorticosterone by addition of cofactor NADP [Moisan et
al., 1990b], In addition the enzyme has long been known to be present in tissues
which are not thought to be aldosterone targets or to contain mineralocorticoid
receptors, many of which have high expression of glucocorticoid receptors (Table
1.1). To explain the presence of 11B-OHSD in these tissues we need to expand our
hypothesis for the modulatory role of enzyme-mediated receptor protection.
The association of 11B-OHSD with glucocorticoid receptors raises the possibility that
11B-OHSD modulates access of Cortisol to these receptors in many tissues. Dr Paul
Teelucksingh first addressed this possibility in this department by employing the skin
vasoconstrictor assay, a bioassay previously used to compare the potency of topical
synthetic glucocorticoid preparations [McKenzie, 1962a; McKenzie & Stoughton,
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1962b]. Cutaneous vasoconstriction has been shown to be a glucocorticoid receptor
mediated response since it can be prevented by topical [Marks et al., 1982] or
systemic [Gaillard et al., 1985] glucocorticoid receptor antagonists, and Paul
confirmed that it was still present in a child with pseudohypoaldosteronism
(congenital deficiency of mineralocorticoid receptors). To determine whether 11B-DH
might control the amount of Cortisol reaching skin glucocorticoid receptors he carried
out a series of studies using this bioassay system. When hydrocortisone (= Cortisol)
was applied to the forearm overnight under an occlusive dressing, there was minimal
vasoconstriction. However, when GE was added to inhibit 11B-DH there was
marked potentiation of the response [Teelucksingh et ah, 1990]. He confirmed with
immunohistochemistry in human skin and in vitro studies of nude mouse skin that
11B-OHSD is present in the basal epidermal layers [Teelucksingh et ah, 1990],
though it is uncertain what physiological role it plays there. This avenue of
investigation has revealed the potential therapeutic benefit of 11B-DH inhibition in
targeting the local actions of hydrocortisone. It also offers an explanation for the anti¬
inflammatory properties of topical GE [Adamson & Tillman, 1955] and
carbenoxolone [Csonka & Murray, 1971], properties which are absent in
adrenalectomised animals [Khan & Sullivan, 1967].
Further evidence that 11B-OHSD modulates access of corticosteroids to
glucocorticoid receptors comes from a recent study of the effects of corticosteroids on
the Na/K ATPase a subunit in rat colon [Fuller & Verity, 1990], It was shown that a
glucocorticoid-specific induction of expression of Na/K ATPase could be reproduced
by the administration of carbenoxolone, but only in animals with intact adrenals.
In the central nervous system our group and others have described wide distribution
of 11B-OHSD bioactivity, immunoreactivity and mRNA [Moisan et al., 1990b;
Monder & Lakshmi, 1990; Lakshmi et al., 1991; Sakai et al., 1992] with very high
expression in the cerebellum which also has a high concentration of glucocorticoid
receptors [Moisan et al., 1990a]. Dr Jonathan Seckl recently showed that cerebral
glucose uptake is influenced by GE administration [Seckl et al., 1991] and that intra-
cerebroventricular GE affects the binding of 3H-corticosterone in the rat brain
(personal communication).
11B-OHSD is also very active in Leydig cells in the testis. It is known that Cortisol
inhibits testosterone production in the rat and the observation that 11B-OHSD
expression suddenly increases in the testes of rats as they reach puberty [Phillips et
al., 1989] raises the possibility that it plays a role in protecting the adult testis from
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excess Cortisol exposure. This is confirmed by recent studies showing that
carbenoxolone potentiates corticosterone-dependent inhibition of LH-induced
testosterone release in isolated Leydig cells [Monder et al., 1991a]. A similar
temporal relationship between 11B-DH activity and function has also been observed in
breast tissue [Quirk et al., 1990],
Finally, the potential significance of placental 118-OHSD in dictating glucocorticoid
exposure of the foetus, originally suggested by Murphy and others (see above), has
been highlighted by more recent work. Epidemiological data suggest that individuals
with low birth weight and high placental weight are more likely to suffer
cardiovascular disease in later life [Barker et al., 1990]. It is possible that
glucocorticoid exposure is responsible for this pattern, since administration of
glucocorticoids in pregnancy is associated with small babies [Reinisch et al., 1978],
large placentae [Gunberg et al., 1957], and hypertension in the offspring [Lindsay et
al., 1992], Moreover, 11B-DH activity is positivelycorrelated with birth weight and
inversely correlated with placental size [Benediktsson et al., 1992]. Further work is
in progress in rats to assess whether inhibition of 11B-DH in pregnant rats will
produce large placentae and low-birth-weight offspring who develop hypertension as
adults.
Given the wide distribution of its physiological roles, the action of 11B-OHSD should
now be integrated into an up-dated model of factors dictating Cortisol sensitivity in
each cell, which must also take account of other recent observations. In addition to
classical cytosolic steroid receptor activation, it has been suspected that steroids,
which are lipid-soluble, interact with cell membranes as they pass through [McEwan,
1991]. This possibility has now crystalised in the recent identification of binding
sites in cell membranes for both corticosterone [Orchinik et al., 1991] and aldosterone
[Wehling et al., 1991]. These receptors are thought to mediate their effects
independently of gene transcription. In addition, the hypothesis [Stephenson et al.,
1984] that CBG is involved in dictating cellular sensitivity to Cortisol should not be
abandoned, since it was recently observed that activated neutrophils release elastase
which promotes local dissociation of Cortisol from CBG and increases glucocorticoid
exposure of the neutrophil [Hammond et al., 1990]. A suggested model for the
determinants of cellular sensitivity to Cortisol is represented in Figure 1.5.
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A = steroid binding domain; B = DNA binding domain; C = immunomodulatory
domain; CBG = Cortisol binding globulin; E = cortisone; F = Cortisol; G = guanine
nucleotide binding protein; hsp = heat shock protein; R = cell surface receptor.
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The model of enzyme-mediated receptor protection has parallels in the target organ
activity of several other hormones. For most of these local metabolism confers an
increased potency on the circulating hormone, contrasting with the protection
observed with 11B-DH. They include the role of 5'-monodeiodinase in converting
thyroxine to tri-iodothyronine [Berry et al., 1991], the role of 5a-reductase in
converting testosterone to dihydrotestosterone [Andersson et al., 1991], the role of
1713-hydroxysteroid dehydrogenase in the conversion of oestrone to oestradiol
[Stewart & Sheppard, 1992], and the role of aromatase in converting androgens to
oestrogens within breast tissue [Aitken et al., 1992]. It seems that for every member
of the steroid receptor superfamily there may be a role for local metabolism in
determining local ligand concentrations.
Until now it has been possible to test the hypothesis that 11B-DH "protects" receptors
from excessive exposure to active glucocorticoid by examining the effects of 11B-DH
inhibitors. However, there is an alternative role for the enzyme analogous to the role
of other "shuttle" systems. While 11B-DH protects some receptors by inactivation of
Cortisol to cortisone (eg mineralocorticoid receptors in kidney and glucocorticoid
receptors in skin), in other sites 11B-OR may amplify the exposure of relatively low
affinity glucocorticoid receptors by activation of cortisone to Cortisol. This might
apply in tissues which apparently favour 11B-OR activity, eg liver. This hypothesis
probably explains the apparent effects of the inactive metabolite 11-
dehydrocorticosterone in toad bladder cells transfected with rat liver 11B-OHSD
(Bernard Rossier, personal communication) and in intact rat kidney [Souness &
Morris, 1991b] when carbenoxolone is present and the 11B-OHSD equilibrium
favours the active steroid.
11B-OHSD and Blood Pressure Control
One of the most exciting implications of the work in 11B-OHSD deficiency is the
possibility that a similar defect contributes to hypertension in more common clinical
syndromes. It is most obvious to seek this association in syndromes where increased
activation of mineralocorticoid receptors occurs and might be attributed to Cortisol.
However, this is not the only mechanism by which Cortisol may induce hypertension,
nor the only route by which 11B-DH deficiency may exacerbate it.
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Extra-Renal Mechanisms for Cortisol-Induced Hypertension
Despite the fact that Gashing's syndrome is the oldest recognised cause of secondary
hypertension, and that the incidence of hypertension in spontaneous Cushing's
syndrome may be anything from 50 to 87% [Plotz et al., 1952; Ross & Linch, 1982;
Howlett et al., 1986], the mechanisms whereby Cortisol raises blood pressure remain
poorly understood [Saruta et al., 1986; Fraser et al., 1989]. It has proved hard to
identify both the receptors involved and the sites of action of the steroid.
It is clear that type 1 receptor activation can raise blood pressure [Nicholls et al.,
1979; Fraser & Padfield, 1985] and that some of the effects of Cortisol may reflect
spill-over onto these receptors. However, hypertension also occurs after synthetic
type 2 receptor agonists when it can be blocked by type 2 receptor antagonists
[Grunfeld et al., 1985; Nieman et al., 1985] but not by type 1 antagonists [Grunfeld
et al., 1985; Gomez-Sanchez & Gomez-Sanchez, 1991]. Furthermore, only 10% of
patients with Cushing's syndrome not due to ectopic ACTH secretion have
hypokalaemic alkalosis [Saruta et al., 1986; Howlett et al., 1986], which is a feature
in at least 70 % of those with primary adrenal adenomas producing aldosterone
[Bravo et al., 1982], Thus type 2 receptor activation can also contribute to raised
blood pressure. It is also possible that some hypertensinogenic effects are mediated
by non-classical steroid receptors. These have been proposed to explain the complex
cocktail of steroids required to reproduce ACTH-dependent hypertension in sheep
[Scoggins et al., 1989].
In attempting to identify the hypertensinogenic site of action of glucocorticoids most
attention has focussed on the effect of Cortisol on sodium retention in the kidney.
However, this does not appear to account for all the effects of glucocorticoids on
blood pressure. In the rat dexamethasone-induced hypertension is accompanied by a
fall in plasma volume [Tonolo et al., 1988] and in man Cushing's syndrome is not
associated with dramatic suppression of the renin-angiotensin-aldosterone axis
[Ritchie et al., 1990]. Moreover, in man ACTH-dependent hypertension [Whitworth
et al., 1983], which can be reproduced by Cortisol [Connell et al., 1987b], is sodium-
modified but not sodium-dependent [Whitworth et al., 1985; Connell et al., 1988]. It
is associated with only a modest kaliuresis and plasma volume expansion [Connell et
al., 1987b]. Several pieces of evidence suggest that actions of Cortisol outside the
kidney may be equally important. Some of these actions may be influenced by 118-
OHSD activity.
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A hypertensinogenic action of Cortisol in the liver was suggested after the
measurement of low plasma renin activity but elevated renin substrate
(angiotensinogen derived from liver) in glucocorticoid excess, from which it was
inferred that bioactive angiotensin II might be elevated and cause vasoconstriction
[Krakoff et al., 1975]. However, with accurate measurement of angiotensin II it has
become clear that it is not elevated [Connell et al., 1987b; 1988], and that this hepatic
effect of glucocorticoids is unlikely to be a significant factor in hypertension.
In the central nervous system corticosteroid receptors are widely distributed and may
mediate elevations in blood pressure. However, in rats the intra-cerebroventricular
administration of corticosterone tends to lower blood pressure while that of
aldosterone raises it [Gomez-Sanchez, 1986; van den Berg et al., 1990]. For
glucocorticoid excess to raise blood pressure therefore might require binding to non-
classical glucocorticoid receptors. As described above 116-OHSD is widely
distributed in brain. Elise Gomez-Sanchez recently reported that the elevation in
blood pressure in rats given systemic carbenoxolone can be attenuated by
simultaneous intra-cerebroventricular administration of a type 1 receptor antagonist,
RU28318 [Gomez-Sanchez & Gomez-Sanchez, 1991]. This suggests that activation
of mineralocorticoid receptors in brain contributes to the hypertension of 11B-DH
inhibition. Having said that, it remains almost impossible to determine whether
defective 11B-OHSD in the central nervous system contributes to elevated blood
pressure in man.
Some of the pressor effect of Cortisol may be mediated by an increased cardiac
output. Glucocorticoid [Funder et al., 1973c; Seleznev et al., 1978] and
mineralocorticoid [Arriza et al., 1987; Funder et al., 1988; Barnett & Pritchett, 1988]
receptors have been reported in cardiac muscle. Glucocorticoid-specific modulation
of protein synthesis occurs in cardiac cell culture [Fukada, 1980; Nichols et al.,
1984b], and mineralocorticoid-specific modulation of RNA polymerase has been
demonstrated in isolated cardiac nuclei [Liew et al., 1972], Increased cardiac output
has been demonstrated in corticosteroid excess [Sudhir et al., 1989] and positive
inotropic effects of both glucocorticoids and mineralocorticoids have been observed
[Sayers & Solomon, 1960; Tanz, 1962], possibly mediated by catecholamines
[Cornish et al., 1978]. In addition, mineralocorticoid receptor activation in cardiac
fibroblasts may promote myocardial fibrosis [Weber & Brilla, 1991], However, in
the original studies of 11B-OHSD distribution the presence of the enzyme in heart
was not recognised [Edwards et al., 1988].
26
Finally, some of the hypertensinogenic effect of Cortisol may be mediated by actions
on vascular smooth muscle cells which determine peripheral vascular resistance. This
area is particularly exciting given Paul Teelucksingh's demonstration with the skin
vasoconstrictor assay that inhibition of 118-DH potentiated the effect of Cortisol on
dermal blood vessels [Teelucksingh et al., 1990](see above). 116-DH activity has
been demonstrated in vascular tissue of both rabbit [Kornel et al., 1982] and rat
[Funder et al., 1989], and in the latter it has been suggested that the distribution of
activity matches the distribution of aldosterone specific corticosteroid receptor binding
by the mesenteric vascular bed [Funder et al., 1989],
Clinical Relevance of 11B-OHSD
In addition to its potential relevance in the pathogenesis of mineralocorticoid
hypertension, the appreciation of the diverse potential roles of the enzyme outside the
distal nephron implies that deficiency of 11B-OHSD may be significant in any number
of disorders which are associated with "too little" or "too much" local glucocorticoid.
Moreover, by inhibiting 11B-DH we may be able to target local glucocorticoid
without incurring systemic effects. In this thesis I limit the discussion to
consideration of the relevance of 11B-OHSD deficiency to hypertension. For a
consideration of other potential applications of these principles see Walker &
Edwards [1992],
One might suggest that 11B-OHSD could be relevant in any hypertensive syndrome,
but in a handful there are particular reasons to suspect that it has a role.
The Syndrome of Apparent Mineralocorticoid Excess "Type 2"
Ulick and colleagues recently reported a "syndrome of apparent mineralocorticoid
excess type 2" in 4 patients with low-aldosterone, low-DOC mineralocorticoid excess
exacerbated by ACTH and improved by dexamethasone [Ulick et al., 1990; 1992a;
Tedde et al., 1992]. In these patients the total Cortisol metabolites in urine are reduced
but the ratios of (THF + allo-THF):THE and allo-THF:THF are normal. In this
respect the type 2 syndrome is similar to that seen after carbenoxolone and may be
caused by congenital deficiency of 118-DH in kidney and 11B-OR elsewhere. In
addition, these patients exhibit deficient A-ring reduction of Cortisol [Ulick et al.,
1992a]. However, two key experiments have yet to be reported in type 2 patients: (i)
confirmation that Cortisol is the unidentified ACTH-dependent mineralocorticoid by
observing the effects of exogenous Cortisol on renal sodium and potassium handling;
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and (ii) measurement of (1 la3H)-cortisol half life, the most sensitive index of 116-
DH activity. Without these experiments it remains uncertain whether the findings in
the type 2 syndrome are explained by: (i) combined deficiency of 116-DH and 116-
OR, as with carbenoxolone; (ii) deficient A-ring reduction as an alternative failure of
normal Cortisol clearance in the kidney; or (iii) the presence of another unidentified
ACTH-dependent mineralocorticoid.
Hypothyroidism
Hypothyroidism is a reversible cause of hypertension [Streeten et al., 1988]. It is
well-documented that in man hypothyroidism is associated with inhibition of 116-
DH, with elevation of (THF+allo-THF):THE ratio [Hellman et al., 1961] and
prolongation of the half life of (1 la3H)-cortisol [Zumoff et al., 1983]. 116-OR is
also inhibited but to a lesser extent [Ichikawa et al., 1977; Zumoff et al., 1983]. The
mechanism of hypothyroid hypertension is disputed. Although suppression of
plasma renin activity and aldosterone occurs [Elias et al., 1986] its relevance to
pathogenesis has been questioned [Waters, 1978; Richards et al., 1985]. If excessive
mineralocorticoid receptor activation does occur then it appears to be limited to the
kidney, since colonic potential difference did not suggest mineralocorticoid excess
[Elias et al., 1986]. Evidence that hypothyroid hypertension is cortisol-dependent
has yet to be reported.
Alcohol Abuse
Alcoholism is another reversible risk factor for hypertension [Saunders et al., 1981].
A study performed in Stockholm showed evidence of impaired 116-OHSD activity in
alcoholic patients, as shown by increased THF:THE ratio [Cronholm et al., 1985].
However, studies performed in Edinburgh in patients withdrawing from alcohol
failed to demonstrate such an abnormality [Edwards & Stewart, 1989]. Alcohol
inhibits 116-OHSD in vitro but when administered to rats in vivo does not appear to
affect the enzyme (Paul Stewart, personal communication).
Renal Failure
As renal function deteriorates plasma cortisone levels fall, irrespective of the cause of
renal failure [Whitworth et al., 1989b]. This suggests that 116-DH is destroyed,
most likely because of non-specific attrition of cells containing the enzyme. When
early work suggested that the enzyme was sited in proximal tubules and played a
paracrine role in the protection of mineralocorticoid receptors in the distal nephron
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Stewart and Edwards suggested that loss of 11B-DH might proceed independently of
loss of mineralocorticoid receptor target cells. This mechanism could leave
mineralocorticoid receptors unprotected from Cortisol and contribute to the sodium
retention and hypertension of renal failure. On arriving in the department I performed
some experiments not included in this thesis in which I examined the effect of
dexamethasone on Na/K balance in patients with renal failure. It was disappointing
to find an antinatriuresis, such as has been observed previously with glucocorticoids
[Clore et al., 1988], rather than the natriuresis seen in congenital 11B-DH deficiency
[Werder et al., 1974; Shackleton et al., 1980; Stewart et al., 1988b; Tedde et al.,
1992] and after liquorice [Hoefnagels & Kloppenborg, 1983]. Since then it has
emerged that an autocrine rather than paracrine relationship exists between 11B-DH
and renal mineralocorticoid receptors (see above) and therefore loss of 11B-DH
independent of loss of mineralocorticoid receptors is unlikely in the context of the
non-specific cellular attrition which occurs in chronic renal failure.
ACTH-Dependent Hypertension
A putative regulator of 11B-OHSD activity is ACTH, acting extra-adrenally.
Administration of ACTH to volunteers produced a rise in the cortisol/cortisone ratio
in plasma with virtually no increase in cortisone [Srivastava et al., 1973; MacKenzie
et al., 1990]. Given the large capacity of 11B-DH in kidney [Hellman et al., 1971] it
seems unlikely that this is due to saturation of the enzyme by increased substrate. A
fall in adrenal secretion of cortisone might be responsible [Srivastava et al., 1973;
Burt et al., 1991], but most likely is the hypothesis that peripheral conversion of
Cortisol to cortisone is decreased by ACTH. This is supported by studies in two
Addisonian patients given ACTH in whom the half life of Cortisol was prolonged and
that of cortisone reduced with a resultant rise in THF:THE ratio [Komel, 1970]. This
hypothesis is explored further in Chapter 4.
The highest levels of bioactive ACTH associated with increased Cortisol production
occur in the ectopic ACTH syndrome, in which hypertension and hypokalaemia are
much more common than in other forms of Cushing's syndrome [Howlett et al.,
1986]. ACTH-dependent inhibition of 11B-OHSD might explain this unusual feature
by allowing Cortisol to flood renal mineralocorticoid receptors. Experiments to test
this hypothesis are presented in Chapter 5.
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Essential Hypertension
By comparison with the majority of hypertensive patients who have "essential"
hypertension all other hypertensive syndromes are rare. As I discussed at the outset,
there is evidence that a sub-group of these patients have hypertension which is
dependent on ACTH secretion since it can be suppressed by dexamethasone
[Hamilton et al., 1979; Whitworth et al., 1989a]. Furthermore, a number of studies
have demonstrated abnormal metabolism of Cortisol in essential hypertensives
[Kornel et al., 1975], Defective enzyme-mediated receptor protection provides a
mechanism by which abnormal Cortisol metabolism could raise blood pressure
through over-exposure of corticosteroid receptors to Cortisol. This subject is
addressed in detail in Chapter 5.
30
Corticosteroids and Vascular Tone
The possible relevance of 11B-OHSD activity to the control of vascular tone in health
and in hypertension interested me from the outset of my work for this thesis. It
presented a number of testable hypotheses which tie in many of the themes discussed
above in relation to the kidney. It also proved to be more relevant to the role of 116-
OHSD deficiency in essential hypertension than we had first supposed (see Chapter
5). Interactions between corticosteroids and vascular tone have been the subject of
scant review in the literature and in the second section of the Introduction I will
present the evidence in detail, in justification of studies of the physiology of 116-
OHSD in vascular tissues presented in Chapter 2 (biochemistry and distribution of
vascular 116-OHSD) and Chapter 3 (116-OHSD and the control of vascular tone),
and to highlight the potential importance of the observations in human hypertensive
patients reported in Chapter 5.
Effects of corticosteroids on vascular tone have been recognised since the 1940s.
However, despite repeated demonstration of pharmacological effects both in vitro and
in vivo, their physiological significance as regulators of tone in health remains to be
established. Evidence that abnormal vascular reactivity is important when adrenal
steroid production is deranged is more convincing, and probably contributes to the
changes in blood pressure seen in conditions of corticosteroid excess and deficiency.
It remains speculative whether the same mechanisms contribute to the pathogenesis of
other hypertensive syndromes and of circulatory shock.
Recently the effects of corticosteroids have been studied in cultured vascular cells.
These studies exploit our improving understanding of the actions of steroid hormones
on their target cells, and better appreciation of the diversity of biochemical signals in
the vessel wall which mediate the response to vasoactive stimuli. They include
measurements of endothelium-derived factors (which act on neighbouring vascular
smooth muscle cells), contractile cell surface receptors, and intra-cellular second
messengers (released within the contractile cell in response to activation of surface
receptors). Such studies have shown a number of interactions between
corticosteroids and newly discovered biochemical messengers. In this section I will
assess whether our interpretation of the older evidence that steroids affect vascular
tone is influenced by recent studies of their cellular effects, and whether we can now
deduce the role of corticosteroids in vascular physiology and pathology. This
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represents the background on which vascular 11B-OHSD activity may play a
modulatory role.
Corticosteroid Receptors in Vascular Smooth Muscle
Binding sites with the characteristics of classical glucocorticoid and mineralocorticoid
receptors have been identified in vitro in homogenates of rabbit [Duval et al., 1977;
Kornel, 1981; Kornel et al., 1982; 1983] and bovine aorta [Hayashi & Kornel,
1990], and in cultured vascular smooth muscle cells from rat aorta [Meyer &
Nicholls, 1981] and human uterine artery [Scott et al., 1987], Recently the presence
of mineralocorticoid receptors in vascular smooth muscle was confirmed
immunohistochemically using an anti-idiotypic monoclonal antibody [Lombes et al.,
1990; 1991]. In vivo studies have shown binding of [3H]-aldosterone in major
vessels of dogs [Hollander et al., 1966] and in rat mesenteric artery [Funder et al.,
1989]. These binding sites seem to function as genomic promoters since induction of
glucocorticoid-responsive proteins has been demonstrated by 2-dimensional gel
electrophoresis in cultures of rat aortic vascular smooth muscle cells [Nichols et al.,
1983b; 1984a] and bovine aortic endothelial cells [Nichols et al., 1983a] exposed to a
variety of corticosteroids for 24 h. If the effects of corticosteroids on tone are
mediated by activation of classical receptors, they should conform to certain
characteristics. They typically have a time course from 20 min over several hours,
involve induction of expression of glucocorticoid-responsive genes, and can be
prevented by inhibitors of protein synthesis (eg actinomycin D or cycloheximide) or
by competitive receptor antagonists (eg RU38486 for glucocorticoid receptors and
spironolactone for mineralocorticoid receptors)[Gustafsson et al., 1987],
In addition, some effects of corticosteroids may be independent of classical receptors,
and of steroid response elements ("non-genomic" effects; see Figure 1.5). These
include interactions between the lipid-soluble steroids and cellular lipid bilayer
membranes, which induce effects over a faster time course than those resulting from
genomic induction. However, this mechanism is hard to confirm since specific
antagonists are not available, and it has not yet been examined in vascular- tissue.
Assuming an autocrine mechanism of 1 lB-DH-mediated receptor protection it is hard
to invoke a role for a microsomal enzyme in protecting cell surface receptors on the
same cell.
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Corticosteroid Effects on Vascular Tone
Corticosteroid Insufficiency
The earliest studies highlighting the potential role of corticosteroids in the control of
vascular tone examined vessel diameter in the exposed mesenteric vascular arcade of
anaesthetised rats. In this model adrenalectomy had a profound vasodilating effect
which could be restored by topical administration of adrenocortical extract [Fritz &
Levine, 1951; Zweifach et al., 1953]. Other investigators used the pressor response
to catecholamine infusion as an indicator of vasoconstrictor sensitivity, and showed
loss of pressor response to catecholamines after adrenalectomy in dogs [Goldstein et
al., 1950; Ramey et al., 1951]. Interpretation of these studies is limited because they
fail to account for the effect of glucocorticoids on cardiac output [Sayers & Solomon,
1960; Cornish et al., 1978] and because these animals also had excision of the
adrenal medullae. Persuasive evidence that the changes were attributable to
glucocorticoid deficiency came later with demonstration that the pressor response to
catecholamines was reduced in rats by administration of the specific glucocorticoid
receptor antagonist RU38486 [Grunfeld & Eloy, 1987], and that the effect of
adrenalectomy was reversed by replacement with the glucocorticoids dexamethasone
[Yagil & Krakoff, 1988] or corticosterone [Darlington et al., 1989] but not by
aldosterone [Yagil & Krakoff, 1988].
Studies of vascular response in humans with adrenal insufficiency are scarce because
of the need for immediate therapy. While the postural hypotension associated with
Addison's disease is in part attributable to depletion of intra-vascular volume, in
ACTH deficiency there is often a significant postural fall in blood pressure which is
independent of sodium balance and might be attributable to impaired vascular
responsiveness. Mineralocorticoids may also be involved in maintenance of tone in
man since administration of the mineralocorticoid receptor antagonist canrenoate led
to hypotension in man associated with reduced peripheral vascular resistance
[Yamakado et al., 1988].
Corticosteroid Excess
In Vitro Studies
A number of investigators have examined the effects of corticosteroids on isolated
vessels in organ baths, sometimes with contradictory results. Steroids were added to
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baths for short periods of up to 20 min. They had no direct effects when added alone
except in one study when a dose of budesonide of 10~3 M caused vasoconstriction
[Angelo-Khattar & Thulesius, 1983]. In aortae from rabbit [Fowler & Chou, 1961;
Kalsner, 1969b; 1969a; Koehler et al., 1979] and dog [Besse & Bass, 1966] 11-
deoxycorticosterone, corticosterone, and hydrocortisone at doses of 10~5 to 1(k7 M
potentiated the constrictor response to catecholamines but not to other agents such as
KC1, angiotensin II, or vasopressin. These findings are broadly in keeping with in
vivo observations described below. However, in doses of 10~4 M corticosteroids
caused inhibition of vasoconstriction to all of these agents [Altura & Altura, 1974;
Bengtsson, 1981; Angelo-Khattar & Thulesius, 1983]. A dose-dependent biphasic
effect was confirmed in vivo in studies of aorta and mesenteric artery in rats treated
with high and low doses of hydrocortisone and methylprednisolone [Altura &
Altura, 1974].
Interpretation of these in vitro studies is difficult. Firstly, the dose of steroid was
generally higher than would be achieved in vivo and inappropriate to the low Kd of
classical corticosteroid receptors or to the pM concentrations of steroids found in
clinical glucocorticoid excess. Secondly, the time course of the steroid effect
observed was often rapid, within seconds or minutes. It seems likely that the in vitro
results could comprise both classical receptor-mediated events and non-genomic
effects of steroids on cell membranes. Which of these responses are relevant in vivo
is hard to deduce. The major contribution of these studies has been to demonstrate
that effects of corticosteroids on vessels do occur, and that in vivo effects are
therefore not necessarily entirely dependent on secondary changes such as altered
renal sodium handling with suppression of angiotensin II production, or effects
mediated by steroid actions in the central nervous system.
In Vivo Studies
In Cushing's syndrome due to adrenal adenoma pressor responses to noradrenaline
and angiotensin II [Saruta et al., 1986] and digital vasoconstriction to noradrenaline
[Mendlowitz et al., 1958] were increased. Systemic administration of Cortisol or
ACTH to healthy volunteers mimicked these findings except that the response to
angiotensin II was not increased [Kurland & Freedberg, 1951; Whitworth et al.,
1986]. These effects preceded the rise in blood pressure but took several days to
develop [Sambhi et al., 1962], Evidence is available to suggest that they reflect
changes in vascular tone rather than intra-vascular volume or cardiac output. Firstly,
the increase in pressor response after oral Cortisol was independent of sodium intake
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[Connell et al., 1987a]. Secondly, brachial artery infusion of noradrenaline produced
a greater fall in forearm blood flow after oral Cortisol [Sudhir et al., 1989], and also
after dexamethasone, 11-deoxycorticosterone and fludrocortisone [Abboud, 1974],
Local administration of glucocorticoids to specific vascular beds in vivo also affects
tone. Infusion of hydrocortisone into the brachial artery had no direct effect on blood
flow in the hand but potentiated vasoconstriction in response to adrenaline [Ginsburg
& Duff, 1958]. Similarly, glucocorticoids cause vasoconstriction when applied to
human conjunctiva [Reis, 1960; Lepri & Cristiani, 1964] or skin [McKenzie &
Stoughton, 1962b; Teelucksingh et al., 1990].
Broadly similar observations have been reported in animal models. Systemic
dexamethasone administration to rats led to an increase in catecholamine
vasoconstriction in isolated perfused mesenteric artery [Russo et al., 1990], and
increased pressor responsiveness to noradrenaline [Schmid et al., 1967; Handa et al.,
1984]. Vasoconstriction has also been observed after local application of
glucocorticoids to vessels in rabbit ear [Ashton & Cook, 1952] and rat hind limb
[Schomig et al., 1976].
In contrast to the lack of evidence that mineralocorticoid insufficiency affects vascular
tone, mineralocorticoid excess has been associated with increased vascular reactivity.
This was demonstrated in experimental mineralocorticoid excess in man by increased
pressor responses [Raab et al., 1950; Chobanian et al., 1979; Distler et al., 1985] and
increased catecholamine sensitivity of forearm vessels [Schmid et al., 1966; Abboud,
1974], Similarly in animals sensitivity to catecholamines was increased in perfused
caudal artery in 11-deoxycorticosterone (DOC)/salt hypertensive rats [Beilin et al.,
1970], and in aortae excised from DOC/salt hypertensive rabbits [Kalsner et al.,
1971] or aldosterone hypertensive rats [Smith et al., 1987; Jones et al., 1988]. In
DOC/salt hypertension the change in vascular reactivity was shown to precede the
elevation of blood pressure [Berecek et al., 1980]. However, topical application or
infusion of mineralocorticoids had no effect on vascular tone.
Corticosteroid Effects on Vascular Biochemistry
In summary, both glucocorticoids and mineralocorticoids have pharmacological
effects which increase vascular tone. Furthermore, glucocorticoids but probably not
mineralocorticoids appear to be required for the maintenance of normal tone. These
effects are not direct, but rely on permissive potentiation of the response to
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catecholamines (particularly noradrenaline) and less consistently to other vasoactive
agents studied (eg angiotensin II or vasopressin). By what biochemical mechanisms
might these effects be mediated? In order to interact with other vasoactive hormones
corticosteroids might influence: a) their local production and/or metabolism; b) their
membrane receptors and post-receptor second messengers; or c) the final effector
mechanisms mediating contraction. Furthermore, these effects may occur in vascular
smooth muscle cells themselves, or in the vascular endothelium.
Some mechanisms of "second messenger" transmission from cell membrane receptor
to functional response in vascular smooth muscle are illustrated in Figure 1.6. Each
of these elements is a potential target for one of the diverse proteins induced by
corticosteroids.
Effects on Vascular Smooth Muscle Cells
Hormone Metabolism
The earliest hypothesis to explain the vascular- effects of corticosteroids was that they
interfere with catecholamine metabolism thus causing increased local catecholamine
concentrations. At high dose in vitro corticosteroids inhibited both extra-neuronal
reabsorption of noradrenaline [Iversen & Salt, 1970] and catechol-o-methyl
transferase metabolism [Kalsner, 1969a; 1969b]. However, in a number of studies
in vivo these effects could not be shown to be relevant [Kalsner et al., 1971; Schomig
et al., 1976; Esler et al., 1981; Sudhir et al., 1989].
In the late '70s and early '80s the importance of the prostaglandin family in vascular-
biology emerged. Glucocorticoids inhibit phospholipase A2 and thus reduce
production of the vasorelaxant eicosanoids prostaglandin Ei and prostacyclin
[Axelrod, 1983; Flower, 1988]. This action was invoked to explain the inhibition by
glucocorticoids of ACTH-induced vasodilatation in rabbit fat pads [Lewis & Piper,
1975] and may also indirectly explain changes in catecholamine sensitivity [Axelrod,
1983]. Glucocorticoid potentiation of catecholamine responses has been mimicked in
a number of models by the phospholipase A2/cyclo-oxygenase inhibitor
indomethacin. These include human skin [Bisgaard et al., 1986] and isolated
perfused rat hind limb, where the effect of corticosterone was reproduced by
indomethacin and abolished by excess arachidonic acid or prostacyclin [Rascher et
al., 1980]. The pressor response to noradrenaline in rats was potentiated by both
indomethacin and by 0.1 mg/day oral dexamethasone, which reduced urinary PGE2
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Figure 1.6 Potential biochemical signals in the vascular wall affected by
glucocorticoids IHI or mineralocorticoids E23.
A I = angiotensin I; A II = angiotensin II; AC = adenylate cyclase; ACE =
angiotensin converting enzyme; ANP = atrial natriuretic peptide; DA = dopamine;
DAG = diacylglycerol; ET = endothelin 1; G = guanine nucleotide binding protein;
GC = guanylate cyclase; NO = nitric oxide; PGEi = prostaglandin Ei; PGI2 =
prostacyclin; PKC = protein kinase C; PLC = phospholipase C; R = cell surface
receptor.
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excretion and attenuated the effect of indomethacin [Handa et al., 1984], Urinary
PGE2 was similarly reduced in patients with Cushing's syndrome [Saruta et al.,
1986]. However, other investigators have not been able to confirm a
pharmacological effect of glucocorticoids on vascular prostaglandin production in
vivo [Rogers et al., 1983]. Furthermore, when the dexamethasone given to rats was
reduced to a sub-pharmacological dose which was not associated with weight loss but
still increased blood pressure, ie 2 [tg/day sc [Tonolo et al., 1988], an increased
response to noradrenaline in the excised perfused mesenteric circulation was not
affected by indomethacin and was not associated with a change in prostacyclin
metabolites (6keto-PGFia) in the effluent perfusate [Russo et al., 1990]. Also, the
activation of adenylate cyclase by prostaglandin Ei, which usually produces
relaxation, was potentiated by dexamethasone in vascular smooth muscle cells
[Yasunari et al., 1988]. Thus involvement of prostaglandins remains unproven when
physiological concentrations of glucocorticoids are administered in vivo.
Receptors and Second Messengers
In membranes from rat aortae the number of a 1-adrenoceptors was decreased by
adrenalectomy and restored by dexamethasone replacement [Haigh & Jones, 1990b].
Similarly in cultured rat aortic vascular smooth muscle cells the number of 6-
adrenoceptor binding sites was increased by dexamethasone at concentrations
appropriate to physiology over 20 hours of incubation [Jazayeri & Meyer, 1988], In
addition to effects on receptor number, in the absence of glucocorticoid the coupling
of adrenoceptors to G-proteins was disturbed [Haigh & Jones, 1990b] and the ratio
of Gi to Gs subunits fell [Haigh et al., 1990a]. Functional significance of these
observations is suggested by studies in vascular smooth muscle cells which
confirmed that dexamethasone potentiated production of inositol triphosphate in
response to noradrenaline (an a 1-adrenoceptor effect)[Liu et al., 1990], and that
concomitant with the increase in 6 receptor number there was a greater cAMP
response to B agonists [Jazayeri & Meyer, 1988]. This latter effect was blocked by
cycloheximide and RU38486 suggesting that it is mediated through glucocorticoid
receptors. Similar effects on angiotensin II receptor number and second messenger
induction have been observed with aldosterone [Ullian et al., 1992], and
mineralocorticoid receptor antagonists also prevent effects of corticosteroids on
noradrenaline-induced inositol phosphate production [Haigh et al., 1991]. Relevance
of these studies to the intact animal is suggested by increased generation of inositol
monophosphate after incubation with noradrenaline by femoral artery tissue slices
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from DOC/salt hypertensive rats [Eid & de Champelan, 1988]. Interestingly, one
group described a direct effect of Cortisol alone to increase inositol triphosphate
concentrations in cultured cells. This was blocked by RU38486, and further
increased by noradrenaline [Steiner et al., 1988; 1989]. However, in most
laboratories direct effects of steroids on these second messengers have not been
observed.
Changes in adrenoceptor number and function are not the only relevant glucocorticoid
effects on second messenger systems. Glucocorticoids affect cAMP synthesis
induced by other stimuli in other tissues [Davies & Lefkowitz, 1984], The cAMP
responses to dopamine (DAi) [Yasunari et al., 1989] and prostaglandin Ei [Yasunari
et al., 1988] in cultured vascular smooth muscle cells from renal artery were
increased by dexamethasone. These effects were maximal at 24 h, occurred at
appropriate concentrations of dexamethasone but not aldosterone, and were inhibited
by actinomycin D and cycloheximide [Yasunari et al., 1988; 1989]. The response to
forskolin (direct activator of the catalytic unit of adenylate cyclase) was increased,
suggesting that the effect of glucocorticoid was not only post-receptor but post-G-
protein [Yasunari et al., 1988; 1989]. Phosphodiesterase inhibition was not
implicated since isobutylmethylxanthine did not interfere with the potentiation.
Increased cAMP would be expected to relax vessel tone, but in the same cells reduced
cGMP generation in response to atrial natriuretic peptide (ANP) after dexamethasone
provides a possible contractile effect [Yasunari et al., 1990]. Similar insensitivity to
ANP was seen in aortae from mineralocorticoid hypertensive rats [Otsuka et al.,
1988]. These observations together with the suppression of ANP production by
glucocorticoids in vivo [Kenyon et al., 1990] suggest that recently recognised
vasoactive agents may be highly significant in mediating corticosteroid effects.
Final Common Pathway ofContraction
Early studies to explain the effects of corticosteroids (particularly mineralocorticoids
because of the analogy with their effects on mucosal Na/K exchange) focussed on
changes in vascular electrolyte permeability. Chronic DOC administration to rabbits
was associated with increased Na influx into vascular smooth muscle cells [Kornel,
1981] but in vitro administration of aldosterone to pig carotid arteries resulted in a fall
in intra-cellular Na [Llaurado et al., 1983]. In rat tail artery aldosterone had two
actions: (i) a rapid increase in Na efflux which was not blocked by actinomycin D;
and (ii) a slow Na efflux which does appeal- to be classically mediated since it was
blocked by actinomycin D and mineralocorticoid receptor antagonists [Moura &
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Worcel, 1984], These effects may in part result from potentiation of a response to
vasopressin [Angeli et al., 1988]. They are not exclusive to mineralocorticoid
receptor agonists, but the change in Na/H exchange seen after glucocorticoids [Berk
et al., 1988] appeal's to be mediated by a different ion transporter since it was blocked
by both amiloride and bumetanide, in contrast to the mineralocorticoid effect which
was only blocked by amiloride [Kornel et al., 1991].
Effects on Endothelial Cells
In recent years the endothelium has been the focus of research attention in vascular
biology. A significant advance was the identification of "endothelium-derived
relaxant factor" as nitric oxide [Palmer et al., 1987]. In addition to the Ca++-
dependent calmodulin-dependent constitutive nitric oxide synthase of endothelium
there is another Ca++-independent endotoxin-inducible enzyme abundant in
macrophages [DiRosa et al., 1990] and recently described in vascular endothelium
[Radomski et al., 1990] and smooth muscle [Knowles et al., 1990; Wood et al.,
1990]. This inducible enzyme is inhibited by glucocorticoids [Knowles et al., 1990;
DiRosa et al., 1990], an effect which is blocked by glucocorticoid receptor
antagonists [Radomski et al., 1990]. A recent in vitro study by Moncada's group
demonstrated the functional consequences of this effect [Rees et al., 1990]. In
untreated rat aortic rings a time-dependent relaxation and loss of response to
phenylephrine occurred between 2 and 8 hours after starting the experiment, in rings
both with and without endothelium. This was potentiated by nitric oxide synthase
substrate (L-arginine), prevented by a nitric oxide synthase inhibitor (L-NMMA), and
associated with endotoxin induction of Ca++-independent nitric oxide synthase.
Dexamethasone at 10"7 M over 8 h prevented this relaxation and loss of response to
phenylephrine and inhibited the induction of nitric oxide synthase in vascular smooth
muscle. This study was superior to any previous organ bath experiments because the
time-course and dose of steroid application were more physiologically relevant (see
above). However, the functional significance of this effect is uncertain. Although
inhibition of nitric oxide synthase in human forearm caused vasoconstriction
[Variance et al., 1989a], implying that basal nitric oxide production is important, it
remains to be seen whether the inducible enzyme makes a significant contribution in
vivo.
Extensive debate has been conducted on the role of corticosteroids both in the
pathogenesis and therapy of circulatory shock. These observations in vitro were
evoked in this debate by proponents of endotoxin-induced nitric oxide production as a
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pathogenetic mediator of circulatory failure in endotoxic shock [Moncada & Palmer,
1991] and in hepatic cirrhosis [Vallance & Moncada, 1991]. They have suggested
that inhibition of nitric oxide production by dexamethasone should encourage the use
of glucocorticoids in shock, though the in vitro data shows prevention rather than
reversal of endotoxin-induced nitric oxide synthesis and therapeutic benefit of
glucocorticoids in endotoxic shock remains unproven [Lillehei et al., 1964; Altura &
Altura, 1974; Hellman & Lundberg, 1985; Chemow & Roth, 1986],
The effects of glucocorticoids on prostaglandin synthesis described above apply
similarly to endothelial cells. Glucocorticoids also induce angiotensin converting
enzyme in endothelial cells [Mendelsohn et al., 1982]. The importance of the tissue
renin-angiotensin system in controlling tone is unknown [Samani, 1991] but
corticosteroids may provide a tool to examine it further.
The Significance of Corticosteroids in the Control of Vascular Tone; a
Potential Role for 11B-OHSD
The evidence that corticosteroid receptor activation affects vascular tone is thus
persuasive and is now supported by studies showing steroid-receptor mediated
effects on vascular biochemistry. However, a confusing variety of biochemical
actions of corticosteroids has emerged and it remains difficult to develop a unifying
model to explain their role in the control of vascular tone. While the predominant
effect when tone has been measured is constriction, glucocorticoids have biochemical
actions with the potential for both vasoconstriction (eg nitric oxide synthase
inhibition, reduced prostacyclin production, increased phosphoinositide pathway
products, increased a-adrenoceptor numbers, decreased cGMP generation) and
dilatation (eg increased cAMP responses, increased G-adrenoceptor numbers).
Corticosteroids may also act by non-genomic mechanisms which could potentially
oppose their genomic effects (eg vasodilatation at high dose).
The most significant differences between corticosteroids and other vasoactive
hormones are their lack of direct effect, their long time course, and their diverse
effector mechanisms. These features suggest that corticosteroids can play a role not
served by short-acting rapidly metabolised mediators with local actions, in providing
a medium-term pattern of vascular responsiveness which is then adapted locally and
in the short-term by other hormones. Another recently described vasoactive agent
with a relatively long time course is endothelin [Yanagisawa et al., 1988].
Interactions between corticosteroids and endothelin have not been described in the
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vessel wall, although in DOC/salt hypertension the clearance rate of endothelin is
reduced resulting in increased pressor sensitivity to the peptide [Yokokawa et al.,
1990].
It is a characteristic of vascular physiology that responses may be site-specific. It
seems most likely that a balance of opposing effects exists with the result depending
on the local milieu. Examples include the well-established differential distribution of
adrenoceptors in different vascular beds, and the more recently appreciated
differences in basal nitric oxide production between arteries and veins [Vallance et al.,
1989a; 1989b]. The studies of 11B-OHSD in the kidney indicate that the activity of
the enzyme dictates local sensitivity to Cortisol in specific sites. Having found 11B-
OHSD activity in vascular tissue we may have stumbled on one of the mechanisms
whereby site-specific modulation of tone occurs in the vascular tree, by differential
sensitivity to glucocorticoids. Similar arguments apply to the potential role of 11B-
OHSD in dictating relative contributions of vascular smooth muscle and endothelial
cell products in the same vessel. The anatomical and cellular distribution of the
enzyme is therefore of primary interest in elucidating its role in the control of vascular
tone.
Outline of the Thesis
In this thesis I bring together many of the strands alluded to above in order to address
a central question: might defective enzyme-mediated receptor protection contribute to
pathophysiology in common forms of hypertension? In Chapter 2 I describe the
distribution, biochemistry and regulation of 11B-OHSD in rat vascular smooth muscle
and heart. In Chapter 3 I examine the physiological importance of the enzyme in
modulating vascular sensitivity to glucocorticoids in rat and in man. In Chapter 4 I
present physiological studies in man which address the putative inhibition of the
enzyme by ACTH. Finally, in Chapter 5 I provide evidence that deficiency of 118-
DH occurs in patients with ectopic ACTH syndrome and in a subgroup of patients
with essential hypertension, and address the mechanisms whereby failure of enzyme-
mediated receptor protection may explain their clinical presentation. These studies
provide a new perspective on the mechanisms whereby 11B-OHSD activity influences
blood pressure and demonstrate that its deficiency is indeed a common observation in
hypertension.
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CHAPTER 2 11B-HYDROXYSTEROID DEHYDROGENASE IN
VASCULAR SMOOTH MUSCLE
I: BIOCHEMISTRY, DISTRIBUTION, AND
REGULATION IN THE RAT
Distribution of Vascular 11B-OHSD
In the introductory Chapter I described in detail the potential role of activation of both
mineralocorticoid and glucocorticoid receptors in the regulation of vascular tone.
11B-DH activity was first identified in homogenates of rabbit aorta by Ludwig Kornel
[Kornel et al., 1982]. More recently Funder and colleagues [Funder et al., 1989]
have shown conversion of corticosterone to 11-dehydrocorticosterone by minced
tissue from rat mesenteric artery and aorta, with apparently less 1113-DH activity in
aorta than in mesenteric artery, but the amount of tissue used for incubation was not
indicated and the conversion of corticosterone to 11-dehydrocorticosterone not
quantified. In order to assess the potential role of 11B-OHSD in modulating vascular
sensitivity to glucocorticoids I first undertook studies to establish its anatomical and
cellular distribution in the vascular tree, and to compare the level of enzyme activity in
vasculature with that in kidney, where we know that the enzyme plays a central
physiological role.
Materials and Methods
11B-OHSD Activity In Vitro
Female Wistar rats weighing 200-250 g were killed by cervical dislocation. Fresh
tissues were pooled in ice-cold Krebs Ringer bicarbonate buffer (KRBG containing
118 mM NaCl, 3.8 mM KC1, 1.19 mM KH2P04, 2.54 mM CaCl2.2H20, 1.19 mM
MgS04.7H20, 25 mM Na HCO3, 11.1 mM d-glucose; gassed with 95 %02/5 %C02
to pH 7.4). Vessels were carefully stripped of surrounding fat and connective tissue.
Renal cortex was dissected from medulla and capsule. Tissues were homogenised in
2 ml KRBG by 3 x 10 sec bursts in an Ystral homogenizer (Scientific Instrument
Centre, Liverpool, UK). Homogenates were centrifuged at 500 x g for 5 min to
remove debris and the supernatant then assayed for protein colorimetrically (BioRad
Laboratories Ltd, UK). Incubations were performed in triplicate at 37 °C in 250 (tl
containing 1.12 x 10~8 M [l,2,6,7-3H4]-corticosterone (Amersham International,
UK; specific activity 84 Ci/mol), ethanol 1 % vol/vol, BSA 0.2 g/dl, and tissue
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homogenate at 500 (ig protein/ml, and in the presence or absence of exogenous
NADP 200 p.M. This protein concentration was chosen after preliminary experiments
with incubations in duplicate at protein concentrations ranging from 0-2000 |ig/ml. In
all experiments 3 blank incubations were performed with no homogenate added.
After 120 min the incubate was made up to 1 ml with ice-cold KRBG, centrifuged at
1500 x g for 15 min, and stored at -70 °C until extraction.
Steroids were extracted with ethyl acetate, dried and re-suspended in ethanol
containing 5 mg/ml of unlabelled corticosterone and 11-dehydrocorticosterone (Sigma
Chemical Co., UK). Separation was by thin layer chromatography on silica gel
plates using chloroform: 95% ethanol (92:8) as solvent. Areas corresponding to
steroids were identified under ultraviolet light and scraped into vials before elution
with liquid scintillant (Cocktail T, BDH Ltd, UK). Radioactivity was quantitated by
counting in a 8 counter to an error of < 2 %. 11B-DH activity is expressed as (cpm
for 3H-1 l-dehydrocorticosterone)-Kcpm for 3H-11-dehydrocorticosterone + cpm for
3H-corticosterone) x 100 %, after correction for blank incubations. Apparent
"conversion" in blank incubations was 1.57 ± 0.12 %.
In order to assess the possible conversion of corticosterone to steroids other than 11-
dehydrocorticosterone an incubation was performed as above and the steroids were
separated by HPLC. After ethyl acetate extraction, steroids were re-suspended in
mobile phase of methanol:water (65:35) and separated on a Cis Microbondapack
reverse phase HPLC column (Millipore Waters, Watford, UK) at a flow rate of 1
ml/min without a gradient. The retention time for corticosterone and for 11-
dehydrocorticosterone was established with a Waters 441 UV detector. Retention
times were 5.45 - 7.00 min for 11-dehydrocorticosterone and 8.00 - 9.15 min for
corticosterone. Fractions were collected at 2.5 min intervals over 25 min and at these
retention times. Eluates were dried under nitrogen, suspended in liquid scintillant and
radioactivity quantitated in a 8 counter. After HPLC recovery was > 90 % when
tested with radioactive steroid standards.
To establish whether significant 11B-OR conversion of 11-dehydrocorticosterone
back to corticosterone occurred under these conditions, a further pair of experiments
was performed in triplicate as above using 3H-11-dehydrocorticosterone (purified to
94% from supernatant of liver homogenate after incubation with 3H-corticosterone) as




Antisera 56-125 and 56-126 were a kind gift from Dr Carl Monder of the Population
Council, New York. They were raised in New Zealand white rabbits inoculated with
purified rat liver microsomal 11B-OHSD [Monder & Lakshmi, 1990]. The
immunohistochemistry was performed with technical assistance from Lawrence Brett
in the Pathology Department, Western General Hospital, Edinburgh.
Female Wistar rats (n=2) were anaesthetised with pentobarbitone (2 ml/kg ip) and
lethally perfused via the left ventricle with 250 ml ice-cold 0.9 % saline followed by
250 ml 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Tissues were
dissected and fixed for 24-48 h in Bouin's fluid before embedding in paraffin.
Sections of 4 (im were deparaffinised and rehydrated through graded alcohols. They
were exposed to 3 % H2O2 for 10 min, washed in tris-buffered saline (TBS),
exposed to BSA/TBS, and incubated with 56-125 at 1:50 dilution, 56-126 at 1:100,
or normal rabbit serum for 30 min at 20 °C. In addition, a series of dilutions of 56-
126 from 1:100 to 1:4000 were used to compare relative absorption in heart and
kidney. Immunodetection was with swine anti-rabbit antibody followed by
peroxidase anti-peroxidase antibody (Dako, UK). Slides were washed with TBS,
exposed to 3,3'-diaminobenzidine/H202, and washed with water before being
counterstained with haematoxylin.
In situ hybridisation
These studies were performed in Dr Jonathan Seckl's laboratory in our department,
with assistance from Dr Joyce Yau. Female Wistar rats (250-300 g, n=2) were killed
by cervical dislocation and the tissues dissected rapidly on ice, frozen on dry ice, and
stored at -85 °C. Sections of 10 pm were cut on a cryostat and mounted on gelatin
and poly-L-lysine-coated slides. Sections were fixed in 4 % paraformaldehyde/0.1 M
phosphate (pH 7.4), washed twice in 2 x SSC and incubated at 50 °C for 2 h with
prehybridisation buffer containing 50 % formamide, 0.6 M NaCl, 10 mM tris-HCl
(pH 8.5), 0.02 % ficoll, 0.02 % polyvinylpyrrolidone, 0.1 % BSA, 1 mM EDTA,
0.5 mg/ml denatured salmon sperm DNA, 0.5 mg/ml total yeast RNA, and 0.05
mg/ml yeast tRNA. T3 polymerase (Gibco BRL, UK) was used to transcribe a 598
base pah- 35S-labelled antisense cRNA probe from .sty/-linearised pBluescript vector
containing the 11B-OHSD cDNA insert [Agarwal et al., 1989]. As a control T7
polymerase (Promega Ltd, UK) was used to transcribe a sense RNA probe of similar
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specific activity. Probes were denatured and added to hybridisation buffer constituted
as for prehybridisation buffer except 0.1 mg/ml denatured salmon sperm DNA, 0.05
mg/ml total yeast RNA , dextran sulphate 0.1 g/ml, and 10 mM DTT. After
hybridisation overnight at 50 °C using 60 pi per slide at 107 cpm/ml, the slides were
rinsed in 2 x SSC and treated with RNase A (30 pg/ml) for 30 min at 37 °C. They
were washed to a maximum stringency of 0.1 x SSC at 60 °C for 60 min and
dehydrated in graded ethanols in 0.3 M Na acetate. Slides were dried in air before
being dipped in photographic K5 nuclear emulsion (Ilford, UK), stored for 21 days at
4 °C, developed and counterstained with haematoxylin and eosin.
Statistics
Differences between tissues were tested by ANOVA followed by unpaired t tests.
Values are quoted as mean ± SE.
Results
11B-OHSD Activity
In order to allow comparison of enzyme activity in different tissues, a protein
concentration was determined at which the amount of protein was rate-limiting.
Results are shown in Figure 2.1 for 2 incubations at different protein concentrations
in the presence of exogenous NADP. With vascular tissues detectable 11B-DH
activity continues to increase in a linear fashion with increasing protein well above
500 pg/ml, but with kidney there is a plateau in the curve reflecting consumption of
substrate. A protein concentration of 500 pg/ml was chosen as a compromise to
achieve measurable activity in vascular tissue and also to allow comparison with
kidney.
An experiment was performed to assess possible conversion of corticosterone to other
steroids, either extractable with ethyl acetate or non-extractable polar metabolites. The
total activity recovered after extraction with ethyl acetate compared with blank
incubations was 102.5 ± 6.4 % in the absence of exogenous NADP and 97.4 ± 7.8
% in the presence of NADP. Thus non-extractable steroids do not constitute a major
metabolic fate of corticosterone in vascular tissues. Conversion of corticosterone to
extractable steroids other than 11-dehydrocorticosterone was examined by HPLC,
after which the radioactivity residing in the fractions containing corticosterone and 11-
dehydrocorticosterone, when expressed as a % of total radioactivity recovered, was
99.0 ± 0.7 % in the absence of NADP and 98.6 ± 0.6 % in the presence of NADP.
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Thus 11-dehydrocorticosterone is the major metabolite of corticosterone in these
tissues.
Experiments to measure the conversion of 11-dehydrocorticosterone to corticosterone
showed that under these incubation conditions there was no significant 116-OR
activity in any of the tissues studied.
Figure 2.1 Effect of increasing protein concentration on 11B-DH activity in
vascular tissues and renal cortex in the presence of 200 |iM NADP
100^
0 500 1000 1500 2000
Protein Concentration (pg/ml)
The conversion of corticosterone to 11-dehydrocorticosterone was quantitated in
homogenates from aorta, superior mesenteric artery, caudal artery and heart, and
compared with conversion in renal cortex. The results from 3 experiments, each with
the pooled tissues of 4 animals incubated in ttiplicate, are shown in Figure 2.2. 116-
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DH activity was demonstrated in all tissues studied. Without NADP vascular activity
was just detectable and there were significant differences (p < 0.05) between vascular
sites [caudal artery (4.2 ± 0.2 %) > mesenteric artery (2.5 ± 0.7 %) = heart (1.67 ±
0.2 %) > aorta (0.79 ± 0.2 %)]. All of these were lower than renal cortex (29.4 ±
1.8 %; p < 0.001). NADP increased conversion in all tissues (p < 0.001), and the
hierarchy was maintained (p < 0.001) except that mesenteric artery and aorta were not
significantly different in this comparison [renal cortex (82.4 ± 0.4 %) > caudal artery
(43.9 ± 2.1 %) > heart (20.6 ± 1.0 %) = mesenteric artery (17.7 ± 3.1 %) = aorta
(11.4 ± 0.4 %); heart > aorta].
Figure 2.2 Relative 11B-DH activity in vascular tissues and renal cortex
Aorta Heart Mesenteric Caudal Renal
Artery Artery Cortex
Immunohistochemistrv
In aorta, mesenteric artery, and caudal artery there was specific cytoplasmic 1113-
OHSD immunoreactivity in smooth muscle cells throughout the vessel wall (Figure
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2.3 A-F). There was also staining of the adventitia of the vessels and of fat cells in
the mesentery, but there was no staining of endothelium. In the heart (Figure 3 G,H)
there was staining of cardiac muscle cells and of smooth muscle in coronary arteries.
Staining was heavier near the endocardium than on the pericardial surface. The signal
intensity in heart was of similar magnitude to that in kidney, since both disappeared at
antibody dilutions between 1:400 and 1:1000. Both antisera gave similar results.
In situ hybridisation
Specific 118-OHSD mRNA expression was localised to vascular smooth muscle in
aorta and mesenteric artery (Figure 2.4 A-D) and was also found in cardiac muscle
(Figure 2.4 E,F). Sense probes showed little or no hybridisation under the stringent
conditions used.
Conclusions
These studies demonstrate 11B-DH bioactivity, and 11B-OHSD immunoreactivity and
mRNA expression in cardiac and vascular smooth muscle cells. 11B-DH bioactivity
has been identified previously in these tissues [Kornel et al., 1982; Funder et al.,
1989], but no quantitative studies have been performed and the cellular localisation of
the enzyme was not known. I have shown that 11B-DH makes the greatest
contribution to in vitro metabolism of corticosterone in these tissues, and that there are
quantitative differences in enzyme activity between different sites.
Greater 11B-DH activity was found in caudal artery and mesenteric artery than in aorta
without NADP, and greater activity in caudal artery than other vessels with NADP.
This suggests that 11B-OHSD is most active in smaller vessels. It is thus
appropriately sited to modulate tone in resistance beds and thereby influence blood
pressure.
Both 11B-OHSD immunoreactivity and mRNA were localised to smooth muscle cells
and not endothelium in heart and blood vessels. Previously, 11B-OHSD antigen and
mRNA have only been reported in cardiac extracts [Monder & Lakshmi, 1990;
Krozowski et al., 1990]. These workers failed to detect 11B-OHSD mRNA in
extracts from mesenteric vascular arcade [Krozowski et al., 1990], but I have
demonstrated hybridisation at this site. It is likely that in situ hybridisation is the
more sensitive technique. This localisation within contractile cells suggests that, if
11B-OHSD modulates the effects of glucocorticoids on tone, then it does so by an
autocrine rather than a paracrine mechanism.
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Figure 2.3 Immunohistochemical localisation of 11B-OHSD in vascular tissues
Sections were counterstained after incubation with antiserum 56-126. Controls were
incubated with normal rabbit serum (NRS). For x40 bar is 100|jm and for x20 bar is
200)j.m. A aorta (x40) with 56-126 B aorta (x40) with NRS C mesenteric artery
(x20) with 56-126 D mesenteric artery (x20) with NRS E caudal artery (x40) with
56-126 F caudal artery (x40) with NRS G heart including coronary artery (x40) with
56-126 H heart (x40) with NRS.
50
Figure 2.4 In situ hybridisation for 116-OHSD mRNA in vascular tissues
Hybridisation was performed with an antisense cDNA probe. Controls were
hybridised with a sense probe. Bar is lOOjxm for x40 and 40jim for xlOO. A aorta,
antisense (x40) B aorta, sense (x40) C mesenteric artery, antisense (x40); dark field
with some refraction artefact around the luminal surface D mesenteric artery, sense
(x40); dark field with refraction artefact around lumen E heart, antisense (xlOO) F
heart, sense (xlOO).
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Despite the abundance of 11B-OHSD immunoreactivity and mRNA expression in
vascular tissues, the conversion of corticosterone to 11-dehydrocorticosterone in
these sites was low relative to that in renal cortex, even when 11B-DH was "driven"
by the addition of NADP. This might reflect lower abundance of 11B-OHSD,
reduced in vitro stability of the enzyme in vasculature, or the possibility that vascular-
specific isoforms of 11B-OHSD exist with different kinetic properties from that in
kidney. I was not able to demonstrate 11B-OR activity under these conditions, but it
would be wrong to conclude that 11B-DH predominates in vivo, since the two
activities of 11B-OHSD vary in their stability [Abramowitz et al., 1982; Lakshmi &
Monder, 1985; 1988; Monder & Lakshmi, 1989]. It may be that the low 11B-DH
activity in vascular tissue, in the face of apparently high immunoreactivity and mRNA
expression, reflects abundant 11B-OR which is too labile for bioactivity to be
demonstrable in vitro. As discussed in Chapter 1, predominant 11B-OR activity in
vivo does not preclude the possibility that 11B-OHSD modulates access of steroids to
receptors in vasculature. For example, 11B-OHSD could act to maintain high local
corticosterone concentrations thus ensuring adequate exposure of glucocorticoid
receptors and maintaining vascular sensitivity to catecholamines.
For these reasons it was important to characterise the biochemistry of the enzyme in
vascular tissue in greater detail, to establish whether it resembled most the isoform
expressed in liver or that in kidney.
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In Vitro kinetics of the 11B-OHSD Isoform Expressed in
Vascular Smooth Muscle
The isoforms of 11B-OHSD in kidney can be distinguished from that in liver by
differences in antigenicity, protein size, and size of mRNA expressed, as well as
differences in the equilibrium between active and inactive steroid (see Table 1.2). It
has also been suggested that the Km of 11B-DH for Cortisol is lower in kidney than it
is in liver [Naray-Fejes-Toth & Fejes-Toth, 1991], although this observation may
depend on differences between the incubation conditions used by different
investigators. Finally, experiments examining the conversion of tetrazolium to
diformazan blue in renal tubules suggested that an NAD-dependent "HB-OHSD2"
may be expressed in the kidney [Mercer & Krozowski, 1992], The same group have
cloned one of the additional mRNA species in kidney which codes for a protein
without the first 26 amino acids of hepatic 11B-OHSD [Krozowski et al., 1992].
This is a hydrophobic putative membrane insertion sequence immediately adjacent to
which is the cofactor binding domain of the enzyme. A change in the N-terminus
might therefore account for altered cofactor binding affinity of the protein. I
examined the kinetic properties of 118-DH in vascular smooth muscle and compared
it with kidney and other tissues.
Methods
Substrate Affinity
The apparent Km and Vmax for an enzyme can be calculated from a reciprocal plot of
substrate concentration vs velocity of product accumulation [Lineweaver & Burk,
1934], It is important for these calculations to ensure that the velocity of reaction is as
close to initial, or saturated, velocity as possible. Tissues were collected from female
Wistar rats. Incubations were performed as described above in the presence of
NADP (200 qM), except that different protein and substrate concentrations and
shorter time periods were used. Protein concentrations were chosen from
experiments similar to that shown in Figure 2.1, such that the protein concentration
was on the linear part of the curve of protein concentration vs % conversion. These
were: 1000 |ig/ml for mesenteric artery and aorta; 500 pg/ml for heart and caudal
artery; and 100 pg/ml for renal cortex. Time of incubation was chosen from
preliminary experiments in which the reaction was terminated with ethyl acetate at 1,
2.5, 5, 7.5, 10, and 30 min. All reactions remained linear up to at least 10 min, so
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this interval was chosen for the velocity measurements. 3H-Corticosterone substrate
concentrations were 2 x 10~7, 1 x 10"7, 3.3 x 10~8, 2 x 10~8, 1 x 10~8, 8 x 10~9, 5 x
10~9, and 2 x 10"9 M. Experiments were performed 3 or 6 times at each substrate
concentration and the mean used for Lineweaver-Burk analysis by simple linear
regression.
Cofactor Affinity
Tissues were obtained from non-pregnant female Wistar rats (250 - 300 g; n = 3 - 5),
placentae at 19 days gestation, or testes from male rats of the same weight. To
separate proximal and distal renal tubules [Edwards et al., 1988], diced renal cortex
was digested at 37 °C for 3 x 30 min in KRBG with 2 % BSA, 600 units/ml
collagenase (type IV, Sigma) and 0.1 % w/v hyaluronidase (Worthington). Tubules
were separated by unit gravity sedimentation on a Ficoll gradient (1 - 12 % Ficoll,
molecular weight 4 x 105, in KRBG). Proximal and distal tubules were counted in a
series of fractions by their morphology in a haemocytometer, and the viability of the
tubules confirmed by Trypan blue exclusion. Fractions were combined to give
suspensions enriched with proximal and distal tubules for homogenisation.
Incubations were in duplicate as in previous experiments in the presence of NAD or
NADP at 0, 5, 25, and 125 |iM. Protein concentrations were: 100 [tg/ml for liver,
testis, lung, renal cortex and tubules; 500 [tg/ml for placenta and hippocampus; 650
(ig/ml for mesenteric artery; and 1000 pg/ml for aorta, heart, and colon.
All experiments were repeated three times. Affinity constants for each cofactor in
each site were not calculated on the grounds that the absolute values are not
meaningful without purification of the enzyme from each site. Instead, the effect of
each cofactor in each tissue was assessed by single-factor ANOVA, and the effects of
NAD and NADP compared by two-way ANOVA. Results are mean ± SE.
Results
Substrate Affinity
Results are shown in Table 2.1. The differences in apparent affinity for
corticosterone are not dramatic, being less than one order of magnitude. Therefore,
no distinction can be made between the enzyme in vascular tissue and in renal cortex
on the basis of substrate affinity.
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Table 2.1 Apparent Km and Vmax for 11B-DH in homogenates of vascular
tissues and renal cortex
Km Vmax
Renal Cortex 3.7 x 10-8 1.9 x 10-9
Mesenteric Artery 1.3 x 10"8 7.2 x lO-9
Aorta 1.6 x 10-8 4.3 x 10-9
Caudal Artery 4.7 x 10-9 2.6 x lO-8
Heart 8.0 x lO-9 6.0 x lO-9
Cofactor Affinity
In liver, testis, hippocampus, heart, mesenteric artery and aorta NAD had no
significant effect and NADP produced a concentration-dependent increase in activity
(single factor ANOVA p < 0.01 except aorta p < 0.05)(Figure 2.5A).
In lung, placenta and colon NAD had a significant effect (single factor ANOVA p <
0.01) but not as great as NADP (two-way ANOVA shown in Figure 2.5B).
Only in renal cortex did the effect of NAD match that of NADP (Figure 2.5B; both
single-factor ANOVA p < 0.001; two-way ANOVA not significant). Tubular
fractionation achieved enrichment of 68 % for proximal tubules and 100 % for distal
tubules. No difference was apparent between these fractions.
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Figure 2.5 Effect of NADP and NAD on 11B-DH activity in homogenised rat
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Bars are SE. NS = not significant, "p" values refer to the effect of individual
cofactors in each tissue (analysed by single-factor ANOVA) and to the comparison
between the two cofactors by two-way ANOVA.
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Figure 2.5 Effect of NADP or NAD on 118-DH activity in homogenised rat


























































Concentration of Cofactor (fiM)
Bars are SE. NS = not significant, "p" values refer to the effect of individual
cofactors in each tissue (analysed by single-factor ANOVA) and to the comparison
between the two cofactors by two-way ANOVA.
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Conclusions
Substrate affinities were not different between vascular tissues and kidney,
suggesting either that all 11B-OHSD isoforms in these tissues have the same substrate
binding site, or that any additional isoforms expressed in kidney with different
substrate affinities are masked by a more abundant isoform. Therefore measurement
of substrate affinity without purifying the relevant isoforms does not appear to be a
useful tool in delineating different enzyme species.
However, several of the tissues can be distinguished by their affinity for cofactors.
These studies illustrate a novel principle which highlights the potential significance of
the expression of tissue-specific 11B-OHSD isoforms: that heterogeneity of 11B-
OHSD is reflected in tissue-specific differences in cofactor utilisation by the enzyme.
Most sites which are distinguished by the utilisation of NAD (kidney, colon, and
placenta) correspond to those in which isoforms have been identified in studies of
protein and mRNA size which differ from those found in liver (Table 1.2). The
exceptions are lung (which uses NAD but is in other respects similar to the liver
isoform; however, the effect of NAD in lung is relatively minor) and testis (which has
additional proteins identified on Western blotting but does not use NAD). Thus on
Western blots the polyclonal antisera to hepatic 11B-OHSD bind proteins with
molecular weights of 34 kD and 68 kD in most sites (including liver, lung, and
colon), and additional species with molecular weights of 40 kD in kidney, 26 kD in
brain, and 47 kD in testis [Monder & Lakshmi, 1990]. Western blots for 11B-OHSD
in vascular tissues and placenta are not available. On Northern blots 11B-OHSD
cDNA hybridises to mRNA of 1700 nucleotides in most tissues (including liver, lung,
hippocampus, and testis), and to additional species of 1500, 1600 and 1900
nucleotides in kidney [Krozowski et al., 1990], 3400 nucleotides in colon
[Whorwood et al., 1992], and larger species in placenta (Susan Low, personal
communication). Northern blots are not yet available for vascular tissues.
Furthermore, it is plausible to suggest that these kinetic differences between isoforms
are reflected in different functioning of the enzyme. The utilisation of NAD broadly
corresponds to the abundance of aldosterone-specific mineralocorticoid receptors.
Thus NAD is used in kidney and colon (where aldosterone-specific mineralocorticoid
receptors abound) but not in hippocampus (where mineralocorticoid receptors are
present but are not aldosterone-specific [Sheppard & Funder, 1987]), nor in liver or
testis (where mineralocorticoid receptors are absent or in low abundance). This
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relationship would be even more convincing if we could demonstrate differences
between cofactor utilisation in proximal and distal renal tubules. The failure to do this
may reflect inadequate purity of separation, which is intrinsic to the density gradient
technique, and this negative result does not exclude differential distribution of the
NAD-dependent isoform within the kidney. Indeed more recent observations of the
kinetics of 11B-DH purified from isolated rabbit cortical collecting duct cells (ie
mineralocorticoid receptor-containing cells) confirm that this enzyme utilises NAD
almost exclusively [Rusvai et al., 1992]. In lung [Krozowski & Funder, 1981] and
heart [Barnett & Pritchett, 1988] mineralocorticoid receptors have been identified in
vitro but their binding specificity in vivo has not been determined. Finally,
coiticosteroid receptors in the placenta are predominantly type 2, though in this organ
the putative functional role of the enzyme is not as an autocrine protector of local
receptors but rather as a barrier preventing maternal glucocorticoids gaining access to
the fetus [Murphy, 1981; Baggia et al., 1990],
Finally, the pattern of utilisation of NAD corresponds to the equilibrium between
active and inactive steroid in different sites. Thus the liver enzyme is not NAD-
dependent and has predominant 11B-OR activity, while the kidney enzyme is NAD-
dependent and has predominant 11B-DH activity. We might now suggest that this
kinetic difference may depend on the response to the cofactor milieu, and accounts in
turn for the diverse function of the enzyme in relation to receptors in different sites.
On this background, the kinetic profile of 11B-OHSD in vascular smooth muscle
raises some contradictions. In rat mesenteric artery, which is the only vascular site so
far examined, mineralocorticoid receptors do display aldosterone-specificity in vivo
[Funder et al., 1989]. Thus the hypothesis presented above would predict that the
vascular enzyme would be NAD-dependent and function as a predominant 11B-DH.
That it does not respond to NAD raises the possibility that 11B-OHSD in vascular
smooth muscle is a functional hybrid between liver (predominantly 11B-OR; NAD-
independent; possible amplification of Cortisol exposure of glucocorticoid receptors)
and kidney (predominantly 116-DH; NAD-dependent; avid inactivation of Cortisol to
protect mineralocorticoid receptors). Perhaps its hybrid kinetics permit the vascular
enzyme to perform different roles in different vascular beds? This putative diversity
of function is addressed in more detail in the following Chapter.
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In Vivo Regulation of 11B-OHSD in vascular smooth muscle
In addition to the potential role of intra-cellular cofactors in dictating the equilibrium
point of 11B-OHSD [Nicholas & Lugg, 1982; Monder et al., 1991] it seems likely
that the expression of the enzyme is under physiological control. The enzyme
contributes to two separate physiological axes: the "hypophyseal-pituitary-adrenal"
axis which dictates activity of glucocorticoids; and the "renin-angiotensin-
aldosterone" axis, which relies on 118-OHSD for its integrity. The putative
regulators of the enzyme which I chose to address are therefore ACTH,
glucocorticoids, and sodium intake. The possible influence of androgens, oestrogens
and thyroid hormones were discussed in Chapter 1 and I have not examined these
further.
Salt diet has been addressed by others in liver, lung and kidney. They reported that
low sodium intake caused elevated mRNA expression in the liver only, and that
bioactivity of the enzyme was not affected in any site [Krozowski et al., 1990], but
they do not show their data. If this manipulation has an effect on the enzyme then it
would prompt a series of experiments to examine the effects of angiotensin II,
aldosterone and potassium. I therefore repeated this experiment in a variety of
tissues.
ACTH seems an unlikely direct regulator of 11B-OHSD, since we usually think that
its effects are mediated by adrenal ACTH-dependent steroids. However, in two
patients with Addison's disease Kornel found that ACTH administration prolonged
the half life of 14C-cortisol and shortened the half life of 14C-cortisone [Kornel,
1970]. He suggested that this represented an extra-adrenal effect of ACTH to inhibit
11B-DH. This mechanism might allow amplification of the tissue response to
glucocorticoids under ACTH stimulation. However, it remains possible that his
patients had some residual adrenal function and that this effect was due to secretion of
an adrenal inhibitor of the enzyme. These possibilities are addressed more fully in
consideration of the control of renal 11B-OHSD in man in Chapter 4. In this Chapter
I examine the effects of ACTH in adrenalectomised rats.
Glucocorticoids induce 11B-OHSD activity in cultured cells [Smith et al., 1973; Lugg
& Nicholas, 1978; Hammami & Siiteri, 1991]. Putative glucocorticoid response
elements are present in the 5' sequences of the rat gene [Moisan et al., 1992a], The
effects of in vivo administration of synthetic glucocorticoid receptor agonists on 118¬
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OHSD bioactivity and mRNA expression have been reported previously by others
from this department for kidney and hippocampus [Moisan et al., 1991; Low et al.,
1992]. Their results show that dexamethasone induces 11B-OHSD expression in
hippocampus but not in kidney when given in high pharmacological doses (50 (ig/day
for 10 days). This tissue-specificity has provided one of the arguments in favour of
multiple isoforms of the enzyme. In the following experiments I wished to test: (i)
whether vascular tissues express an isoform which is regulated by glucocorticoids;
(ii) whether the effect of dexamethasone could be demonstrated at doses which are
equivalent to physiological glucocorticoid levels (ie do not cause profound cachexia);
and (iii) whether the effect of dexamethasone is attributable to suppression of ACTH
levels and loss of ACTH-dependent inhibition of the enzyme.
Methods
Effect of Sodium Intake on 11B-DH Activity
Groups of 3 female Wistar rats (200-250 g) were given ad libitum drinking water
containing 0 % Na CI (low salt), 1 % Na CI (normal salt), and 3 % Na CI (high salt)
for 7 days before sacrifice by cervical dislocation. Fluid consumption and body
weight was similar in the three groups. Tissues from each animal were dissected,
homogenised, and incubated as above in triplicate with 3H-corticosterone in the
presence of 200 |lM NADP for 120 min. Protein concentrations were 100 pg/ml for
renal cortex and liver, and 1000 |lg/ml for heart and aorta.
Results were compared by single-factor ANOVA. All results are mean ± SE.
Effect of Adrenalectomy, Dexamethasone Replacement, and ACTH on 11B-DH
Activity
Male Wistar rats were adrenalectomised or sham operated and had subcutaneous
miniosmotic pumps (Alzet, UK) inserted under pentobarbitone anaesthesia. Surgery
was performed by June Noble, senior technician in our Animal Unit. Animals were
given 0.9 % NaCl to drink until sacrifice by decapitation on day 9.
ACTH (1-24; Acthar gel, Rorer Pharmaceuticals; 20 (tg/d) or oil vehicle were
administered daily at 0900 h by subcutaneous bolus.
Dexamethasone (2 |ig/d or 50 |ig/d) or 0.9 % NaCl vehicle was given continuously
by subcutaneous pump.
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At sacrifice truncal blood was collected for radioimmunoassay of ACTH (performed
by Dr John Bennie in the MRC Brain Metabolism Unit, Edinburgh [Fink et al.,
1988]). Data from 1 sham and 1 adrenalectomised animal treated with dexamethasone
50 pg/d were excluded from analysis because of inappropriate changes in body
weight and plasma ACTH suggesting surgical error and pump failure respectively.
Tissues from each animal were dissected, homogenised, and incubated as above in
duplicate with 3H-corticosterone in the presence of 200 |iM NADP for 120 min.
Protein concentrations were 50 (ig/ml for liver, 100 pg/ml for renal cortex, 500 pg/ml
for hippocampus, and 1000 pg/ml for aorta and heart.
Results were compared by single-factor ANOVA. All results are mean ± SE.
Results
Effect of Sodium Intake on 11B-DH Activity
Results are shown in Figure 2.6. Salt intake had no effect on 11G-DH activity in any
tissue studied.
Effect of Adrenalectomy. Dexamethasone Replacement, and ACTH on 11B-DH
Activity
Adrenalectomy produced a non-significant fall in 11G-DH activity in hippocampus
and aorta and had no effect in renal cortex, liver, or heart (Figure 2.7).
After adrenalectomy low-dose dexamethasone replacement (2 (ig/d) had no effect on
11B-DH activity in any tissue. High-dose dexamethasone (50 pg/d) increased 11B-
DH activity in hippocampus, aorta and heart, but had no effect in renal cortex and
liver (Figure 2.8).
Exogenous ACTH (1-24) had no effect on dexamethasone induction of 11B-DH
activity in any tissue (Figure 2.9) despite achieving ACTH levels in animals receiving
dexamethasone similar to those in untreated adrenalectomised rats (Table 2.2).
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Figure 2.6 Effect of 7 days of controlled sodium intake on 1113-DH activity in
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Table 2.2 Body weights, and plasma ACTH concentrations in animals treated
by adrenalectomy/sham surgery and given dexamethasone ± ACTH
[ACTHJ pg/ml Body weight day 1 Body weight day 9
<&L M.
Sham 84 ±41 208.5 ±11.0 251.2 ± 11.0
ADX
+ vehicle
3644 ± 376 210.2 ± 9.9 225.6 ± 8.0
ADX
+ DEX 2 |4g/d
212.7 ± 5.7 225.3 ± 2.7
ADX
+ DEX 2 jig/d
+ ACTH 20 |lg/d
211.3 ± 12.7 235.3 ± 17.0
ADX
+ DEX 50 ng/d
13 ± 13 202.4 ± 9.5 165.2 ± 8.0
ADX
+ DEX 50 |ig/d
+ ACTH 20 (J.g/d
3478 ± 570 202.3 ± 5.9 163.0 ± 5.1
ADX = adrenalectomy; DEX = dexamethasone
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Figure 2.7 Effect of adrenalectomy on 118-DH activity in liver, renal cortex,
aorta, heart and hippocampus
PI Sham operated (n=8)
□ Adrenalectomised (n=9)
100






Figure 2.8 Effect of in vivo administration of dexamethasone on 1113-DH
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Figure 2.9 Effect of in vivo ACTH administration on dexamethasone induction
of 11G-DH activity in liver, renal cortex, aorta, heart and
hippocampus
M ADX + DEX 2|ig/day (n=3)
□ ADX + DEX 2jig/day + ACTH (n=3)
□ ADX + DEX 50ji,g/day (n=5)
Renal Cortex Liver Hippocampus Heart Aorta
ADX = adrenalectomised; DEX = dexamethasone
Conclusions
If the renin-angiotensin-aldosterone axis regulates 11B-OHSD activity then this did
not emerge from the experiment with manipulation of salt diet described here. The
negative results in liver and kidney should be interpreted with caution because the
basal 11G-DH activity was relatively high, leaving relatively little scope for enzyme
induction to be apparent. However, given the consistency with other reports
[Krozowski et al., 1990] and the negative results in other tissues, I elected not to
pursue this further.
The present results confirm that dexamethasone induces 11B-DH activity in
hippocampus. By contrast in renal cortex, as shown by others [Moisan et al., 1991;
Low et al., 1992], and also in liver there was no demonstrable change. However, it
is interesting that there was no significant change in hippocampus after adrenalectomy
or after low dose dexamethasone replacement. This dose of dexamethasone is a
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reasonable approximation to physiological glucocorticoid levels in the rat, but is
certainly not inadequate, since it does not make animals lose weight but does produce
elevations in blood pressure [Tonolo et al., 1988]. It may be that within
physiological ranges of glucocorticoid concentration the effects on 118-DH activity
are not relevant.
The tissue specificity of glucocorticoid induction is difficult to interpret and again is
subject to the limitation that basal 118-DH activity was relatively high in the tissues in
which no induction was seen. However, there is some teleological logic in these
results. In tissues where 11B-DH is induced (hippocampus, aorta and heart) this
could limit the response to a surge of glucocorticoid secretion. In tissues where
induction does not occur (liver and renal cortex) 118-DH may either be constantly
fully active as a barrier to glucocorticoids (eg kidney), or may remain inactive to
facilitate maximal receptor exposure when adrenal secretion is increased (eg liver).
Finally, if ACTH inhibits 118-OHSD (discussed above) then it is possible that
apparent induction of enzyme activity by dexamethasone is mediated indirectly by
suppression of ACTH secretion. However, administration of ACTH with
dexamethasone did not reverse the dexamethasone induction of 118-DH activity, thus
ACTH does not act by an extra-adrenal mechanism to inhibit the enzyme and does not
account for the effect of dexamethasone in the rat. This result is discussed in the
interpretation of the effects of ACTH on 118-DH activity in man in Chapter 4.
Summary
In this Chapter I have described the expression and distribution of 118-OHSD in
vascular smooth muscle and cardiac muscle. I have confirmed that it is appropriately
sited to modify the vascular response to glucocorticoids, and observed that several of
its characteristics in vitro and in vivo distinguish the vascular enzyme from that in
other tissues. The next Chapter describes experiments in which I examine the
hypothesis that manipulation of 118-OHSD activity influences vascular tone in rat and
man.
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CHAPTER 3 11B-HYDR0XYSTER0ID DEHYDROGENASE IN
VASCULAR SMOOTH MUSCLE
II: SIGNIFICANCE IN THE CONTROL OF
VASCULAR TONE IN MAN AND RAT
The stimulus for the experiments presented in the previous Chapter was the
preliminary evidence that 11B-OHSD activity might influence vascular tone. This
came firstly from experiments in human skin showing that the vasoconstrictor
response to Cortisol, a glucocorticoid receptor-mediated phenomenon [Marks et al.,
1982; Gaillard et al., 1985], was potentiated by inhibition of 11B-DH with topical
glycyrrhetinic acid [Teelucksingh et al., 1990]. However, it was not clear where
glycyrrhetinic acid has its effect because immunostaining for 11B-DH in skin is
present in both dermal vascular smooth muscle and epidermis [Teelucksingh et al.,
1990]. Secondly, it was demonstrated that mineralocorticoid receptors in rat
mesenteric vascular arcade bind aldosterone in preference to corticosterone [Funder et
al., 1989], suggesting that the enzyme in vascular smooth muscle may also be
required to protect mineralocorticoid receptors, analogous to its role in the distal
nephron. On the other hand, the kinetic data presented in Chapter 2 emphasise the
differences between the enzyme in vasculature and that in kidney.
This Chapter describes experiments which address the physiological relationship
between 11B-DH activity and vascular sensitivity to glucocorticoids. The most
consistent effect of corticosteroids on blood vessels is potentiation of their sensitivity
to noradrenaline rather than any direct effect on tone (see Chapter 1). I therefore
began by testing the hypothesis that loss of 11B-DH activity in human blood vessels
results in increased vascular sensitivity to Cortisol and hence to noradrenaline. I
examined the effects of oral 11B-DH inhibitors on vascular responses to these agents
in healthy subjects, and repeated the studies in our patient with the syndrome of
apparent mineralocorticoid excess type 1 (GB), who remains the only adult case of
congenital 11B-DH deficiency to have been reported [Stewart et al., 1988].
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The Influence of 11B-OHSD on Vascular Sensitivity to
Cortisol and Noradrenaline in Man
Methods
All subjects gave written informed consent. Local Ethics Committee approval was
obtained. Cannulae were inserted using local anaesthesia with 1 % lignocaine.
Studies were performed on ad libitum sodium intake. Noradrenaline was measured
by radioenzymatic assay [Ball et al., 1981] by Dr Gordon Inglis (MRC Blood
Pressure Unit, Western Infirmary, Glasgow). Blood pressure was measured using a
Takeda semi-automated sphygmomanometer (A&D UA-751)[Jamieson et al., 1990].
Mean arterial pressure was calculated as (diastolic pressure) + (pulse pressure -s- 3).
Drug Preparations
Liquorice was a kind gift from Geo. Bassett's Ltd, UK. Carbenoxolone sodium
tablets were obtained from Biorex Labs, UK and crushed into 50 mg capsules.
Placebo was lactose in identical capsules. For skin vasoconstriction studies Cortisol
(as hydrocortisone-21 -acetate; Sigma, UK) and beclomethasone dipropionate (BDP;
Steraloids, UK) were dissolved in 95 % ethanol; 5 % H2O. For brachial artery
infusions Cortisol (as hydrocortisone-21-succinate; Solucortef, Upjohn, UK) was
dissolved in 0.9 % NaCl, and noradrenaline (Levophed, Winthrop Labs, UK) diluted
in a solution containing 1 mM ascorbic acid and 0.9 % NaCl. The ascorbic acid was
added to prevent oxidation of noradrenaline.
Skin Vasoconstrictor Assay Method
This was performed as previously described [Teelucksingh et al., 1990]. The more
potent synthetic glucocorticoid BDP was used as a positive control, because it is
protected from 11B-DH metabolism by its 9a-chloro group. Twelve solutions
containing Cortisol (0.1, 0.3, 1, 3, 5, and 10 mg/ml) or BDP (0.1, 0.3, 1, 3, 5, and
10 |ig/ml) were prepared on the morning of the test. In the afternoon (1600-1700 h)
12 squares of 7 x 7 mm were outlined on the volar aspect of the subject's forearm
with silicone grease. The squares had 10 |il of steroid solution applied, with a
different solution for each square. The order of application was randomised and
double-blind. After evaporation the site was occluded with Saran wrap (Dow, UK)
which was removed at 0800 h the following morning. Intensity of dermal
vasoconstriction for each square was assessed at 1, 2, 3, 4, 6 and 8 h later by a
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blinded observer using a visual analogue scale from 0-3 . The response to each
steroid solution was expressed as the sum of scores obtained over time for that square
(max = 18 units). The response to Cortisol and BDP in each subject was represented
by the area under the dose-response curve and designated the "blanching score" for
each drug (maximum = 180 units.gig.ml*1 for BDP and 180 units.mg.ml-1 for
Cortisol).
Forearm Blood Flow Method
I performed these studies in Dr David Webb's laboratory in the Clinical Research
Centre, Western General Hospital. Before starting the experiments subjects rested
supine for at least 30 min. Room temperature was maintained at 27 ± 1 °C. The left
brachial artery was cannulated with a 27 standard-wire-gauge steel cannula (Cooper's
Needle Works, Birmingham, UK). Vehicle, noradrenaline or Cortisol solutions were
infused at a constant rate of 1 ml/min. At least 30 min elapsed between arterial
cannulation and the start of experimental recordings. Forearm blood flow was
measured in both arms using venous occlusion plethysmography with temperature-
compensated indium/gallium-in-silastic strain gauges [Whitney, 1953; Seidelin et al.,
1991]. During recording periods the hand circulation was excluded by inflation of
wrist cuffs to 200 mmHg and flows were measured for 10 s in every 15 s by repeated
inflation of upper arm cuffs to 40 mmHg. Recording periods lasted for 4 min (when
lower body negative pressure (LBNP) was not required) or 6 min (when LBNP was
applied during the second 3 min). The interval between recording periods was at least
6 min. After each recording period the gauges were calibrated on-limb and blood
pressure was measured in the right arm. Data was collected and analysed on a
Macintosh micro-computer. The mean of the final five measurements from each
recording period was used for analysis.
Effects of infusion are represented by the percentage change in forearm blood flow
calculated as:
C \ d // /v
(7Fd - 100%
where I and NI represent measured blood flows in the infused and non-infused arms
respectively during periods of drug (d) and vehicle (v) administration. Using this
calculation the non-infused arm acts as a control for non-specific variations in blood
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flow [Greenfield & Patterson, 1954]. Forearm vascular resistance is derived from
(mean arterial pressure in mmHg)/(flow in ml. 100ml"1.min"1).
When LBNP was required it was applied, as described previously [Zoller et al.,
1972; Seidelin et al., 1991], for the second half of the recording period. Subjects
rested supine in a plastic-covered steel cage enclosing the lower limbs and hips and
sealed around the waist above the level of the anterior superior iliac spines. Suction
was applied using a vacuum pump to produce a constant 20 cm H2O negative pressure
(compared with atmospheric). The alteration from atmospheric pressure was both
applied and relieved rapidly. This degree of LBNP induces a sympathetically-
mediated reflex which reduces forearm blood flow without measurable effect on heart
rate or blood pressure 2 min after application [Seidelin et al., 1991].
Study 1: Effect of 1113-DH Inhibitors on Vascular Sensitivity to Cortisol
(i) In Dermal Vascular Bed
Six healthy subjects (3 male, 3 female) aged 22-33 yr (mean = 26) had skin
vasoconstrictor assays performed before and after 7 days of oral liquorice (200 g
daily).
(ii) In Forearm Vascular Bed
Six healthy males aged 26-32 yr (mean = 29) had forearm blood flow studies on 2
occasions in random order, either with or without pre-administration of 7 days oral
liquorice (200 g daily). Infusions were with vehicle for 12 min, then Cortisol at 200
(ig/min for 30 min, and finally vehicle again for a 36 min washout period.
Recordings were made with and without LBNP during the first 6 of every 12 min.
Study 2: Vascular Sensitivity to Cortisol in Congenital 11B-DH Deficiency
Our patient with apparent mineralocorticoid excess [Stewart et al., 1988] was
described in Chapter 1. He was aged 25 yr at the time of this study. His maintenance
therapy was dexamethasone 0.25 mg at 0900 h and 0.75 mg at 2300 h, frusemide 40
mg at 0900 h, and captopril 25 mg 12 hrly. Plasma Cortisol was undetectable, supine
plasma renin activity 5.4 ng Angiotensin LmH.h"1 (normal range 0.3-1.5), plasma
aldosterone 380 pmol/1 (30-440), and blood pressure 127/72 mmHg. His last doses
of frusemide, captopril and dexamethasone were 30 h, 16 h, and 6 h respectively
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before the experiments. He had both the skin vasoconstrictor assay and intra-arterial
Cortisol infusion performed as described above.
Study 3: Effect of 1113-DH Inhibitors on Vascular Sensitivity to Noradrenaline
(i) In Forearm Vascular Bed and (ii) During Systemic Noradrenaline Infusion
Carbenoxolone was used for 116-dehydrogenase inhibition in this study in part to
allow a placebo-controlled double-blind design, in part because it may be a more
potent inhibitor of 116-DH than liquorice (see Table 1.3), and in part to avoid the
gastrointestinal side effects of liquorice. Six healthy males aged 26-33 yr (mean =
30) attended on 2 occasions after 7 days of oral carbenoxolone (100 mg 8 hrly) or
placebo, in random double-blind order. A 21 gauge cannula was inserted in a right
ante-cubital vein for blood sampling. Intra-arterial infusions were with vehicle for 12
min followed by incremental doses of noradrenaline (12 min each at 10, 20, 40, and
80 ng/min). LBNP was not applied in this study and recordings were made during
the last 4 min of each infusion.
Immediately after the intra-arterial study the cannula was removed. A 21 gauge
venous cannula was sited in the left arm and infused with incremental doses of
noradrenaline (5 min each at 1, 2, 4, and 8 pg/min). Blood pressure was recorded in
the right arm at 90 sec intervals.
For measurement of plasma noradrenaline concentrations 6 ml blood was withdrawn
from the right arm cannula into Lithium Heparin at 4 °C: at the beginning of the
experiment; during the highest dose of the intra-arterial infusion; and during systemic
infusion with 2 and 8 pg/min noradrenaline. Plasma was stored at -70 °C until
assayed.
Statistics
Results are given as mean ± SE. For intra-arterial Cortisol infusion time-points were
compared by paired multi-factorial ANOVA. For noradrenaline infusions dose-
response curves were compared by multiple regression with "% change in flow" or
"mean arterial pressure" as the dependent variable and "dose noradrenaline" and "pre-
treatment" (placebo versus carbenoxolone; assigned values of 0 and 1) as controlling
variables. Paired two-tail Student's t tests were used for two-group comparisons.
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Results
Dermal Vasoconstrictor Sensitivity to Cortisol
Results are shown in Figure 3.1. Oral liquorice potentiated the intensity of
vasoconstriction in response to topical Cortisol (p < 0.04) but not BDP. Dermal
vasoconstriction in GB was greater after Cortisol and less after BDP compared with
healthy subjects either with or without liquorice.
Figure 3.1 Effect of congenital and acquired 1113-DH deficiency on dermal

























GB is our patient with the syndrome of apparent mineralocorticoid excess type 1.
Bars are SE. NS = not significant.
Forearm Vascular Sensitivity to Intra-Arterial Cortisol ± LBNP
Results are shown in Table 3.1 and Figure 3.2. Resting blood flow, mean arterial
pressure, derived forearm vascular resistance, and degree of vasoconstriction in
response to LBNP at the start of the infusions were not affected by liquorice and were
not remarkable in GB (Table 3.1). During Cortisol infusions there was no
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Figure 3.2 Effect of congenital and acquired 11B-DH deficiency on forearm















































GB is our patient with the syndrome of apparent mineralocorticoid excess type 1.
Recordings were made with (Figure 3.2 B) and without (Figure 3.2A) the
application of lower body negative pressure (LBNP). Results are expressed as %
change from baseline of ratio: (flow in the infused arm)/(flow in non-infused arm).
Bars are SE.
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confounding systemic effect since neither mean arterial pressure, nor blood flow in
the non-infused arm, changed significantly. In healthy subjects, either with or
without liquorice, Cortisol infusion affected neither forearm flow without LBNP
(Figure 3.2A) nor vasoconstriction in response to LBNP (Figure 3.2B). However,
in GB there was vasoconsttiction during Cortisol infusion which was exaggerated by
LBNP. This was followed, during the washout period, by relative vasodilatation in
the absence of LBNP.
Vascular Sensitivity to Noradrenaline
Results for intra-arterial noradrenaline infusions are shown in Tables 3.1 and 3.2 and
Figure 3.3. Resting blood flow, mean arterial pressure, and derived forearm vascular
resistance at the start of the infusions were not affected by carbenoxolone (Table 3.1).
During infusions noradrenaline had no confounding systemic effect since neither
mean arterial pressure nor blood flow in the non-infused arm changed significantly.
Furthermore, in neither study did plasma noradrenaline levels rise in the contra-lateral
arm during intra-arterial infusions (Table 3.2). Carbenoxolone caused potentiation of
noradrenaline-induced forearm vasoconstriction (Figure 3.3; p < 0.01).
Results for systemic noradrenaline infusions are shown in Table 3.2 and Figure 3.4.
After carbenoxolone the levels of noradrenaline in the contralateral arm were
significantly lower during infusion with 8 pg/min noradrenaline (Table 3.2). Even
so, carbenoxolone potentiated the pressor response to noradrenaline (Figure 3.4; p <
0.001).
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Results are expressed as % change from baseline of ratio: (flow in the infused
arm)/(flow in non-infused arm). Bars are SE. Comparison of curves by multiple
regression p < 0.01. Paired Student's t tests: * = p < 0.03.
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Bars are SE. Comparison of curves by multiple regression p < 0.001. Paired
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Conclusions
These studies in man show that: (i) cortisol-induced dermal vasoconstriction is
increased in congenital 11B-DH deficiency and after oral liquorice; (ii) cortisol-
induced forearm vasoconstriction occurs in congenital 11B-DH deficiency (when it is
potentiated by the sympathetic stimulus of LBNP) but not in healthy volunteers either
before or after liquorice; and (iii) both forearm vasoconstriction induced by intra¬
arterial noradrenaline and pressor response induced by systemic noradrenaline are
potentiated by carbenoxolone. This is consistent with 11B-DH modulating the access
of Cortisol to receptors in blood vessels, and thereby influencing their sensitivity to
noradrenaline.
A number of points complicate the interpretation of these data. Firstly, in GB there
was cortisol-induced forearm vasoconstriction which was not reproduced in normal
volunteers by liquorice. It must be acknowledged that the interpretation of GB's
responses is compromised to some extent by his long-term therapy with
dexamethasone and angiotensin converting enzyme inhibitors. Nonetheless, the
consistency of the results of topical vasoconstriction between congenital and acquired
11B-DH deficiency support the contention that the same mechanism is responsible.
The difference in forearm responses possibly reflects the severity of 11B-DH
deficiency in GB. The half life of (1 la3H)-cortisol, which measures 11B-DH
activity, was 42 ±2 min in 19 controls, prolonged to 131 min in this patient [Stewart
et al., 1988] and 123 min after carbenoxolone [Stewart et al., 1990], but was only 85
min after liquorice [Stewart et al., 1987] (see Table 1.3).
Secondly, is it possible that the renal effects of 11B-DH inhibition account for these
results? For example, increased plasma volume consequent on renal sodium retention
might increase vascular sensitivity. However, previous investigators have shown
that, although volume expansion due to administration of mineralocorticoids increases
forearm vasoconstrictor sensitivity [Abboud, 1974] and volume expansion due to salt
loading increases pressor responses to noradrenaline [Pusterla et al., 1988], salt
loading (with suppressed plasma renin activity and aldosterone) leads to relative
relaxation of vessels in the forearm [Abboud, 1974], Since endogenous
mineralocorticoid secretion is suppressed when 11B-DH is inhibited it is unlikely that
our findings in the forearm are secondary to renal sodium retention. Similarly,
elevated blood pressure alone might increase vascular sensitivity. However, blood
pressure was no different after 7 days of carbenoxolone or liquorice. Furthermore,
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although GB had a history of hypertension and had higher blood pressure on the day
of this study, he had been normotensive on therapy during the three years
beforehand.
Thirdly, it may be important that both liquorice and carbenoxolone have actions
additional to their effect on 11B-DH. As discussed in Chapter 1, they inhibit a
number of enzymes which metabolise steroids [Monder, 1991] and prostaglandins
[Baker & Fanestil, 1991], and may act directly on steroid receptors [Armanini et al.,
1983] and cell membranes [Baron & Green, 1986]. However, it is unlikely that these
effects are relevant because similar abnormal vascular responses were found in
congenital 11B-DH deficiency, and because previous experiments have shown that
plasma concentrations of liquorice derivatives at the doses used in these experiments
are not high enough to produce other biochemical effects [Stewart et al., 1987;
Teelucksingh et al., 1991].
Mechanism of Increased Vascular Responses
The present results are consistent with many others in vivo and in vitro in which
corticosteroids increased the response to noradrenaline. This effect is common to
agonists of both mineralocorticoid and glucocorticoid receptors (see Chapter 1). In
the kidney it is predominantly mineralocorticoid receptors which are protected by 11B-
DH [Edwards et al., 1988; Funder et al., 1988]. However, cortisol-induced dermal
vasoconstriction is mediated by glucocorticoid receptors [Marks et al., 1982; Gaillard
et al., 1985]. Therefore in vascular tissue it is, at least in part, the access of Cortisol
to glucocorticoid receptors which is controlled by 11B-DH.
In addition, it is possible that some effects of steroids are mediated by cell surface
receptors [Orchinik et al., 1991; Wehling et al., 1991]. These would act more rapidly
than classical receptors because they are not dependent on gene induction. Activation
of surface receptors could account for the rapid vasoconstriction after intra-arterial
Cortisol in GB. By contrast, the time course of the dermal response potentiated by
liquorice is consistent with gene induction, being maximal at 12-15 hours [Trikam &
Morton, 1985].
The mechanism linking steroid receptor activation and increased response to
noradrenaline is uncertain. As discussed in Chapter 1, one possible explanation is
glucocorticoid-dependent inhibition of extra-neuronal noradrenaline uptake [Iverson
& Salt, 1970] and catechol-O-methyltransferase [Kalsner, 1969]. However, there is
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no evidence that these effects are important in vivo [Sudhir et al., 1989]. In this
study noradrenaline clearance was if anything increased by carbenoxolone, as judged
by noradrenaline levels during infusions. Perhaps of greater relevance are recent
observations, described in Chapter 1, of the influence of corticosteroids on
adrenoceptor numbers and second messenger sensitivity.
Relevance to Blood Pressure Regulation
The contribution which increased vascular tone makes to the hypertension of 11B-DH
deficiency is difficult to quantify. After liquorice there is a dissociation between
sodium retention (which occurs in the first few days and reaches equilibrium within
10 days) and elevated blood pressure (which occurs only after chronic administration
[Farese et al., 1991]). This delay is longer than the few days in which blood pressure
rises after administration of exogenous mineralocorticoids [Nicholls et al., 1979;
Fraser & Padfield, 1985]. Therefore the rise in blood pressure may be independent
of renal mineralocorticoid excess. In the present study, despite increased sensitivity
to noradrenaline, resting forearm vascular resistance was no different after 7 days of
carbenoxolone and blood pressure had not risen. This is consistent with findings
during dexamethasone administration to rats, when increased vascular sensitivity
[Russo et al., 1990] and pressor response [Handa et al., 1984] to noradrenaline
preceded the rise in blood pressure.
In summary the studies in man support the hypothesis that 11B-DH activity dictates
vascular sensitivity to Cortisol and thereby to noradrenaline. In order to confirm that
this effect is mediated by increased access of glucocorticoids to receptors in vascular
smooth muscle cells, and not by a secondary neurogenic or cardiovascular reflex, I
have applied the principles of the studies in man to experiments with isolated rat
vessels.
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Influence of llfi-DH Inhibitors on Vascular Responses to
Noradrenaline in Rat aortic Strips
The influence of corticosteroids on vascular tone has been investigated most
extensively in rats. Many of these experiments examined the effects of corticosteroid
insufficiency or excess in vivo on vascular reactivity ex vivo. This offers little
advantage over the experiments in man described above. A second approach has been
to infer the mechanism of a change in tone by studying biochemical changes in
cultured vascular smooth muscle cells. However, it remains to be seen whether
biochemical observations correspond with function in vivo. A third approach has
been to administer corticosteroids to vessels in isolated preparations in vitro, where
observed effects cannot be mediated indirectly by plasma volume expansion,
neurogenic reflexes, or hypertension. Unfortunately, many of these studies have
been performed at doses of steroids and time courses which are irrelevant to classical
steroid-induced transcription-dependent effects (see Chapter 1). The most common
mistakes have been to use too high a concentration and too short a time course. In the
experiments which follow I re-examine the effect of corticosterone on noradrenaline
sensitivity in rat aortic strips, and assess the effect of 11B-DH inhibition with
carbenoxolone.
Methods
Aortic Strips in Organ Baths
I was assisted in these experiments by Kathleen Sang, an Honours B.Sc. student
working under my supervision. Male Wistar rats (250-300 g) were killed by
decapitation. When required they were adrenalectomised under fentanyl anaesthesia
between 2 and 7 days before the experiment. Surgery was performed by June Noble,
and truncal blood collected for assay of plasma corticosterone to confirm its success.
After decapitation aortae were carefully dissected from the animal and connective
tissue removed. They were cut helically and the endothelium removed by abrasion.
Strips measuring 15x3 mm were mounted on transducers with silk sutures in a 5 ml
organ bath chamber which was gassed continuously with 95 % O2 / 5 % CO2.
Resting tension was adjusted to 2 g by internal calibration. The chamber was
perfused at 5 ml/min with KRBG (same composition as in Chapter 2 except without
albumin) containing steroids ± carbenoxolone. Both the chamber and perfusate were
warmed to 37 °C by water jackets.
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At the end of 2 or 5 h the perfusion was stopped. A cumulative dose-response curve
to noradrenaline stimulation was performed by adding 50 |il of each of a series of
stock solutions to the chamber. Contractions plateaued after 3-5 min and the next
dose of noradrenaline was added. Noradrenaline (Arterenol, Sigma) was diluted
fresh each day in 0.9 % NaCl containing 1 mM ascorbic acid to give final chamber
concentrations from 10~12 M to 10~4 M. At the end of the noradrenaline dose
response a maximal contraction was elicited by adding 100 (il of KC1 to the chamber
to a final concentration of 50 |iM.
All steroids and inhibitors were obtained from Sigma, except RU38486 (a
glucocorticoid receptor antagonist [Gaillard et al., 1984]) which was obtained from
Roussel UCLAF (Paris, France). Steroids were prepared in ethanol solutions and
added to the perfusate at <0.01 % final ethanol concentration. Carbenoxolone was
diluted directly in KRBG. The dose of steroids used was an approximation to their
Kc] for classical type 2 glucocorticoid receptors or, in the case of spironolactone and
RU38486, for their Ki for steroid binding. The exception was carbenoxolone. The
apparent Kj for 118-DH in microsomal preparations is ~10~9 M [Monder et al.,
1989], but the data in Figure 3.5 illustrate that in homogenates, and by inference in
whole aortic strips, it is significantly higher. This experiment was performed as in
Chapter 2 with a protein concentration of 500 |lg/ml and in the presence of 200 |lM
NADP and concentrations of carbenoxolone diluted in KRBG as shown. In order to
ensure adequate 116-DH inhibition in aortic strips a carbenoxolone concentration of
10~5 M was employed.
Dose-response curves were compared by two-way repeated measure ANOVA.
Results are mean ± SE and all experiments were performed on at least 6 aortic strips.
Results
Typical dose-response curves to noradrenaline are shown in Figure 3.6. Basal tone
after 2 h was not significantly different in all preparations therefore none of the steroid
treatments were directly vasoactive. The most dramatic differences were apparent in
the maximum contraction obtained rather than in the ED50 for noradrenaline. For that
reason, and to simplify visual comparison of multiple dose-responses, the data are
presented as maximum contraction achieved rather than showing the whole curve for
each drug. Nonetheless, the statistics refer to ANOVA of the whole curve.
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All changes observed in noradrenaline sensitivity were also reflected in responses to
KC1, so that results are all presented as absolute values of mg contraction rather than
as % of maximal contraction with KC1. The efficacy of removal of endothelium was
confirmed in preliminary experiments which showed vasoconstriction in response to
acetyl choline (10"6 M).
Non-adrenalectomised Rats
Results are shown in Figure 3.7. After perfusion for 2 h both corticosterone (10"7M)
and carbenoxolone (10~5M) reduced sensitivity to noradrenaline (p < 0.001), and the
combination of the two was indistinguishable from carbenoxolone alone. However,
when the experiments were repeated with perfusion for 5 h, carbenoxolone
potentiated the response to noradrenaline (p < 0.001) but corticosterone produced a
non-significant reduction of response. The combination of corticosterone and
carbenoxolone for 5 h was associated with responses similar to controls, significantly
lower than carbenoxolone alone (p < 0.001), but significantly greater than
corticosterone alone (p < 0.001).
Adrenalectomised Rats
Results are shown in Figure 3.8, after perfusion for 2 h. The response to
noradrenaline was not significantly different in aortae from adrenalectomised
compared with non-adrenalectomised rats. Carbenoxolone produced a dose-
dependent increase in the response to noradrenaline. Corticosterone had no
significant effect. The combination of carbenoxolone with corticosterone produced a
reduction in response, which was much lower than carbenoxolone alone (p < 0.001)
and also lower than corticosterone alone (p < 0.04). 11-Dehydrocorticosterone (10"
7M) had a non-significant potentiating effect when added alone and when added with
carbenoxolone was not different from carbenoxolone alone.
The potentiating effect of carbenoxolone was not affected by RU38486 (10"6M) but
was blocked by spironolactone (10"5M). RU38486 and spironolactone had no
significant effects when added alone.
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Figure 3.7 Maximum contraction to noradrenaline in aortic strips from non-
adrenalectomised rats
Control CBX B B+ CBX
Control CBX B B+ CBX
B = corticosterone (10"7M); CBX = carbenoxolone (10"5M). p values without
brackets refer to comparison with control data.
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A: manipulation of 11B-DH activity with carbenoxolone (CBX) and the response to
corticosterone (B; 10~7M) and 11-dehydrocorticosterone (A; 10~7M); B: effect of
competitive antagonists of glucocorticoid (RU38486; 10~6M) and mineralocorticoid
(spironolactone = SPIR; 10~5M) receptors on the response to carbenoxolone (10"5M).




The original explanation offered for the mineralocorticoid hypertension induced by
liquorice and carbenoxolone was that these agents bind directly to mineralocorticoid
receptors and activate them [Ulmann et al., 1975; Armanini et al., 1983]. In vivo in
man sufficiently high concentrations of liquorice and carbenoxolone are not achieved
and their direct effects are probably irrelevant [Teelucksingh et ah, 1991]. However,
in aorta in vitro, in order to ensure inhibition of 11G-DH, I have used much higher
concentrations of carbenoxolone. Similar conditions prevailed in previous studies on
lymphocytes in vitro when a change in sodium efflux was demonstrated with mM
concentrations of carbenoxolone [Baron & Green, 1986]. The current studies show
that carbenoxolone potentiates the response to noradrenaline at 10~5M but not
significantly at 10"7M. Potentiation only occurred in the absence of corticosterone
(either when the animals had been adrenalectomised, or when endogenous
corticosterone had been washed out for 5 h from the preparation of aortae from non-
adrenalectomised animals). This effect of carbenoxolone is probably mediated by
mineralocorticoid receptors since it can be blocked by spironolactone. The
observation that contraction to KC1 is also affected in the same direction as the
response to noradrenaline suggests that carbenoxolone affects the final common
pathway of contraction, rather than its effects being limited to a single second
messenger pathway.
In the presence of corticosterone (either present endogenously in the first 2 h
following removal from the non-adrenalectomised animals, or added at physiological
concentrations to preparations from adrenalectomised animals), the effect of
carbenoxolone was dramatically different. Thus in aortae from adrenalectomised
animals, although corticosterone had little effect alone, when added with
carbenoxolone there was attenuation of response relative to both corticosterone alone
and to carbenoxolone alone. Similarly, in aortae from non-adrenalectomised animals
the potentiation of response by carbenoxolone after 5 h was substantially blunted by
corticosterone, albeit that in this preparation the net effect when carbenoxolone and
corticosterone were combined remained a modest potentiation of response. These
data are consistent with carbenoxolone opening access for coiticosterone to receptors
which promote relative vasodilatation, ie attenuate the response to noradrenaline.
Thus 11G-DH may act physiologically to protect these receptors from corticosterone
and thereby influence vascular tone.
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The identity of the contraction-attenuating receptors activated by corticosterone is not
clear, but it is unlikely that they are mineralocorticoid receptors since we suspect that
mineralocorticoid receptor activation by carbenoxolone results in potentiation of the
response to noradrenaline. Furthermore, they are unlikely to be glucocorticoid
receptors because in a similar preparation Rees and colleagues [1990] showed that the
glucocorticoid receptor agonist dexamethasone potentiated the response to
noradrenaline over a similar time-course. It may be that the attenuating effect of
corticosterone is mediated by a third class of receptor in vascular smooth muscle. In
rabbit and bovine aorta Kornel and colleagues have demonstrated intra-cellular
binding sites with higher affinity for Cortisol than for dexamethasone, in addition to
binding sites with characteristics of mineralocorticoid and glucocorticoid receptors
[Komel et al., 1982; Hayashi & Kornel, 1990]. These may represent intra-cellular
CBG or binding to 11B-OHSD. Alternatively, they may be site-specific corticosteroid
receptors which are normally protected from glucocorticoids by 116-DH. To identify
the receptor which mediates corticosterone-induced attenuation in the presence of
carbenoxolone I have attempted to combine these two agents with spironolactone or
RU38486, but have found that these combinations result in very poor responses in
the vessels. It is hard to establish the mechanism of this loss of response, but it
probably relates to non-specific effects of high concentrations of several lipid-soluble
agents on cell membranes.
Finally, 11-dehydrocorticosterone was without effect either with or without
carbenoxolone, suggesting that 11B-OR does not act in rat aorta to amplify exposure
to glucocorticoids by converting the pool of inactive steroid to active corticosterone.
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Summary
In this Chapter I have demonstrated that manipulation of 11B-DH activity and
congenital deficiency of 11B-DH are associated with changes in vascular sensitivity to
glucocorticoids and catecholamines in man and rat. In human dermal and forearm
vessels this increases vascular reactivity; is probably mediated by glucocorticoid
receptors; and might contribute to the pathophysiology of hypertension. By contrast,
in rat aorta 11B-DH inhibition leads to relative loss of noradrenaline responsiveness,
mediated by an unidentified receptor. There are several possible explanations for this
discrepancy: (i) there may be differences between species; (ii) there may be site-
specific differences between vascular beds; or (iii) the removal of the endothelium
from the rat aortae may be significant.
The first possibility is difficult to test. Although there are different effects of enzyme
inhibitors on potassium balance and 11B-OR activity in man and rat (see Chapter 1),
we have no evidence that the physiological role of the enzyme in the kidney is
different between species. Furthermore, enzyme-mediated receptor protection is a
phylogenetically well-conserved mechanism, since it has been demonstrated in toad
bladder mucosa [Gaeggeler et al„ 1989; Brem et al., 1989].
The second possibility is testable. As I stressed in conclusion in Chapter 1, the action
of glucocorticoids in blood vessels may offer site-specific regulation dependent on the
local milieu. In Chapter 2 this possibility was emphasised by the apparent hybrid
character of the 11B-OHSD in the vessel wall: having the kinetic parameters of the
liver enzyme in the functional setting of the renal enzyme. The significance of site-
specificity could be corroborated by two experimental strategies: (i) to demonstrate in
another rat vascular bed that inhibition of enzyme activity is associated with increased
responsiveness to noradrenaline, as seen in man; and (ii) to demonstrate in aortic
vascular smooth muscle cells that a vasodilator second messenger is increased when
corticosterone is administered together with carbenoxolone, while this does not occur
in cells from another rat vascular bed. At the time of writing I am investigating the
effects of corticosterone and carbenoxolone on: (i) noradrenaline responsiveness in
perfused rat superior mesenteric arcade; and (ii) cAMP generation in vascular smooth
muscle cells in primary culture from rat aorta and mesentery.
Finally, the role of the endothelium in mediating the response to corticosteroids is
unclear. I chose to study rat aortic strips without endothelium because 11B-OHSD
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immunoreactivity and mRNA expression are not present in endothelial cells (see
Chapter 2). Furthermore, previous studies with dexamethasone have shown that the
presence or absence of the endothelium makes no difference to the effect on
noradrenaline sensitivity [Rees et al., 1990]. However, from the present data I
cannot exclude the possibility that changes in endothelium-derived paracrine
mediators (either increased release of a promoter of vasoconstriction or decreased
release of a promoter of vasodilatation) are responsible for the effect of Cortisol in
man when 1113-DH is inhibited or deficient. In the rat aorta, when 11B-DH is
inhibited, the absence of such an endothelial effect might allow a less potent
attenuating effect of corticosterone in the vascular smooth muscle cells to
predominate.
Thus although the mechanism is complex, these data confirm that the expression of
11G-OHSD in vascular smooth muscle cells is functionally significant, and suggest
that the enzyme plays diverse site-specific roles within the vascular tree. In
investigating the role of 11B-OHSD deficiency in human hypertension it will clearly
be important to consider the possible contribution made by increased vascular tone.
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CHAPTER 4 REGULATION OF 11B-HYDROXYSTEROID
DEHYDROGENASE BY ACTH IN MAN
The factors which regulate 11B-OHSD activity are poorly understood. A number of
observations led me to address the possibility that ACTH might influence enzyme
activity. Firstly, Ludwig Kornel showed that ACTH infusion in two Addisonian
patients was associated with a prolonged half life of 14C-cortisol and a reduced half
life of 14C-cortisone, suggesting that ACTH acts extra-adrenally to inhibit 11B-DH
[Komel, 1970]. Secondly, others had shown that infusion of exogenous ACTH does
not increase plasma cortisone concentrations despite a rise in Cortisol [Srivastava et
al., 1973; MacKenzie et al., 1990]. Finally, work with which I was involved
examining the activity of 11B-OHSD in bovine adrenocortical cells in primary culture
showed that basal synthesis of cortisone is substantial, but that ACTH does not
stimulate the secretion of cortisone after 60 min [Burt et al., 1991], suggesting that in
the presence of ACTH the proportion of Cortisol converted to cortisone is reduced.
(We have since shown that this apparent inhibition is less pronounced when ACTH is
administered for 6-24 h [Williams et al., 1992], perhaps reflecting induction of
adrenal 11B-OHSD expression by glucocorticoids).
I first addressed the hypothesis that ACTH inhibits 11B-DH by an extra-adrenal
mechanism in an experiment in adrenalectomised rats presented in Figure 2.9. Under
these conditions ACTH (1-24) had no measurable effect on the enzyme. By contrast,
administration of ACTH to non-adrenalectomised rats resulted in increased 11B-DH
activity in the kidney in vitro [Stewart et al., 1989], but this may reflect glucocorticoid
induction of the enzyme. In order to establish whether ACTH has an inhibitory effect
on 11B-DH activity when the adrenals are intact I turned my attention to man and
undertook the following experiments in healthy volunteers.
To test the hypothesis that ACTH inhibits 11B-DH requires measurement of enzyme
activity in subjects with varying plasma Cortisol concentrations. The most sensitive
measurement of cortisol-cortisone conversion is the half life of (lla3H)-cortisol
[Stewart et al., 1987; 1988; 1990]. However, the affinity of the labelled steroid for
11B-DH is less than that of endogenous Cortisol because of its primary isotope effect
[Hellman et al., 1971]. Therefore, the technique is not valid to compare Cortisol
inactivation as endogenous plasma Cortisol concentrations change. A more
conventional method is the measurement of urinary metabolites of Cortisol and
cortisone by gas chromatography and mass spectrometry. However, this did not
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detect 11B-0HSD deficiency after carbenoxolone administration [Stewart et al., 1990]
and is a laborious procedure. For these reasons I chose to measure cortisol/cortisone
ratios in peripheral blood as an index of 11B-DH activity. This is as sensitive as the
measurement of urinary metabolites in 11B-DH deficiency [Stewart et al., 1987;
1990](Table 1.3), and it offers the advantage that the estimation of 11B-DH activity in
single plasma samples allows more detailed examination of the physiology of the
enzyme. In order to relate changes in peripheral cortisol/cortisone ratios to changes in
renal 11B-DH activity it was also necessary to identify the major sources of plasma
cortisone in man using selective venous catheterisation.
Methods
Local Ethical Committee approval and written informed consent were obtained.
Plasma Cortisol was assayed directly by the method of McConway and Chapman
[1986] using a sheep antiserum from the Scottish Antibody Production Unit (Carluke,
UK). Plasma cortisone was assayed after ethyl acetate extraction and HPLC
separation with an in-house rabbit antiserum [Whitworth et al., 1989].
Selective Venous Catheterisation
Blood samples were obtained by Dr Cheok Song in the Cardiology department, from
24 patients undergoing routine left and/or right heart catheterisations for ischaemic or
valvular heart disease. Positioning of the catheter was confirmed radiographically for
each site. Sampling was not simultaneous.
Orcadian Blood Sampling
Seven healthy males on no medication aged 26-35 yr had a 21 gauge cannula inserted
in a forearm vein at 1200 h. They drew their own samples at 4 hrly intervals during
waking hours for the following 24 h.
Insulin Tolerance Tests
Three healthy males on no medication aged 28, 29 and 32 yr had a 21 gauge cannula
inserted in a forearm vein and were injected with insulin (0.15 units soluble human
insulin / kg body weight) at 0900 h. Samples were drawn at 15 min intervals for 105
min. Plasma glucose fell to < 2.0 mM and hyperadrenergic symptoms and signs were
noted in all cases.
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Infusions of ACTH and Cortisol
Five healthy males on no medication aged 26-33 yr attended at 0900 h on 2 occasions
after oral dexamethasone (1 mg at midnight and 0.5 mg at 0800 h). Bilateral forearm
cannulae were inserted, and one was infused on one occasion with 1-24 ACTH
(Synacthen, Ciba, UK) and on the other occasion with Cortisol (hydrocortisone-21-
succinate, Solucortef, Upjohn, UK), both diluted in 0.9 % NaCl. ACTH infusion
was for 10 min each at 0.1, 0.25, 0.5, 1, 3, and 6 |ig/min followed by 30 min at 12
pg/min. Cortisol infusion was for 10 min each at 50, 100, 140, 180, 220, 260, and
300 pg/min followed by 20 min at 400 pg/min. Samples were drawn from the non-
infused arm at 10 min intervals. One subject only attended for Cortisol infusion, so
that 50 data points are available for Cortisol and 40 for ACTH infusions.
Statistics
Results are expressed as mean ± SE. Student's unpaired two-tail t test was used to
compare data from two groups. Multiple groups were compared by single-factor
ANOVA followed by Fisher's PLSD test. Interval data in the circadian and insulin
tolerance studies were compared by repeated measure ANOVA and Fisher's PLSD.
Relationships between continuous variables were assessed by linear regression, and
differences between these relationships assessed by multiple regression (where
necessary assigning non-continuous variables values of 0 and 1).
Results
Principal Site of Cortisone Production
Results of selective venous catheterisation are shown in Figure 4.1. Plasma Cortisol
was not different between sites. However, plasma cortisone was low in hepatic vein
(p < 0.01) and cortisol/cortisone ratio was low in renal vein (p < 0.05) and high in
hepatic vein (p < 0.01).
Response of Cortisol and Cortisone to Endogenous ACTH
(i) Circadian Rhythm
Results are shown in Figure 4.2. Plasma Cortisol peaked as expected at 0800 h and
reached a nadir at 2400 h (repeated measure ANOVA p < 0.001). Plasma cortisone
showed no significant circadian rhythm.
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Figure 4.1 Concentrations of Cortisol and cortisone, and cortisol/cortisone ratio,


















(ii) Insulin Tolerance Tests
Results are shown in Figure 4.3. A significant rise in plasma Cortisol in response to
hypoglycaemic stress was accompanied by a non-significant fall in mean plasma
cortisone.
(iii) Dexamethasone Suppression
Dexamethasone (given in preparation for the study with Cortisol and ACTH infusion)
resulted in a non-significant fall in mean basal plasma cortisone from 77 ± 16 nM to
28 ± 11 nM (p = 0.16) on the first study morning when plasma Cortisol was
suppressed from 514 ± 68 nM to 37 ± 3 nM (p < 0.001).
Response of Plasma Cortisol and Cortisone to Exogenous ACTH
The relationships between plasma Cortisol and cortisone during infusion with Cortisol
and ACTH are shown in Figure 4.4. Infusion of Cortisol resulted in a significant rise
in cortisone (R2 = 0.18, p < 0.002), but infusion with ACTH had no effect (R2 =
0.005, p > 0.6). Multiple regression showed a significant difference between Cortisol
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Figure 4.2 Orcadian variations in plasma Cortisol and cortisone
Time of Day
Bars are SE. By repeated measure ANOVA the variations in Cortisol were significant
(p < 0.001) while those in cortisone were not.
Figure 4.3 Response of plasma Cortisol and cortisone to insulin-induced
hypoglycaemia
Time after Insulin (min)
Bars are SE. By repeated measure ANOVA Cortisol rose significantly (p < 0.001)
while cortisone showed a non-significant fall following insulin.
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Figure 4.4 Plasma Cortisol and cortisone concentrations during infusion with
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The results shown are for linear regression analysis. Multiple regression showed a
significant difference between the curves (p < 0.03).
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Conclusions
The present data confirm that the major site of peripheral conversion of Cortisol to
cortisone is the kidney rather than the liver, a finding which was suggested by the
observation of reduced plasma cortisone levels in patients with chronic renal failure
[Whitworth et al., 1989]. Furthermore, it confirms the hypothesis presented in
Chapter 1 that the activity of 11B-OHSD in the liver is predominantly 11B-OR.
One possible source of cortisone which was not assessed is the adrenal cortex. We
were not the first to show that cortisone is produced by isolated adrenocortical cells
[Whitehouse et al., 1967], and previous studies in man have shown a cortisone
concentration gradient from adrenal vein to peripheral vein of 2.9:1 [Bailey & West,
1969; Dazord et al., 1972], Our data from bovine cells show that acute ACTH
stimulation may be associated with an increased secretion of Cortisol relative to
cortisone from the adrenal [Burt et al., 1991] and this might also be relevant to the
observations of acute changes in cortisol/cortisone ratio presented here.
Acute increases in endogenous ACTH levels, during circadian rhythm and insulin-
induced hypoglycaemic stress, were associated with an increase in cortisol/cortisone
ratio. This might be explained if: (i) ACTH, or an ACTH-stimulated adrenal
precursor steroid, inhibits the adrenal production of cortisone acutely; (ii) increased
coitisol concentrations of this magnitude saturate 11B-DH and clearance of Cortisol is
no longer first order; or (iii) ACTH, or an ACTH-stimulated steroid, inhibits the
peripheral conversion of Cortisol to cortisone in the kidney. These possibilities were
dissected in the study presented in Figure 4.4 which demonstrates that, when adrenal
cortisone production is suppressed, over a range of plasma Cortisol concentrations
from 0 to 1500 nM 11B-DH is not saturated since plasma cortisone levels increase.
By contrast, similar Cortisol concentrations produced by ACTH do not elevate
cortisone levels, implying that ACTH, or an ACTH-dependent factor, inhibits the
peripheral conversion of Cortisol to cortisone. The failure of exogenous ACTH to
raise plasma cortisone levels has been described before [Srivastava et al., 1973;
MacKenzie et al., 1990] but this is the first study to distinguish between saturation
and inhibition of 11B-DH. Interestingly, endogenous ACTH does induce a circadian
rhythm in salivary cortisone [Katz & Shannon, 1969]. This suggests that ACTH-
dependent inhibition of 116-DH may be tissue-specific.
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Given that the kidney is the major site of peripheral 11B-DH activity, we can infer that
increased ACTH concentrations are not only associated with increased adrenal Cortisol
secretion, but also cause an increase in renal sensitivity to Cortisol. This raises the
possibility that in physiological circumstances when ACTH is high, Cortisol may act
as a mineralocorticoid. This might be important in dictating circadian rhythms of
sodium excretion and blood pressure [Millar-Craig et al., 1978].
At present the mechanism of ACTH-dependent 11B-DH inhibition is obscure.
Kornel's hypothesis of an extra-adrenal action of ACTH may be flawed because both
of the Addisonian patients he studied could have had some residual adrenocortical
function [Komel, 1970]. In intact rats, chronic administration of ACTH resulted in
increased in vitro renal 116-DH activity [Stewart et al., 1989]. By contrast, in
adrenalectomised rats ACTH had no measurable effect on the enzyme (Figure 2.9).
These results probably reflect glucocorticoid-dependent induction of 11B-OHSD
expression in the longer term (Figures 2.7 - 2.9), but they raise the possibility that
ACTH does not inhibit 11B-DH in the rat. Thus the most likely explanation for the
present observations in man is that the effect of ACTH is mediated by an ACTH-
dependent corticosteroid which inhibits 11B-DH, and which may not be produced in
rat adrenal. Many steroids are competitive inhibitors of 11B-DH [Monder &
Shackleton, 1984](Table 1.4), including several ACTH-dependent 17-hydroxylated
progestogens not produced by rat adrenal.
This mechanism might even explain the paradox that in sheep the hypertension
induced by ACTH administration cannot be reproduced by infusion of the major
glucocorticoid and mineralocorticoid hormones, but is reproduced with the addition of
17a-hydroxyprogesterone and 17,20a-dihydroxyprogesterone, steroids which are
devoid of intrinsic corticosteroid agonist activity [Scoggins et al., 1989]. These
progestogens may act as ACTH-dependent inhibitors of 11B-DH, thus potentiating the
hypertensinogenic action of Cortisol. Similarly, an effect of ACTH to increase
mineralocorticoid receptor sensitivity to Cortisol might explain why kaliuresis induced
by exogenous Cortisol in man appears to be mediated by glucocorticoid receptors,
while ACTH-induced kaliuresis is mediated by mineralocorticoid receptors [Clore et
al., 1988]. However, the relevance to ACTH-dependent hypertension in man remains
uncertain since, by contrast with sheep, it seems that ACTH-dependent hypertension
can be reproduced by Cortisol alone in man [Connell et al., 1987].
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It is possible that ACTH-dependent inhibitors of 11B-DH have already been
measured, albeit inadvertently, when Morris and colleagues demonstrated that extracts
of human urine have inhibitory activity for 11B-DH in vitro IMorris et al., 1992]. The
excretion of these factors increases during pregnancy, suggesting that they may be
progesterone metabolites or precursors. I am currently investigating whether
manipulation of ACTH secretion affects the levels of extractable urinary inhibitory
activity in man.
Finally, the observation of ACTH-dependent inhibition of 11B-DH may be important
in a clinical syndrome in which ACTH levels are grossly elevated and hypokalaemic
alkalosis is a common feature: the ectopic ACTH syndrome. The possibility that 11B-
DH deficiency is important in this and other hypertensive syndromes is addressed in
Chapter 5.
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CHAPTER 5 11B-HYDR0XYSTER0ID DEHYDROGENASE
DEFICIENCY IN HYPERTENSIVE SYNDROMES
In the preceding chapters I have described the elucidation and implications of the
mechanism of 116-OHSD-mediated protection of corticosteroid receptors. I have
illustrated how hypertension may be associated with 1113-DH deficiency, not only
because of increased cortisol-dependent mineralocorticoid receptor activation in distal
renal tubules, but also because of increased sensitivity to Cortisol (and thereby to
noradrenaline) in blood vessels. Furthermore, I have demonstrated that 11I3-DH may
be impaired, not only in the congenital syndrome of apparent mineralocorticoid excess
and after administration of the 11G-DH inhibitors liquorice and carbenoxolone, but
also as a result of endogenous ACTH-dependent inhibition. In the present chapter I
address the clinical implications of these observations by measuring 11G-DH activity
in hypertensive patients.
The most obvious syndromes in which 116-DH deficiency may contribute to
pathophysiology are those in which Cortisol is suspected to mediate mineralocorticoid
excess. This applies in the rare syndrome of apparent mineralocorticoid excess type 2
(see Chapter 1) and also in a much more common syndrome, that of ectopic secretion
of ACTH. However, given the diversity of mechanisms described in this thesis by
which 11B-DH activity may influence blood pressure, it is also possible that enzyme
deficiency is important in syndromes in which mineralocorticoid excess is not a
feature, but in which Cortisol is suspected to mediate the hypertension. This applies in
a subgroup of patients with essential hypertension.
Ectopic ACTH Syndrome
Ectopic ACTH secretion can be distinguished from other causes of Cushing's
syndrome by a high incidence of hypokalaemic alkalosis (> 90 % compared with 10
% in Cushing's syndrome of other aetiologies)[Howlett et al., 1986]. This probably
reflects increased secretion of an endogenous steroid with high affinity for
mineralocorticoid receptors but its identity remains uncertain. It is not aldosterone
which is invariably suppressed [Christy & Laragh, 1961]. It is widely supposed that
either corticosterone [Cost, 1963b] or 11-deoxycorticosterone (DOC) [Crane &
Harris, 1966; Schambelan et al., 1971] are responsible. However, some
hypokalaemic patients have normal corticosterone and DOC levels [Christy & Laragh,
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1961] while corticosterone and DOC are both raised in normokalaemic patients with
pituitary-dependent Cushing's syndrome [Ritchie et al., 1990]. In fact, it is the
secretion rate of Cortisol which correlates best with the degree of mineralocorticoid
excess [Christy & Laragh, 1961]. For Cortisol to account for the mineralocorticoid
excess would require breaching of the protection which 11B-DH normally confers on
mineralocorticoid receptors. The conclusion in Chapter 4 that ACTH indirectly
inhibits 11B-DH suggests that this could occur. In patients who have the highest
ACTH secretion rates, ie those with ectopic rather than pituitary ACTH excess, this
effect might be of sufficient magnitude to provoke cortisol-dependent
mineralocorticoid excess.
In the following studies 11B-DH activity is estimated using the peripheral plasma
cortisol/cortisone ratio in 26 patients with Cushing's syndrome of various aetiologies.
Having confirmed a defect in Cortisol inactivation in patients with ectopic ACTH
syndrome, I then assessed the relative contributions of 11B-DH deficiency, and
plasma DOC and corticosterone concentrations in predicting the mineralocorticoid
status of these patients.
Patients and Methods
Local Ethical Committee approval and written informed consent were obtained.
Plasma Cortisol and cortisone were assayed as in Chapter 4. Urine free Cortisol was
measured with the Amerlex kit (Amersham, UK). DOC and corticosterone were
measured by Dr Robert Fraser, MRC Blood Pressure Unit, Glasgow Western
Infirmary, using radioimmunoassays after extraction and partial purification by paper
chromatography [Fraser et al., 1975]. ACTH was measured by two-site
immunoradiometric assay [White et al., 1990] by Dr Anne White, Hope Hospital,
Manchester.
Samples were drawn after 5 min sitting between 0900 h and 1000 h from: (i) 20
healthy subjects (18 males) on no medication aged 19-62 yr (mean 36 yr); (ii) 12
hypopituitary patients (8 males) on oral hydrocortisone replacement for at least 12
months (from 7.5 to 30 mg daily in divided doses) aged 27-61 yr (mean 47 yr); (iii)
13 patients (9 males) on hydrocortisone replacement for primary adrenal insufficiency
aged 18-80 yr (mean 52 yr); and (iv) 26 patients with Cushing's syndrome described
in Table 5.1. Fifteen of the 26 patients with Cushing's syndrome were recruited at the
Queen Elizabeth Hospital, Birmingham by Dr Paul Stewart.
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All patients diagnosed as having pituitary-dependent Cushing's disease had > 50 %
suppression of urinary free Cortisol after high dose oral dexamethasone (2 mg 6 hrly
for 48 h) and, in the subjects tested (n=l 1), a > 100 % increase in ACTH following
100 |ig iv corticotrophin releasing hormone. All but two of the patients with ectopic
ACTH secretion had no suppression of urinary free Cortisol with high dose
dexamethasone (two patients had no dynamic test performed but had very high plasma
Cortisol and hypokalaemia). Histological confirmation was obtained in 14/15 patients
with pituitary adenoma and in all those with ectopic ACTH secretion. Patients with
adrenal adenomas both had undetectable ACTH and radiological evidence of a
unilateral adrenal mass. Histological confirmation was obtained in one of these
patients.
Statistics
Results are expressed as mean ± SE. Multiple groups of subjects were compared by
single-factor ANOVA followed by Fisher's PLSD test. Relationships between
continuous variables were assessed by linear regression, and differences between
these relationships assessed by multiple regression (where necessary assigning non-
continuous variables values of 0 and 1).
Results
Cortisol/Cortisone Equilibrium
Results are shown in Table 5.1 and in Figure 5.1 for the levels of plasma Cortisol,
cortisone, and cortisol/cortisone ratios. 0900-1000 h plasma Cortisol in patients with
pituitary-dependent and non-ACTH-dependent Cushing's syndrome were not
significantly higher than in controls but plasma Cortisol was higher in patients with
ectopic ACTH syndrome (p < 0.05). Patients on hydrocortisone replacement for
hypopituitarism also had high plasma Cortisol (p < 0.05), reflecting either differences
in the timing of sampling after their morning dose of oral hydrocortisone or
inappropriately high doses prescribed for these patients. However, patients on
hydrocortisone replacement for primary adrenal insufficiency had plasma Cortisol
levels within the normal range.
Plasma cortisone levels were more variable, and not significantly different between
groups.
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Table 5.1 Patients with Cushing's syndrome
Sex Age Histology Plasma Plasma Plasma Urine free Plasma
Cortisol cortisone K+ Cortisol ACTH
(yr) (nM) (nM) (mM) (nmol/day) (pM)
Pituitary-dependent Cushing's syndrome
F 57 Pituitary 606 226 3.3 722 2
adenoma
F 54 Pituitary 663 66 3.5 3106 2
adenoma
M 47 Pituitary 713 81 3.5 1854 19
adenoma
F 49 Pituitary 782 48 4.4 1050 13.6
adenoma
F 21 Pituitary 979 55 4.1 490 11.6
adenoma
F 31 Pituitary 601 40 4.2 1650 5.8
adenoma
F 41 Pituitary 864 55 3.8 530 5.8
adenoma
F 37 Pituitary 590 48 4.1 504 28.4
adenoma
M 44 Pituitary 1357 48 4.3 2500 20.5
adenoma
F 40 Pituitary 512 55 3.9 3800 3.2
adenoma
F 24 Pituitary 1236 40 4.1 2369 10.0
adenoma
F 41 Pituitary 611 133 4.2 770 3.8
adenoma
F 33 seef 641 120 4.4 3600 4.5
F 56 Pituitary 632 133 4.4 720 9.9
adenoma























F 57 SCLC 2760 243 1.9 15090 57




837 81 2.0 6700 151




3843 40 2.5 1200 57




1471 194 2.7 6500 18
F 63 SCLC 3311 67 1.5 no data no data





516 113 4.3 1668 undetect
-able
F 60 (died; no
post
mortem)
737 116 3.5* 561 undetect
-able
SCLC = small cell carcinoma of lung
* = on K+-sparing diuretic
t This patient had normal pituitary radiology and no adenoma was seen at trans¬
sphenoidal surgery, but radical hypophysectomy resulted in cure.
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Figure 5.1 0900-1000 h plasma Cortisol and cortisone concentrations and
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The most striking differences emerged from examination of the cortisol/cortisone
ratios (Figure 5.1). These were much higher in the ectopic ACTH group than in any
other, including hypopituitary patients who had similar, albeit short-term, elevations
in plasma Cortisol. Furthermore, cortisol/cortisone ratios were lowest in the two
patients with non-ACTH-dependent Cushing's syndrome.
11B-OHSD. Coiticosterone and DOC as Determinants of Hvpokalaemia
The levels of plasma cortisol/cortisone ratio, corticosterone and DOC in patients with
Cushing's syndrome are shown in Figure 5.2. There is overlap between the groups
in all parameters. In general those patients with high cortisol/cortisone ratios also
have high corticosterone and DOC levels. However, some patients in the ectopic
ACTH group with normal cortisol/cortisone ratios have very high plasma
corticosterone. No patients were identified with low DOC and corticosterone levels
and a high cortisol/cortisone ratio.
Regression analyses were performed to con-elate plasma potassium concentrations (in
patients who were not on diuretics) with: plasma Cortisol, cortisone, cortisol/cortisone
ratio, DOC, corticosterone, ACTH and urinary free Cortisol. No significant
correlations were found when the patients with ectopic ACTH syndrome or with
pituitary-dependent Cushing's syndrome were considered alone. Results when all
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patients were included are shown in Table 5.2. The severity of Cushing's syndrome
(assessed by ACTH concentration; urinary free Cortisol; and plasma Cortisol) was
negatively correlated with plasma potassium, reflecting the fact that Cortisol secretion
was higher in the group with ectopic ACTH syndrome (Table 5.1). Furthermore,
plasma corticosterone, DOC and cortisol/cortisone ratios all correlated negatively with
plasma potassium. However, in a multiple regression analysis none of these
correlations was independent, therefore the level of no single steroid predicted the
degree of hypokalaemia.
Table 5.2 Correlations between ACTH and steroid concentrations and the
degree of hypokalaemia
Linear Regression"! Multiple Regression
R value p value p value
ACTH -0.63 0.002 0.08
Urinary Free Cortisol -0.70 0.0004 0.96
Plasma Cortisol -0.75 0.0001 0.06
Plasma Cortisone 0.4 0.89
Cortisol/Cortisone Ratio -0.45 0.03 0.19
Plasma Corticosterone -0.74 0.0003 0.81
Plasma DOC -0.76 0.0002 0.17
t Patients on K+-sparing diuretics were excluded from this analysis (1 adrenal
adenoma, 1 ectopic ACTH and 1 pituitary adenoma). In addition within each row the
following data were excluded: 2 ectopic ACTH and 2 pituitary adenomas for whom
insufficient plasma samples were available for corticosterone and 11-
deoxycorticosterone assays; 2 ectopic ACTH for whom urinary free Cortisol was






























































These data illustrate that Cortisol inactivation by 11B-DH is less complete in patients
with ectopic ACTH secretion than in those with other forms of Cushing's syndrome.
These patients generally have Cortisol concentrations outwith the range studied in the
experiment presented in Figure 4.4, and their failure to inactivate Cortisol by this route
may reflect a combination of ACTH-dependent inhibition and saturation of renal 1113-
DH.
A number of observations in older literature lend weight to this interpretation.
Chromatographic techniques have been used in attempts to differentiate the pattern of
urinary metabolites in different forms of Cushing's syndrome. Although not often
discussed in detail several of these studies measured the ratio of urinary metabolites of
Cortisol (THF and allo-THF) to those of cortisone (THE) (Figure 1.2). Two
consistent abnormalities were observed in Cushing's syndrome: decreased 11B-DH
activity (increased ratio of [THF+allo-THF]/THE)[Cost, 1963a; Phillipou, 1982]; and
decreased A-ring reduction by 5a-reductase (increased ratio of
etiocholanolone/androstenedione [Jailer et al., 1959; Moolenaar & Van Seters, 1971;
Phillipou, 1982] and of THF/allo-THF [Cost, 1963a; Phillipou, 1982]). The same
pattern was found in patients with chronic stress [Gold et al., 1958; Ichikawa, 1966],
and in volunteers and patients receiving exogenous ACTH [Jailer et al., 1959; Cost,
1963c]. The 5a-reductase defect correlated with ACTH secretion, since it was most
obvious in ectopic ACTH, less so in pituitary-dependent disease and least in adrenal
adenomas [Moolenaar & Van Seters, 1971], It could also be reproduced by
administration of the ACTH-dependent precursor, dehydroepiandrosterone [Kirschner
& Lipsett, 1964]. In this respect the mechanism may be very similar to that which I
propose in Chapter 4 for ACTH-dependent inhibition of 11B-DH, ie inhibition of the
enzyme by an ACTH-dependent steroid. However, the correlation between ACTH
secretion, diagnosis, and 11B-DH activity has not been examined previously. Most
studies failed to separate patients according to their aetiology and, until recently, (THF
+ alloTHF)/THE ratios had only been reported in two patients with definite ectopic
ACTH syndrome whose results were not separated from those of 4 patients with
pituitary-dependent Cushing's disease [Phillipou, 1982], Very recently, Ulick and
colleagues [1992b] reported two more patients with ectopic ACTH syndrome who had
deficient Cortisol clearance both by 11B-OHSD and by A-ring reduction (measured by
urinary metabolite profiles). It is concluded that deficient Cortisol inactivation is
responsible for the hypokalaemia in these patients. Unfortunately, these authors do
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not acknowledge that the abnormalities have been described before in Cushing's
syndrome, and do not have any data for comparison from normokalaemic patients
with other causes of the syndrome.
Conventionally, hypokalaemic alkalosis in ectopic ACTH syndrome has been
attributed to increased secretion of DOC [Schambelan et al., 1971] or corticosterone
[Cost, 1963b]. Both of these steroids mediate mineralocorticoid excess in other
circumstances, including 116-hydroxylase deficiency, 17-hydroxylase deficiency
[Schambelan et al., 1971], and adrenal tumours [Crane & Harris, 1966; Hogan et al.,
1977; Ishikawa et al., 1988]. However, the absolute levels of DOC in these patients,
although above the normal range, are orders of magnitude lower than the levels of
Cortisol and corticosterone (Figure 5.2). Thus the contribution of DOC to activation
of mineralocorticoid receptors is probably insignificant. By contrast, corticosterone
levels are substantially elevated in the patients with ectopic ACTH syndrome.
Corticosterone is also a substrate for 11B-DH [Monder & Shackleton, 1984], and its
increased concentration may reflect inhibition of 11B-DH in addition to increased
adrenal corticosterone secretion.
11B-DH deficiency offers an alternative mechanism for the hypokalaemic alkalosis of
ectopic ACTH syndrome. In this study 11B-DH is impaired in ectopic ACTH
syndrome and not in other forms of Cushing's syndrome, and the degree of enzyme
impairment correlates with the degree of hypokalaemia. However, there is also
considerable overlap between groups for cortisol/cortisone ratios, suggesting some
heterogeneity in the degree of 11B-DH impairment. Furthermore, cortisol/cortisone
ratio is not an independent predictor of mineralocorticoid excess (Table 5.2).
It seems most likely that a combination of factors is responsible for hypokalaemic
alkalosis in these patients. Moreover, it is possible that the impaired 11B-DH activity
and increased DOC secretion have more than an additive effect in inducing kaliuresis.
This possibility is raised by Morris's observations in rats that carbenoxolone not only
increases renal mineralocorticoid receptor sensitivity to corticosterone and Cortisol
[Souness & Morris, 1989] but also increases sensitivity to DOC and aldosterone
[Moms & Souness, 1990]. The mechanism of this interaction is unknown, but it
raises the possibility that the loss of 11B-DH activity in ectopic ACTH syndrome may
potentiate the response not only to Cortisol and corticosterone, but also to DOC.
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Essential Hypertension
Not only is Cushing's syndrome associated with hypertension in approximately 75%
of patients [Fraser et al., 1989], but circumstantial evidence suggests that Cortisol is a
significant mediator in some patients with essential hypertension. This comes
principally from the observation that dexamethasone therapy is associated with a fall in
blood pressure in some essential hypertensives [Hamilton et al., 1979; Whitworth et
al., 1989a]. Furthermore, although circulating concentrations and secretion rates of
Cortisol are not elevated [Vermeulen & Van der Straeten, 1963], Cortisol metabolism is
abnormal resulting in increased excretion of polar derivatives of Cortisol (non-A-ring-
reduced 20-hydroxy and 6-hydroxysteroids)[Kornel et al., 1975]. These
abnormalities might all be explained if 11B-DH is deficient in these patients.
Methods
Patients and Subjects
Twenty patients with no clinical or biochemical features of secondary hypertension
were recruited from Dr Paul Padfield's Hypertension Clinic and compared with 19
normal controls. All were Caucasian. Exclusion criteria were: alcohol intake > 4
units/day; abnormal liver, renal or thyroid function on biochemical screening; body
weight > 120 % of predicted; a history of depressive illness; previous corticosteroid
therapy; and in controls only, a first degree relative with hypertension. Female
subjects were studied on day 5 of the menstrual cycle if pre-menopausal. All but 4
patients were studied either before the institution of anti-hypertensive therapy or after
therapy had been discontinued for at least 6 weeks. The patients studied during
continuing therapy had demonstrable complications of hypertension, either left
ventricular hypertrophy or a history of cerebrovascular disease, and were included to
avoid bias towards mild disease. The matching criteria for hypertensives and controls
are shown in Table 5.3. Local Ethical Committee approval and written informed
consent were obtained.
Half Life of (\ la3H)-cortisol
(1 la3H)-cortisol is acted on by 1 lB-dehydrogenase to produce 3H-H20 and
unlabelled cortisone. Preparation and use of this isotope has been described
previously [Hellman et al., 1971; Ulick et al., 1979; Stewart et al., 1988]. The
subject was supine with an ante-cubital iv cannula in situ for 30 min before blood was
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withdrawn for baseline investigations and blood pressure measured by the mean of 3
recordings from a Copal automatic sphygmomanometer. At 0900 h an iv bolus of
1.20-1.54 MBq of (lla3H)-cortisol containing 0.7 mg of Cortisol diluted in 15 ml 2
% ethanol/water was injected over 20 s. Sequential 10 ml blood samples were
collected in Lithium Heparin at 15-30 min intervals for 120 min, centrifuged at 4 °C,
and the plasma stored at -20 °C. Plasma and the 3H-H20 collected from it after
sublimation were both counted in Picofluor-30 scintillant (Packard Canberra, UK) to
an error of < 2 % and corrected for quench.
From these data 1 lB-dehydrogenase activity can be estimated either: (i) as the rate of
accumulation of 3H-H20 product (calculated by linear regression as the slope of
[(dpm/ml for 3H-H20)/(dpm/ml for plasma) x 100%] versus [time]); or (ii) as the rate
of disappearance of (1 la3H)-cortisol substrate (calculated as a half life by linear
regression from the elimination phase between 45 and 120 min of a plot of
log[(dpm/ml for total radioactivity in plasma)-(dpm/ml for 3H-H20)] versus [time]).
In order to choose between these two methods we examined their mathematical
precision. There was excellent correlation between 3H-H20 accumulation rate and
half life of (lla3H)-cortisol (R = 0.57; p < 0.0001). However, the mathematical fit
of individual 3H-H20 accumulation rates was less precise (R > 0.77) than the first
order elimination curves for the half life of (1 la3H)-cortisol (R > 0.96). For this
reason the half life of (1 la3H)-cortisol was chosen as the summary statistic reflecting
1 lB-dehydrogenase activity.
This method may be subject to artefact if (1 la3H)-cortisol is converted to other
steroids which retain the 3H label but are not metabolised by llB-dehydrogenase.
This was addressed by extracting steroids with ethyl acetate [Whitworth et al., 1989b]
from plasma samples taken at +80 or +90 min from 15 of the controls and 17 of the
hypertensives. The steroids were separated by reverse phase HPLC using a CI8
pBondapack column (Millipore-Waters) with mobile phase of methanokwater (1:1) at
flow rate 1.3 ml/min. The elution of 3H-steroids was monitored in 3 s fractions for 25
min by on-line radioactive detection using a Berthold Z1000 cell with scintillant flow
rate of 3.9 ml/min. The integrated counts within peaks were analysed by Berthold
HPLC software on a PC. The radioactivity eluting with Cortisol averaged 98 % of the
total extracted radioactivity and no other consistent peaks were observed in the
chromatograms. Moreover, the extracted radioactivity eluting with Cortisol averaged
84 % of the radioactivity in plasma attributed to (1 la3H)-cortisol in the calculation of
half lives. The extraction efficiency of Cortisol by ethyl acetate is 90 %, therefore 93
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% of radioactivity in the non-aqueous plasma fraction was extracted by ethyl acetate
and eluted with Cortisol on HPLC. Thus, conversion of (lla3H)-cortisol to steroids
which retain the 3H label averaged 2 % for ethyl acetate extractable steroids, and 7 %
for non-extractable steroids. Furthermore, neither of these errors correlated with the
half life of (lla3H)-cortisol, therefore they were not considered to compromise the
interpretation of our results.
Finally, the primary isotope effect of 3H (which makes the affinity of (lloc3H)-
cortisol for the 11B-dehydrogenase active site lower than that of endogenous Cortisol
(Hellman et al. 1971)) dictates that apparent 11B-dehydrogenase activity will be
artefactually reduced when endogenous Cortisol levels are very high. In the present
study endogenous plasma Cortisol concentrations were similar in the groups of
subjects studied, and did not correlate with the half life of (1 la3H)-cortisol. Thus the
primary isotope effect was not a determinant of the differences observed.
Other Assays
Radioimmunoassays were performed as described in Chapter 4 for Cortisol and
cortisone. Plasma renin activity (PRA)[Haber et al., 1969], aldosterone (Coat-a-
Count kit; Diagnostic Products Corporation, USA), and electrolytes (ion-selective
method on a Beckman CX3) were measured by Susan Walker in our Metabolic Unit.
ACTH [Nicholson et al., 1984], dehydroepiandrosterone sulphate (DHEA-S) and
androstenedione [Semple et al., 1988] were measured by Dr Christina Gray in the
Department of Clinical Biochemistry, Glasgow Royal Infirmary.
Aliquots of 24 h urine collections were stored and transported at -20 °C before
analysis of urinary steroid metabolites by gas chromatography/mass spectrometry
(GC/MS), performed by Dr Cedric Shackleton in Oakland, California [Shackleton et
al., 1985],
Cortisone assay was not available for the first 20 subjects in the study, and for them
full urinary metabolite profiles were also not available, though the ratios of the major
Cortisol metabolites were quantified.
Sequential Dexamethasone Suppression
Ten patients and 5 controls, as shown in Table 5.3, were given oral dexamethasone in
increasing doses ranging from 100 qg to 3 mg at 2400 h on 5 occasions, separated by
at least 48 h. The following morning they lay supine from 0830 h to 0900 h before
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blood pressure recording and withdrawal of blood for measurement of plasma for
Cortisol, PRA, aldosterone, Na+, and K+. An aliquot of urine was collected for Na+
and K+ assay. Sodium intake was ad libitum. Subjects on anti-hypertensive therapy
were included only in the analysis of Cortisol and blood pressure.
Skin Vasoconstrictor Assay
Eleven patients and 11 controls had this test and are described in Table 5.3. The
technique is as described in Chapter 3 with minor modifications. The steroids applied
were: beclomethasone dipropionate (BDP)(Steraloids, UK) at 0.1, 0.3, 1, 3, 5, 10,
20, 40, 70, and 100 qg/ml; and hydrocortisone-21-acetate (Sigma, UK) at 0.1, 0.3,
1, 3, 5, and 10 mg/ml. Intensity of vasoconstriction for each square was assessed at
1, 2, 3, 4, and 5 h after removal of the occlusive dressing. The effect of each dose
was expressed as the sum of the readings over 5 h (maximum =15 units) and the
response to each drug represented by the area under the dose-response curve
(maximum = 150 units. 10|ig.ml"1 for BDP and 150 units.mg.ml"1 for
hydrocortisone).
Statistics
Hypertensive and control groups were compared by two-tailed unpaired Student's t
tests for quantitative data and contingency tables with chi-squared tests for qualitative
data. For ACTH and DHEA-S assays, for which some results were below the lower
limit of detection, comparison was by Mann-Whitney U. The distribution of half life
of (1 la3H)-cortisol in each group was assessed using kernel density estimates by the
method of Silverman [1981]. Analysis of factors influencing half life and of the effect
of increasing doses of dexamethasone was by multiple regression analysis in which
qualitative data were assigned values of 0 and 1. Results are described as mean ± SE
throughout. Analyses were performed with assistance from Dr Bill Adams in the
Medical Statistics Unit, University of Edinburgh.
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Results
11B-OHSD Activity
Half life of (llofH)-cortisol
See Figure 5.3. Half lives for controls showed a normal distribution of 42.3 ± 2.3
min. In the hypertensives the distribution was bimodal (p < 0.05) with an overall
mean of 53.2 ± 3.6 min. Seven individuals were identified with half lives > 2 SD
above the control mean, ie > 62.4 min. These 7 had mean half lives of 72.5 ± 2.9
min, while the rest of the hypertensives had a distribution very similar to controls of
42.9 ± 2.0 min. Other parameters described below have been illustrated separately for
the hypertensives with half lives > 62.4 min compared with hypertensives with half
lives < 62.4 min, but statistical comparison is by multiple regression analysis.
Clinical data for patients with long half lives are presented in Table 5.4. Apart from a
relatively high prevalence of hypertension during pregnancy in this group, there were
no other remarkable clinical features.
Multiple regression analysis with half life as the dependent variable and diagnosis,
blood pressure, age, sex, and family history as controlling variables, confirmed that
half lives were significantly longer in hypertensives (p < 0.05). The only other
variable with a significant interaction was mean arterial blood pressure which
correlated positively with half life (p < 0.02).




























Known durationof hypertension (mo)
Blood pressureat presentation* (mmHg)
Previous anti¬ hypertensive medication




































































































*bloodpressureattimefstudyra h rhanr rp esentationwasu ef stati ticalan lyses.














































































































Comparison between hypertensives and their normotensive controls and between
hypertensives with half life of (1 la3H)-cortisol > 62.4 min ("long half life") with
those with half life < 62.4 min ("normal half life"). Plasma cortisone assay and full
urinary metabolite profile for assessment of Cortisol production rate were not available
for early subjects in the study, nor did these subjects have ACTH or adrenal
androgens measured. Results expressed as mean ± SE. Significance level: p < 0.01
for a versus b.
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Cortisol and its Metabolites
Results are shown in Table 5.5. Plasma Cortisol and cortisone were not different
between hypertensives and controls nor between hypertensives with prolonged half
life and those with normal half life. Urinary free Cortisol by radioimmunoassay was
lower in hypertensives than controls (p < 0.01). There were no differences between
groups in urinary metabolite profiles. Specifically, there was no increase in the ratio
ofmetabolites of Cortisol (THF + allo-THF) to those of cortisone (THE), no reduction
in THF:allo-THF ratio, no fall in Cortisol production rate estimated by summation of
urinary metabolites [Zumoff et al., 1974], and no fall in ring A reduction constant
[Ulick et al., 1992a] in the hypertensives. Normal adrenal Cortisol production was
also reflected in normal ACTH and adrenal androgen levels.




































































Comparison between hypertensives and their normotensive controls and between
hypertensives with half life of (1 la3H)-cortisol > 62.4 min ("long half life") with
those with half life < 62.4 min ("normal half life"). Plasma Na and urinary
electrolytes were not assessed in earliest subjects in the study. Four hypertensives
taking therapy were excluded from this analysis. Results expressed as mean ± SE.




Results are shown in Table 5.6. None of the differences between groups were
statistically significant.
Acute Response to Dexamethasone
Dexamethasone produced a dose-dependent fall in 0900 h plasma Cortisol (p <
0.0001) which was independent of diagnosis (hypertensive versus control), age, half
life, family history or sex (Figure 5.4). The resultant plasma Cortisol after
dexamethasone correlated with the urinary Na+/K+ ratio in the 0900 h aliquot of urine,
such that a higher dose of dexamethasone and lower plasma Cortisol were associated
with lower urinary Na+/K+ ratio (R = 0.59; p < 0.01). This relationship was
independent of diagnosis, but urine Na+/K+ ratio fell more markedly with increasing
half life (p < 0.01). The fall in Na+/K+ ratio comprised both antinatriuresis and
kaliuresis, neither of which were significant alone. There was no relationship between




The response to both steroid preparations was greater in hypertensives than controls
(Figure 5.5). Differences were: a) for hydrocortisone, 31.9 ± 4.8 units for
hypertensives versus 16.6 ± 3.6 for controls (p < 0.02); and b) for BDP, 100.0 ± 6.6
versus 75.1 ± 9.5 (p < 0.04). By transforming this data to square roots of the values
the difference in variance between readings of high and low intensity was eliminated.
After this transformation the difference between hypertensives and controls was no
greater for hydrocortisone than for BDP. Half life of (1 la3H)-cortisol did not
correlate with the degree of vasoconstriction to either drug.
Sequential Dexamethasone Suppression
As described above, there were no differences between groups in the suppression of





Suppression of plasma Cortisol by dexamethasone in essential
hypertension
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-■— Hypertensives, long half life
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Effect on 0900 h plasma Cortisol of sequential doses of oral dexamethasone at 2400 h
in normotensive controls (n = 5), and hypertensives divided by their half life of
(1 la3H)-cortisol into "long half life" (> 62.4 min, n - 4) and "normal half life" (<
62.4 min, n = 6). Plasma Cortisol levels at doses from 1 to 3 mg were all suppressed
below 30 nM and are not shown. Results are mean ± SE.

























Intensity of dermal vasoconstriction in 11 hypertensives and 11 controls following
topical application of beclomethasone dipropionate (BDP) and Cortisol
(hydrocortisone-21-acetate). Results are mean ± SE.
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Conclusions
These data show that 11B-DH activity, when measured by half life of (lloc3H)-
cortisol, is reduced in a subgroup of patients with essential hypertension. This finding
has been reproduced very recently in another study of essential hypertensives in whom
the ratio of cortisol/cortisone metabolites was elevated in urine and plasma following
administration of 4-14C-cortisol (Kornel & Margolis, 1992). It had also been
suggested in an older un-controlled study in which urinary and plasma Cortisol
metabolites were measured in hypertensive patients [Lewicka et al., 1991]. The
magnitude of the abnormality (with a maximum of 82.5 min, mean for all
hypertensives of 53.2 min, and mean for those hypertensives outwith 2 SD of normal
of 72.5 min) compares with half lives of 84.3 ± 5 min after liquorice [Stewart et al.,
1987], 123 ± 3 min after carbenoxolone [Stewart et al., 1990], and 131 min in our
patient with congenital enzyme deficiency [Stewart et al., 1988](Table 1.3). As after
carbenoxolone, and in type 2 apparent mineralocorticoid excess syndrome, plasma
cortisone and ratios of urinary metabolites were normal. As discussed in Chapter 1
this suggests that both 11B-DH and 11B-OR activities are deficient.
The half life technique does not locate 11B-OHSD deficiency in essential hypertension
to a particular organ. Recent evidence for the existence of multiple tissue-specific
isoforms of 116-OHSD (see Chapters 1 and 2) makes it possible that a tissue-specific
defect in the enzyme accounts for the defect in essential hypertension. The proportion
of injected (1 la3H)-cortisol metabolised by the kidney was estimated to be as little as
10 % in original studies employing renal vein sampling [Hellman et al., 1971], so
there is scope for other organs to make a significant contribution. When 11B-OHSD
deficiency does affect the kidney urinary free Cortisol is usually high, and plasma
cortisone levels low (Table 1.3). In the present study urinary free Cortisol was lower
in hypertensives than controls, plasma cortisone was no different, and neither were
different in the subgroup with prolonged half lives of (lla3H)-cortisol. These data
suggest that in essential hypertension the defect in 11B-OHSD is extra-renal.
By contrast with all previously recognised syndromes of 11B-DH deficiency, patients
with essential hypertension and 11B-OHSD deficiency did not have hypokalemia or
low-renin, low-aldosterone hypertension, and the administration of dexamethasone
resulted in antinatriuresis rather than reversal of mineralocorticoid excess. Therefore
their hypertension is unlikely to be due to excessive activation of renal
mineralocorticoid receptors by Cortisol. Whether increased renal mineralocorticoid
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receptor activation occurs in any patients with essential hypertension is uncertain.
Although 20-30 % of patients have low levels of plasma renin activity, it is by no
means clear that this reflects expanded plasma volume or total body sodium [Fraser &
Padfield, 1985]. The identification of patients who might have excess renal
mineralocorticoid activity is made more difficult by the paradox that up to a quarter of
patients with proven primary hyperaldosteronism have normokalaemia [Bravo et al.,
1982], Significantly, in neither of the studies of essential hypertensives in which
dexamethasone was shown to decrease blood pressure was it suggested that these
patients' hypertension was dependent on renal mineralocorticoid receptor activation,
since those subjects who responded to dexamethasone in the first study did not have
lower PRA than those who did not respond [Hamilton et al., 1979], and in the second
study successful therapy was associated with a fall in plasma renin activity [Whitworth
et al., 1989a]. Therefore, to explain both the efficacy of dexamethasone and the
relevance of 11B-OHSD deficiency in essential hypertension requires a
hypeitensinogenic mechanism independent of renal mineralocorticoid receptors.
As illustrated in Chapters 2 and 3, an alternative mechanism exists whereby 11I3-DH
deficiency might contribute to hypertension: by increased sensitivity to Cortisol in
vascular smooth muscle. Others have assessed vasoconstrictor sensitivity to
glucocorticoids in essential hypertensives indirectly, and demonstrated greater
potentiation of the response to catecholamines by glucocorticoids in hypertensives
[Mendlowitz et al., 1961; Solomon et al., 1965]. In our hypertensive patients we
found increased direct vasoconstrictor sensitivity to both Cortisol and beclomethasone
dipropionate.
However, the mechanism of the increase in dermal vascular glucocorticoid sensitivity
is unclear. From these data it cannot be attributed to 1113-OHSD deficiency since it
was not specific to steroids metabolised by 11B-DH (BDP has a 9a-chloro group
protecting it from the enzyme) and there was no correlation with half life of (1 la3H)-
cortisol. On the other hand the statistical power of such a correlation is limited by the
small number of subjects studied (n = 5) in whom abnormal 11B-OHSD activity had
been demonstrated. The design of this study included BDP as a positive control
[Teelucksingh et al., 1990], anticipating that the response to this steroid would be the
same in hypertensive and normotensive subjects. No non-steroid agent is available
with a comparable time course which would serve as a control. Given that a
difference was observed with BDP the result with Cortisol must be interpreted with
caution. It may be that glucocorticoids should be added to the long list of vasoactive
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agents which induce a non-specifically greater response in vessels exposed to high
blood pressure [Doyle et al., 1959; Panza et al., 1990]. However, in almost all
experimental circumstances corticosteroids are not directly vasoactive and their effect
depends on modulation of responses to other agents. A non-specific influence of
hypertension on vascular responsiveness might increase basal sensitivity to direct
vasoactive agents, but seems less likely to increase the glucocorticoid-dependent
increment of response. Thus the difference between hypertensives and controls is
unlikely to be a consequence of the hypertension alone, and may indeed contribute to
the abnormal sensitivity to other vasoactive agents.
Corticosteroid-induced dermal vasoconstriction is mediated by glucocorticoid
receptors [Marks et al., 1982; Gaillard et al., 1985]. As an alternative to abnormal
Cortisol metabolism, the increased sensitivity in the hypertensives may be explained if
they express glucocorticoid receptors with higher intrinsic affinity for Cortisol. This
possibility is supported by a recent observation in the Edinburgh Ladywell family
blood pressure study that a larger allele of the glucocorticoid receptor gene is more
frequent in young people who are genetically predisposed to hypertension [Watt et al.,
1992]. However, when functionally abnormal glucocorticoid receptors have been
demonstrated in association with hypertension, they have been relatively resistant
(rather than relatively sensitive) to activation by Cortisol [Brandon et al., 1989], and
the hypertension is probably due to increased secretion of DOC. Moreover, in the rare
syndrome of congenital generalised glucocorticoid receptor hypersensitivity blood
pressure is normal [Iida et al., 1990]. This probably reflects increased hypothalamic-
pituitary glucocorticoid sensitivity and compensatory reduction in Cortisol production
rate. Thus, to induce cortisol-dependent hypertension glucocorticoid receptors of
increased sensitivity would have to be distributed in peripheral tissues and not in
hypothalamus and pituitary. Furthermore, if abnormal glucocorticoid receptor
sensitivity explains the effect of dexamethasone in lowering blood pressure in some
essential hypertensives [Hamilton et al., 1979; Whitworth et al., 1989a], then the
receptor abnormality must increase the response to Cortisol but not to dexamethasone,
otherwise dexamethasone would also act peripherally to induce hypertension.
Glucocorticoid sensitivity to dexamethasone in the hypothalamus-pituitary was
measured in the current study by suppression of plasma Cortisol. The normal results
suggest that abnormal glucocorticoid sensitivity in the skin is tissue-specific and/or
steroid-specific, ie that it either does not include glucocorticoid receptors in the
hypothalamus-pituitary and/or does not include the response to dexamethasone. If
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both of these inferences are true then the present results provide an explanation for
both cortisol-dependent hypertension (mediated by increased peripheral vascular
sensitivity in the face of normal Cortisol production rate) and suppression of the
hypertension by dexamethasone (to which the peripheral glucocorticoid receptors are
not hypersensitive). Site-specific 11B-DH deficiency remains a most plausible
explanation for this pattern, but a large number of subjects may be required to confirm
it.
Finally, in the studies reported above I have not addressed the mechanism of 11B-
OHSD deficiency in essential hypertension. ACTH-dependent steroids are not
measurably secreted in excess in this condition [Vermeulen & Van der Straeten,
1963], a conclusion underlined once more by the normal urinary steroid metabolite
profile in this study. Thus the mechanism for inhibition of 11B-DH which I propose
in Chapter 4 and in ectopic ACTH syndrome does not seem relevant. However, in
collaboration with Dr David Morris (in Providence, Rhode Island) we have examined
the possibility that the urine of these subjects contains an increased amount of
"glycyrrhetinic acid-like factors" (GALFs), ie endogenous inhibitors of the enzyme
which he originally detected in urine of pregnant women [Morris et al., 1992]. We
extracted the urines with Sep-Paks and methanol and added an aliquot of the extract to
a preparation of rat liver and kidney microsomes incubated with 3H-corticosterone.
After incubation the conversion to 3H-11-dehydrocorticosterone was measured and the
extent of inhibition compared with a glycyrrhetinic acid standard curve. In the small
number of subjects studied to date (n = 20) we have found significant amounts of
GALF, and their excretion rates correlated positively with blood pressure and with the
half life of (lla3H)-cortisol, and negatively with plasma aldosterone concentration.
However, the nature of these inhibitory compounds is unknown and their significance




In this chapter I have demonstrated deficient 11G-OHSD activity in two clinical
syndromes of hypertension. The first is ectopic ACTH syndrome, in which 11B-DH
rather than 11B-OR is deficient; the defect affects the kidney; and there is a correlation
between the impaired inactivation of Cortisol to cortisone and the degree of
hypokalaemia. Thus, in this syndrome deficiency of 11B-DH may allow Cortisol to
activate mineralocorticoid receptors in the kidney. The second is essential
hypertension, in which both 11B-DH and 11B-OR are deficient; the defect probably
lies outwith the kidney; and the extent of enzyme deficiency bears no relation to
indices of mineralocorticoid receptor activation. In this condition vascular sensitivity
to glucocorticoids is increased, and although this does not correlate with the extent of
enzyme deficiency in the small numbers studied, it remains possible that these two
observations are related. Thus circumstantial evidence suggests that dysfunction of
1 lB-OHSD-mediated receptor protection contributes to clinical hypertension by
mechanisms dictating either sodium balance or peripheral vascular resistance.
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CHAPTER 6 CONCLUDING COMMENTS
The hypothesis of enzyme-mediated receptor protection for renal mineralocorticoid
receptors was coined in a clinical context [Edwards et al., 1985; Stewart et ah, 1987;
1988]. In the few years which have elapsed since it was confirmed in the rat
[Edwards et ah, 1988; Funder et ah, 1988], there has been a remarkable explosion of
research activity which has focussed principally on the basic science of 11B-OHSD
expression and distribution in rat kidney and elsewhere. The most significant
advances have been the recognition that 11B-OHSD may modulate access of Cortisol to
receptors in many extra-renal sites, and that different isoforms of the enzyme may be
responsible for its diverse functions.
In parallel with these observations, I have addressed a principally clinical question:
might defective enzyme-mediated receptor protection contribute to pathophysiology in
common forms of hypertension? It rapidly became clear that the potential role of the
enzyme in vascular smooth muscle, and similarly in the central nervous system, could
not be ignored when considering the mechanisms of hypertension in 11B-OHSD
deficiency. The effect of corticosteroids on the central nervous system remains
difficult to study in man. However, the hypothesis that 11B-OHSD regulates Cortisol
sensitivity in the vascular tree lent itself to clinical investigation in health and disease.
The studies presented in Chapter 2 are most significant for their description of the
anatomical and cellular localisation of 11B-OHSD in vascular smooth muscle. The
simultaneous identification ofmultiple isoforms of the enzyme in the kidney and liver
[Monder & Lakshmi, 1990; Krozowski et al., 1990; 1992; Mercer & Krozowski,
1992; Moisan et al., 1992a] stimulated me to examine the kinetic characteristics of
11B-DH in vascular tissues. The affinity for substrate does not discriminate vascular
from renal 11B-DH. However, on the grounds of utilisation of cofactors, the vascular
enzyme is kinetically similar to the hepatic isoform and distinguishable from the renal
enzyme. These data presaged those of Naray-Fejes-Toth and her colleagues [Rusvai
et al., 1992] who showed that 11B-OHSD purified in the microsomal fraction of
isolated cortical collecting duct cells utilises NAD almost exclusively over NADP, and
is therefore distinct from 11B-OHSD elsewhere in the kidney. This may have
important implications for the relative activity of 11B-DH and 11B-OR at each site, and
therefore may be crucial in the local physiological role of the enzyme. In collaboration
with Dr Jonathan Seckl and Susan Low we are currently performing Northern blots to
identify the size of mRNA for 11B-OHSD expressed in vascular smooth muscle. With
126
Dr Simon Walker and Moira Nicol at the Royal Infirmary, Edinburgh, we are
performing Western blots with Carl Monder's antisera. Preliminary data from these
experiments confirm that the vascular enzyme is similar to the liver in molecular size
and in the size ofmRNA from which it is probably translated.
What remains unclear is whether NAD utilisation is a marker for avid inactivation of
cortisol/corticosterone. In other words, might the failure of 11B-OHSD from vascular
tissue to utilise NAD prevent it from "protecting" local corticosteroid receptors? At
present we cannot reliably measure the equilibrium between 11B-DH and 11B-OR in
vivo, and in vitro measurements are unlikely to reflect the balance in vivo. I am
currently setting up a system for perfusion of rat mesenteric artery in which we hope
to establish the relative activities and relate them to effects on vascular responsiveness.
However, from data in Chapter 3, we already know that 11-dehydrocorticosterone
was inactive in rat aortic str ips, suggesting that avid 11B-OR activity does not occur in
that preparation.
The studies on regulation of 11B-DH in rat presented in Chapter 2 principally serve to
underline an observation made by others that in some tissues the enzyme is induced by
glucocorticoids, and to demonstrate that the vasculature is one of these sites. In no
site have consistent changes in activity resulted from manipulation of sodium intake.
These data also suggest that glucocorticoid regulation may not be physiologically
significant in the sites where it occurs, since it can only be demonstrated with
pharmacological doses of dexamethasone. Finally, they show that the effect of
dexamethasone is not mediated indirectly by suppression of ACTH.
The demonstration of 11B-OHSD expression in vascular smooth muscle invited the
next series of experiments, presented in Chapter 3, in which I showed that inhibition
of 11B-DH activity and congenital 11B-DH deficiency are associated with increased
vascular sensitivity to Cortisol in man. This result highlights the significance for
cardiovascular regulation of the observation that topical glycyrrhetinic acid increases
the vasoconstrictor response to Cortisol in skin [Teelucksingh et al., 1990].
Associated with the increased sensitivity to Cortisol in man were increased
vasoconstrictor and pressor responses to noradrenaline. It is presumed that this is
secondary to increased Cortisol exposure, which we know can produce these effects
[Sudhir et al., 1989]. However, confirmation of this presumption would be difficult
in man. For that reason I elected to pursue the same hypothesis in an isolated rat
vessel where the interactions between glucocorticoids (in this case corticosterone) and
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noradrenaline could be examined without confounding systemic influences. The
results in rat aorta confirm that inhibition of 11B-DH results in a corticosterone-
dependent change in sensitivity, but paradoxically this is an attenuation rather than
potentiation of the response to noradrenaline. This may reflect site-specific differences
in the expression of corticosteroid receptors and of their target second messenger
systems. I am currently addressing this possibility in studies of vascular smooth
muscle cells in primary culture and in studies of another isolated rat vascular
preparation, the perfused mesenteric artery. In these models I hope to be able to
measure binding to both mineralocorticoid and glucocorticoid receptors in vascular
smooth muscle cells and relate these to 11G-OHSD function.
From a clinician's point of view, the justification of the intense research interest in
11G-OHSD lies in the results presented in Chapter 5. Here I chose two clinical
syndromes of hypertension: in the first, ectopic ACTH syndrome, there was good
reason to suspect cortisol-dependent mineralocorticoid excess, but the mechanism
whereby 11B-OHSD might be involved was unclear; and in the second, essential
hypertension, the pathophysiological mechanisms were not understood, but there was
evidence to suggest that Cortisol is a mediator in some patients, and there would be
immense benefit from elucidating the cause of hypertension even in a small fraction of
this enormous population.
The hypothesis that ectopic ACTH syndrome includes 11B-DH deficiency led me to
perform the initial experiments in healthy volunteers presented in Chapter 4. I showed
that increased ACTH secretion is associated with decreased inactivation of coitisol to
cortisone. The selective venous catheterisation studies confirm that the most likely site
for this action is the kidney. Taken together with the failure of ACTH to influence
11B-DH bioactivity in adrenalectomised rats (Chapter 2) I suggest that there are
ACTH-dependent endogenous factors secreted from the adrenal which inhibit the
enzyme. Thus a mechanism exists whereby 11B-DH activity may be inadequate in
ectopic ACTH syndrome. Its significance is confirmed in Chapter 5, in which patients
with ectopic ACTH syndrome are shown to have increased plasma cortisol/cortisone
ratios and corticosterone levels compared with patients with other forms of Cushing's
syndrome. However, this abnormality is not universal in the hypokalaemic patients,
and is not separable from the increased secretion of DOC and corticosterone, which
might also contribute to mineralocorticoid excess.
To clarify the relative contribution of ACTH-dependent 11B-DH inhibition versus
increased secretion of corticosterone and DOC to mineralocorticoid receptor activation
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in these syndromes will require a study in patients whose Cortisol concentrations are
not so dramatically elevated that they might saturate 118-DH in the kidney. This
should be achieved in a study currently underway with the Respiratory Physicians in
which we are correlating indices of 11B-DH activity, DOC and corticosterone secretion
and mineralocorticoid excess in patients with small cell carcinoma of lung (many of
whom will have sub-clinical ectopic ACTH syndrome) and in patients with other
bronchial tumours.
Finally, in Chapter 5 I have assessed the activity of 11B-DH and related it to Cortisol
sensitivity in the kidney and in dermal blood vessels in patients with essential
hypertension. The evidence for 11B-DH deficiency in this syndrome comes from the
half lives of (1 la3H)-cortisol, the most sensitive index of 116-DH activity in man. It
seems that enzyme deficiency in this syndrome differs from that in all other conditions
of 11B-DH deficiency, including ectopic ACTH syndrome, because the defect not only
affects both 11B-DH and 11B-OR activities but also appeai-s not to affect the isoform
of 11B-OHSD expressed in the kidney. The increased vascular sensitivity to
glucocorticoids which I demonstrate in the hypertensives is therefore all the more
exciting, since it could represent an alternative link between 11B-DH deficiency and
hypertension. However, in studies to date I have not confirmed a relationship
between abnormal enzyme activity and abnormal sensitivity to glucocorticoid, perhaps
because of inadequate numbers of subjects with reduced 11B-DH activity.
We are only just beginning to address the mechanism of 11B-OHSD deficiency in
patients with essential hypertension. Indeed, cloning of the human gene on
chromosome 1 has yet to result in identification of a mutation in any patient with
congenital 11B-DH deficiency [Dr Perrin White, personal communication], so that this
syndrome also remains in a sense unexplained. One experimental stalling point in this
area is the ability to measure glycyrretinic acid-like factors (GALFs) in human urine.
Clearly a great deal of experimental time will need to be devoted to characterising the
nature of these factors, but this task may provide clues to the pathogenesis of 11B-DH
inhibition both in essential hypertension and in ACTH excess. Having established
David Morris's assay for GALFs in Edinburgh I am now examining their
physiological regulation and clinical distribution in greater detail.
It will important to increase the numbers of hypertensive subjects identified with the
phenotypic abnormality of 11B-OHSD deficiency. Having shown a prolonged half
life of (lla3H)-cortisol in this group it is ethically difficult to proceed with a larger
screening study which involves radioisotopic exposure. For that reason we have
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arranged for the synthesis of a deuterated Cortisol compound which we can measure
by GC/MS. This approach has been employed with some success by Ulick's group
[Linberg et al., 1991]. We will then seek to correlate half life of 9a, 11 a, 12a, 126-
2H4-cortisol, excretion rate of GALFs, and vasoconstrictor sensitivity in two
populations of untreated individuals to whom we have access: (i) middle-aged adults
taking part in a screening programme with ambulatory blood pressure monitoring at
Ferranti's in Edinburgh; and (ii) young subjects in the Ladywell Family blood
pressure study who have defined genetic predisposition to hypertension [Watt et al.,
1992]. Only when larger scale studies are complete will we be confident that the
enzyme has a pathophysiological role in essential hypertension.
The elucidation of the mechanism of 1 lB-OHSD-mediated receptor protection has laid
down a challenge to biochemists and molecular biologists to detail its operation at a
cellular level; to physiologists to understand its significance and regulation in each
organ; and to clinicians to determine its potential importance in the pathogenesis of
hypertension. In this thesis I describe work which contributes at each of these levels.
In addressing the potential significance of 11B-OHSD activity in the control of blood
pressure, and of its deficiency in common hypertensive conditions, I have brought the
story of 118-OHSD full circle: from serendipitous clinical observation to testable
hypotheses on the laboratory bench, and finally to application in clinical populations.
We can be confident that future manipulation of the "hypothalamic-pituitary-adrenal-
11B-OHSD" axis will reap considerable clinical reward.
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